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ABSTRACT
Sigma receptors are endogenous proteins with potential utility in treating psychological dis-
orders, ischemia, the psychological and convulsive eﬀects of drugs of abuse, and as an imaging
agent for cancerous tissues, among others. Drug design eﬀorts targeting these receptors have been
hindered by a lack of structural information of the receptors themselves. Traditional ligand-based
approaches have succeeded in generating many compounds with high aﬃnity, and quite a few with
selectivity for σ-1 receptors. There are few selective ligands for use as pharmacological probes for
the σ-2 receptor. Much eﬀort has gone into exploring the structure activity relationships of ligands
targeting these receptors.
A critical review of the existing literature covering pharmacophore development for σ receptors
was undertaken with the intent to develop computational models to assist in ligand-based drug
design eﬀorts. Inspired by the lack of pharmacophore models with general utility, and confronted
by the obstacles of data heterogeneity, a database of σ ligands and their binding aﬃnity data was
collected. Cohorts of data collected under similar experimental methodologies were assembled
and clustered by measures of scaﬀold dissimilarity. Multiple-Instance Learning techniques were
used to train classification models that diﬀerentiated molecules as active or inactive, and to assist
in the identification of relevant conformations of σ ligands at their macromolecular targets. Confor-
mations of high-aﬃnity ligands were then used to develop general pharmacophore models as part
of a virtual screening approach. Structure-activity relationship models based on virtual screening
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D2 Dopamine 2 receptor
H1 Histamine 1 receptor
σ-1 Sigma-1
σ-2 Sigma-2
CoMFA Comparative Molecular Field Analysis
CoMSIA Comparative Molecular Similarity Indices Analysis
CPU Central Processing Unit
CSV Comma-Separated Values
DDR Double Data Rate
DTG 1,3-di-o-tolyl-guanidine
EA External Accuracy











MILES Multiple Instance Learning via Embedded instance Selection
PE Prediction Error
PGRMC1 Progesterone Receptor Membrane Component 1
PLS Partial Least Squares
PTZ (+)-pentazocine
QSAR Quantitative Structure–Activity Relationship
RCSB Research Collaboratory for Structural Bioinformatics
RMS Root-Mean-Square
SAP Significance Analysis of Pharmacophores
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1. INTRODUCTION
Introduce such an intoxicant, and start
it to ferment in humanity’s blood, and
it may spread from soul to soul, until,
before the world is advised of its
possible results, the ever-increasing
potency will gain such headway as to
destroy, or debase, our civilization,
and even to exterminate mankind.
Etidorpha
John Uri Lloyd
Research into σ receptors and their ligands began in 1976 with the proposal of a “sigma opioid”
class of receptors to explain aberrant behavior upon exposure toN-allyl-normetazocine (SKF-10047,
NANM) in the chronic spinal dog model of precipitated opioid abstinence.1 The use of racemate
NANM in initial binding studies complicated matters, implicating binding to phencyclidine (PCP)
sites,2 and to multiple opioid sites.3 In the following years, it was determined that sigma sites were
distinct from opioid and PCP receptors,4 and that the psychotomimetic eﬀects of NANM were not
a result of sigma aﬃnity.5
1.1 Therapeutic potential of σ receptor ligands
Many neuroleptics and antidepressants have aﬃnity for σ receptors and consequently their
role in motor side eﬀects of antipsychotics and as modulators of serotonergic and glutamatergic
neurotransmission in depression have beenwell established.6,7 In the early 1990s, σ antagonists were
also demonstrated to attenuate the psychostimulant eﬀects of cocaine8 and methamphetamine,9
and more recently 3,4-methylenedioxymethamphetamine (MDMA).10 There is evidence that σ
1
ligands may also be of use in treating ischemia and certain cognitive disorders.11 Sigma sites are
particularly interesting targets for cancer imaging agents due to their role in apoptosis and their
overexpression in a wide range of cancers, where saturation of σ-2 receptors is associated with
selective cytotoxicity towards several cancer cell lines.12
1.2 Sigma receptor subtypes
1.2.1 Sigma-1 receptor
Sigma-1 receptors have beenwell characterized, displaying a rank order of aﬃnity for haloperidol
(HAL), 1,3-di-o-tolyl-guanidine (DTG), (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine (R-(+)-
3-PPP), (–)-cyclazocine, (+)-NANM, PCP, etoxadrol, dexoxadrol, and MK-801.13 These sites are
distributed in both the central nervous system and peripheral tissues. The σ-1 receptor was initially
cloned by Hanner et al. in 1996,14 and was demonstrated to be a 223 amino acid 25.3 kDa peptide
whose closest known homologue is the yeast C8 sterol isomerase. To this day, the tertiary structure
of σ-1 receptors or close homologs have not been elucidated by crystallography. As a consequence,
structure-based drug design is not currently a viable option for the design of novel σ-1 ligands.
Although a homology model has recently been developed for the σ-1 receptor,15 ab initio and
comparativemodeling techniques are currently insuﬃcient tomake confident structural predictions
for a protein of this size.
1.2.2 Sigma-2 receptor
In the late 1980s it became clear that the σ ligand DTG bound to a second class of receptor
sites with rank order aﬃnities to benzomorphans that contrasted themselves from classical sigma
sites.16 These sites were dubbed σ-2 sites, and for many years now, a great challenge in σ research has
been to discover substances with selectivity towards this subsite. Very recently, a σ-2 receptor was
putatively identified as the 21.7 kDa Progesterone ReceptorMembrane Component 1 (PGRMC1).17
PGRMC1 has a conserved cytochrome b5-like heme/steroid binding domain, and the presence of
close homologs in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data
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Bank18 suggests that homology modeling may be a feasible approach for generating models for
structure-based drug design. Nevertheless, a comprehensive database of ligand structures with σ-2
binding aﬃnities and associated scaﬀolds will be of significant utility for ligand-based drug design
and QSAR. Until a more comprehensive correlation of PGRMC1 and σ-2 ligands is carried out,
ligand-based drug design strategies may well prove more meaningful.
1.2.3 “Sigma-3”
For several years, Booth, Wyrick, Myers and others described a putative “σ-3” site with bind-
ing aﬃnities diﬀerent still from σ-1 or σ-2.19–22 These sites were labeled by 1-phenyl-2-amino-
1,2,3,4-tetrahydronaphthalenes and were later determined to be histamine H1 receptors.
23 Sub-
sequent literature dropped the reference to σ-3, but this points out the importance of scaﬀold
recognition and diligent pharmacological classification of “novel” receptors.
1.3 Sigma pharmacophore and QSAR development: 1980–2011
Medicinal chemists often assess the performance of molecules in targeted biological assays
in terms of a pharmacophore. What is meant by a “pharmacophore” can diﬀer quite a lot from
one practitioner to another. There are numerous examples of diﬀerent usage of the term in the σ
literature. In order to be clear about the terminology, and to explain why many of the references to
pharmacophores are not included in the following review, two usages of the term are distinguished.
Pharmacophore motifs are abstract generalizations of molecular moieties or scaﬀolds that attempt to
explain, in a retrospective sense,why certain molecules possess binding aﬃnity at a macromolecular
target. Pharmacophore models, on the other hand, are specific, well-defined combinations of features
that have some predictive utility in assessing the potential of a molecule to bind to the target.
Pharmacophore motifs were quite common in the early σ literature. To this day, ligand-based
drug design eﬀorts are couched in terms of their agreement to those motifs, and they merit review
because of their longstanding influence on the interpretation of σ ligand aﬃnity. Several very
predictive pharmacophore models have also been developed over the years. Many of these models
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highlight several exemplary features possessed by almost all σ ligands developed to date; others
attempt to elaborate upon putative binding site features that imply complementary features of
the ligands themselves. Descriptor- or fingerprint-based QSARs are not reviewed if they do not
elaborate upon a pharmacophore model (for the curious, see references 24–34).
1.3.1 Non-selective σ models
1.3.1.1 Manallack topological pharmacophore model
Manallack et al.35,36 developed the first pharmacophoremodels for σ ligands based on themethod
of Lloyd and Andrews 37 in an attempt to diﬀerentiate the binding requirements of NMDA and σ
ligands. This method distinguishes three receptor features that are built around each ligand, namely
two “hydrophobic” features that are aligned normal to the plane of an aromatic ring at its centroid,
and a third receptor feature represented by a vector from the lone pair electrons of a ligand N to a
postulated H-bond acceptor belonging to the receptor. Receptor and ligand features are presented













Figure 1.1: Manallack’s topological pharmacophore combines receptor features R1, R2, and R3,
with two ligand-based features comprising the centroid of the aromatic ring and the position of
the basic nitrogen atoms. Reprinted with permission from Manallack et al. 35 Copyright (1998)
American Society for Pharmacology and Experimental Therapeutics.
common volume overlaps to the template structure were used to guide the alignment process.
Themodelwas designed around the crystal structure of trans-(4aR,10bR)-9-OH-N-n-propyl-octa-
hydrobenzo[f]quinoline, a relatively rigid ligand that demonstrated a high eudismic ratio for σ
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receptor sites.38 High-aﬃnity ligands towards σ sites defined by the radioligand [3H](R)-3-PPP were
selected as active analogues, although (R)-3-PPP was later shown to have mixed relative aﬃnities
with respect to σ-1 and σ-2 sites.4 Crystal structures of [3H](R)-3-PPP and d-NANM, and the
modeled structures of DTG and HAL were used in the alignment process. Torsional analysis was
required for the modeled structures and (R)-3-PPP, whereas the pseudochiral configuration about
the N of d-NANM required inversion for a better fit to the template ligand.
The final model suggested a distance of 5.06Å between the aromatic and N features. Additional
electrostatic calculations were employed in their study with equivocal results depending upon the
scaﬀold of the analogs fitted to the model. A lipophilic pocket was hypothesized to accommodate
steric features of some ligands that did not detrimentally impact aﬃnity. While the construction of
a model for the “σ” receptor is useful from a conceptual standpoint, this model regrettably suﬀers
from a paucity of ligand-based features.
1.3.1.2 Gund pharmacophore (1991)
Gund and Shukla developed a three-point pharmacophore model based upon the structures of
HAL, (R)-3-PPP, progesterone and dextropentazocine39 in their neutral ionization states. Conforma-
tional analysis, molecular superposition, and electrostatics were all considered in the construction
of the final model. The optimal superposition of all compounds produced 4 separate pairwise
pharmacophore distance measurements.
The inclusion of progesterone as an “active” compound is questionable because of its low σ aﬃnity,
and marked diﬀerences in the pharmacophore features compared to the other active ligands used in
their model development. Namely, progesterone lacks both the aromatic- and N-moieties present
in the other compounds. This required special alignments of the centroid of ring B to the centroid
of HAL’s fluorophenyl ring or alternatively to selected atoms of (R)-3-PPP and dextropentazocine
aromatic rings. Oxygen lone pair electrons from ring D of progesterone were aligned to the N lone
pairs of the other compounds. These special alignment considerations and the use of a non-selective
radioligand restrict the general applicability of the resulting model.
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1.3.1.3 Gund pharmacophore (1992)
Gund et al. reinvestigated their prior model39 after the identification of PRE-084 as a selective
σ ligand.40 As part of their modification, molecules were superimposed upon a single ligand, HAL.
Template features selected as references for superposition were the fluorophenyl moiety, the basic
N-atom, and the lone-pair of the N-atom (Figure 1.2). As with the prior model, special alignment
considerations were required, especially in the case of progesterone. The positioning of the cyclo-
hexyl moiety of PRE-084 in their final model was hypothesized to explain its selectivity towards σ
receptors.
Figure 1.2: Gund’s (1992) HAL-based pharmacophore model.40 Reprinted with permission from
NPP Books.40 Copyright (1992) NPP Books.
1.3.1.4 Ablordeppy pharmacophore and CoMFAmodel (1992)
Themodel of Ablordeppey et al. 41 (Figure 1.3) was based upon trans-(4aR,10bR)-7-OH-N-n-pro-
pyloctahydrobenzo[f]quinoline, similar to the template utilized in the model of Manallack and
Beart.36 This was the first application of CoMFA42 to σ QSAR development. Training and test set
data for the study were generated from a variety of assay methodologies using the non-selective
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radioligand [3H]DTG without a σ-1 site masking agent. Assay variability may have been amplified
in this model because of the combination of both𝐾i and IC50 data.
Figure 1.3: Ablordeppey’s41 template molecule trans-(4aR,10bR)-7-OH-N-n-propyloctahydro-
benzo[f]quinoline, showing proposed molecular alignment sites. Reprinted with permission from
Ablordeppey et al. 41 Copyright (1992) Springer SMB NL.
Basic pharmacophore features identified in theirmodel were an aromatic ring centroid separated
from a positive ionizable N by a minimum of an ethylene spacer, and an pendant propyl chain on
the N-atom. Training and test set ligands were aligned to a minimum of 3 of the proposed sites,
although the exact details of individual alignments were not specified. In addition, some of the
ligands in the dataset possessed unresolved centers of asymmetry, and the rationale for the selection
of one isomer for alignment over the other(s) was not described. A CoMFA based on the alignment
of training set molecules exhibited remarkable internal consistency (𝑟2 = 0.979, 𝑞2 = 0.843; 4 PLS
components), and the external test set statistics (𝑄2 = 0.88, 0.67; two diﬀerent sets) reflected a high
quality model.
1.3.1.5 Seri-Levy eudismic analysis
While not a pharmacophore model per se, Seri-Levy et al. employed conformational analysis
and superposition of a series of 3-(3-hydroxyphenyl)piperidines (3-HPPs)44 to investigate the
stereochemical requirements of σ receptors.43 The original data were generated from competition
binding experiments using [3H](R)-3-PPP as the radioligand. Stereoisomers of 3-HPP were aligned
in two diﬀerent ways for the calculation of electrostatic potential and shape chirality indices, and the
superposition of the 3-hydrophenyl rings was found to be optimal. Correlation of the shape chirality
7
indices to eudismic indices revealed “non-Pfeiﬀer behavior”45 for the homologues investigated and
questioned the importance of an H-bond acceptor lying in proximity to these ligands within the σ
receptor.
1.3.1.6 Beart pharmacophore model
Beart et al. examined the conformational requirements of a series of ifenprodil-related hetero-
cyclic amino alcohols.46 Their investigation used [3H](R)-3-PPP as a radioligand. Receptor and
ligand sites (see Figure 1.4), as well as the template ligand, were defined using the same criteria
proposed by Manallack et al. 35 Low energy conformers were generated with by the application of
MD or torsional analysis, and molecular models were superimposed by a three-point fit to within
0.6Å. All of the compounds investigated fit the model well, with tight RMS fit and low energy with
respect to the global minimum found through the conformer search protocols.
Figure 1.4: Beart’s pharmacophore model46 elaborated upon the template of Manallack,35 focusing
on the SAR of ifenprodil analogues. Reprinted with permission from Beart et al. 46 Copyright (1994)
Elsevier Science Publishers
1.3.2 Sigma-1 models
1.3.2.1 Carroll pharmacophore model
Carroll et al. developed a σ-1 pharmacophore by modification of their previously proposed PCP
pharmacophore motif.47,48 While not strictly a σ-1 model, as the activity values were derived from
experiments using both [3H](R)-3-PPP and [3H]dextropentazocine as radioligands, the features of
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benzomorphan scaﬀolds aligned to their PCPmodel were the basis for pharmacophore development.
Like the model of Manallack et al.,35 three receptor features were assigned based upon a vector
placed normal to the plane of the aromatic ring at its centroid along with a H-bond vector feature
involving the lone pair on the N atom, although the exact placement of the N was deliberately left
unspecified. An additional receptor feature was proposed to comprise a lipophilic pocket in the
receptor capable of inducing selectivity for dextrorotatory benzomorphans depending upon the
nature of the pendant N-alkyl substituents.
1.3.2.2 Elaborated Carroll pharmacophore model
Carroll et al. revisited their previous molecular modeling study47 with a deeper investigation
into the flexibility of N-substituted N-normetazocine side-chains.49 This modification allowed the
formation of additional hypotheses (see Figure 1.5) regarding the common volumes occupied by
the benzomorphan side-chains and the volumes unique to the side-chains of high- and low-potency
ligands.
Figure 1.5: Carroll’s N-substituted N-normetazocine based pharmacophore.49 The authors investi-
gated flexibility of side-chains at the proposed Lipophilic site 2. Reprinted with permission from
NPP Books: Ann Arbor, MI, 1992.49 Copyright (1992) NPP Books.
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1.3.2.3 Gilligan pharmacophore
Gilligan et al. provided the first model explicitly investigating the nature of σ-1 binding require-
ments50 utilizing d-NANM as a competitive binding radioligand. Based on the pharmacodynamic
characteristics of 15 compounds with selectivity for σ-1 receptors over dopamine D2 and 5-HT2A,
four pharmacophore features were identified as important elements for σ-1 aﬃnity. These features
comprise a basic N attached to two separate hydrophobic moieties, with an H-bonding feature
between the nitrogen and its farthest hydrophobic partner (preferably an aromatic moiety).50 The
distances between such features were calculated by conformational analysis, averaged and published
along with their standard deviations, all of which fell within 2Å. While this pharmacophore is
historically significant, the relative contribution of each feature is not readily apparent due to the use
of a fairly congeneric series of compounds for pharmacophore elucidation and the same magnitude
of receptor aﬃnity of these compounds (8–51 nM).50
1.3.2.4 Hudkins pharmacophore motif
Hudkins et al. 51 described a pharmacophore based upon a set of caramiphen analogues. They
proposed a “lipophilic site 1” associated closely with a N-binding site, together corresponding to
ligand features of benzomorphans and 4-aryl-piperidines. A distal “lipophilic site 2” and alternative
binding mode was proposed to explain the aﬃnity of the arylcyclopentyl ester scaﬀold of their
designed analogues and HAL. Distances were discussed in terms of methylene spacers, and no
discussion of intersite angles was presented.
1.3.2.5 Glennon pharmacophore motif
Glennon et al. proposed a general three-point motif for σ-1 binding based upon a congeneric
series of relatively flexible phenylalkylamines using [3H]dextropentazocine as radioligand.52 The
salient features of their model include a hydrophobic site in the receptor, a proton-donating site
corresponding to the almost requisite amine motif, and a secondary hydrophobic site with a propen-
sity for accommodating bulky groups.52 While there are three site points to this model, they were
10
Figure 1.6: Hudkins’ 3-site pharmacophore51 recapitulates the presence of two hydrophobic sites
separated by a positive-ionizable N-binding site. Reprinted with permission from Hudkins et al. 51
Copyright (1994) American Chemical Society.
presented in terms of the distances of each hydrophobic site to the N-atom. The distances between
the hydrophobic groups was not stated, likely because of the wide range of distances tolerated
between the primary hydrophobic site and the amine-N.This pharmacophore model was revisited
in a comprehensive review of their group’s σ-1 drug development strategy,53 and also used to ra-
tionalize the SARs of 6,8-diazabicyclo[3.2.2]nonan-2-one and 6,8-diazabicylo[3.2.2]nonen-2-one
derivatives.54,55
Figure 1.7: Glennon’s 3-site model52 provided general intersite distance information and proposed
a receptor region tolerating hydrophobic bulk. Reprinted with permission from Glennon et al. 52
Copyright (1994) American Chemical Society.
1.3.2.6 Ablordeppey pharmacophore and CoMFAmodel (1998)
Aspart of an investigation of the configurational requirements of the endo- and exo-stereoisomers
of the high-aﬃnity ligand SC-50691, Ablordeppey et al. revisited the model of Glennon et al. 52
with a CoMFA analysis based upon dextropentazocine as a template.56 After aligning 1-(5-phenyl-
pentyl)-piperidine to the template, the remaining compounds in the dataset were aligned to either
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the template or to the representative piperidine. The distance between the “phenyl-B” site and
the amine-N of either the template or of the piperidines was held constant through a heuristic set
of RMS fitting criteria while the remainder of each molecule was allowed to attain an extended
conformation in the sterically accommodating “phenyl-A” region.56
Significantly more care was taken in the development of this model than in the their prior
non-selective σ pharmacophore.41 The training set represented alkyl- and aryl-amines, piperidines,
piperazines, and a variety of compounds from diﬀerent pharmacologic classes with σ-1 aﬃnity,
some with significant eudismic ratios. The test set was well sized, comprising 25% of the total
number of compounds, and was also well within the domain of applicability of the training set.
This was reflected in the external test statistic (𝑄2 = 0.65) and the accurate prediction of the aﬃnity
constants of the resolved isomers of SC-50691. Their final model based on 64 total compounds
demonstrated remarkable internal correlation and consistency (𝑟2 = 0.989, 𝑞2 = 0.732; 7 PLS
components).
1.3.2.7 Huang pharmacophore and CoMFAmodel
Thework of Huang et al. 57 focused on derivatives ofN-(1-benzylpiperidin-4-yl)-3-bromophenyl-
acetamide (BPP). Through conformational analysis of BPP and superimposing a low-energy con-
former onto pentazocine with a few manual adjustments, the authors were able to align a set of 79
BPP derivatives57,58 for CoMFA studies. As part of their investigation, they sought to probe the
importance of the carbonyl-to-N distances on σ-1 aﬃnity. Intersite distances of BPP features in
common with those present in the Glennon et al. pharmacophore52 were also enumerated. The full
matrix of intersite distances was not disclosed.
CoMFA results for 76 molecules in the dataset provided a model with superb correlation and
consistency (𝑟2 = 0.91, 𝑞2 = 0.61; 6 PLS components)57 for the σ-1 dataset, but failed to perform
suitably for the σ-2 dataset. The steric diversity around the benzyl-group corresponding to Glen-
non’s secondary binding site was much less than that presented by the arylacetamide moieties
corresponding to the primary hydrophobic site. Because of this choice, the steric tolerance of the
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secondary binding site could not be corroborated. However, the steric and electrostatic nature of
the primary hydrophobic receptor site were substantially more well defined by the CoMFA study.
1.3.2.8 Cao CoMFAmodel
Cao et al. used [3-(cis-3,5-Dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]-N,N-bis(4-fluo-
rophenyl)amine as template for the alignment of piperazinyl bis(4′-fluorophenyl)amine derivatives.
Two alignments based on alternative assignment of the piperazine N-atoms as the ubiquitous amine-
N feature present in σ pharmacophores were utilized, with the fluorophenyl-ring systems serving
as the classic σ hydrophobic groups. The preferred alignment based upon the CoMFA results
indicated that the proximal-N to the bis(4-fluorophenyl)amine served as a better surrogate for
the requisite N-feature. Although precise intersite distances were not presented, the best CoMFA
model had a respectable level of internal correlation and consistency (𝑟2 = 0.929, 𝑞2 = 0.521; 4 PLS
components).59
1.3.2.9 Gund pharmacophore model (2004)
Themodel published byGund et al. in 200460was templated uponPD144418, with superposition
of spipethiane, dextropentazocine, and HAL onto the general CNS motifs described by Lloyd
and Andrews 37 along with an optional O- or S- feature present in a number of the molecules.
Electrostatic potential contours were used to characterize the placement of electronegative features,
suggesting that the secondary binding site plays an important role in ligand aﬃnity. The final model
included a total of 3 ligand features, and the performance of σ-1 selective agents vs progesterone in
fitting the pharmacophore was notable.
1.3.2.10 Jung DISCOtech pharmacophore and CoMFAmodel
Jung et al. employedDISCOtech on a series of spipethiane analogues, piperidine- and piperazine-
analogues of caramiphen, benzoxazolones, benzothiazolones, and several notably σ-1-selective
molecules from the literature to develop a pharmacophore alignment and subsequent CoMFA
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model.61 The training set comprised a total of 43 compounds and a test set of 5 compounds, and
both sets represented diverse scaﬀolds ranging over 3 orders of magnitude in aﬃnity for dextropen-
tazocine defined sites. An initial 3-point pharmacophore including the aromatic ring centroid, the
N-atom, and a projected H-bond from the N provided CoMFA models with poor results. They
successfully overcame this obstacle by further optimization of conformers with semiemperical AM1,
Hartree-Fock, DFT, or MP2 calculations, in tandem with scaling the projected H-bonding distance
down to 1.4Å. The reoptimization was followed by a very specific atom-based alignment scheme,
and CoMFA analysis. AM1 charges provided better fits for electrostatic contributions, whereas
the HF geometries provided more significant steric contributions to the PLS regression. The HF
methodology also enhanced the external test set predictivity.
1.3.2.11 Laggner HypoGen pharmacophore model
Laggner et al. used training and test sets of diverse pharmacological classes and a wide range of
activities to develop pharmacophoremodels for σ, emopamil binding protein, and yeast ERG2.62The
training set of 23 compounds was deliberately chosen to reflect diverse structures and a substantial
range in aﬃnity, as encouraged by the HypoGen documentation,63 although the σ-1 aﬃnity data
were not spread equally through the range. Pharmacophores for all three targets presented 5
common features; four hydrophobic ligand sites and a single positive ionizable N-atom. The top
σ-1 model had high correlation (Pearson 𝑟 = 0.926) and cost function analysis following response
randomization indicated a high degree of confidence that the correlation was not spurious (95%
confidence level). Estimated aﬃnities were reported for a test set of 9 ligands, although the aﬃnity
of one of the σ-1 compounds was not determined. While the authors did not explicitly state
the performance of the pharmacophore model on this external test set in terms of the Pearson
correlation coeﬃcient, the value is readily calculated from their data (𝑟 = 0.403). An agreement
was found between their σ-1 pharmacophore and that developed by Glennon et al. 52 Furthermore,
application of their pharmacophore model to a virtual screening protocol resulted in the discovery
of 5 unique hits with𝐾i ≤ 100 nM.
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Figure 1.8: Laggner’s 5-feature HypoGen pharmacophore62 incorporated compounds from a di-
verse set of structural classes. Reprinted with permission from Laggner et al. 62 Copyright (2005)
American Chemical Society.
This model was later applied to two series of alkenyl- and arylalkyl-amines where it was found
to consistently overestimate aﬃnity values.64 The discrepancy in predicted vs observed binding
aﬃnity was ascribed to interlaboratory variations and the inclusion of the particularly high-aﬃnity
compound fenpropimorph in the original training set.
1.3.2.12 Zampieri HypoGen pharmacophore model
Zampieri et al. used HypoGen methodology to derive an interesting pharmacophore from a
series of 31 benzooxazolones.65 While the aﬃnity range of training set structures and the size of the
dataset fit the suggested criteria found in theHypoGen documentation,63 the diversity of the selected
structures is questionable, as the main diﬀerence in each “series” is the length of the linker from the
N-feature to the benzooxazolone-N (i.e. 3–4methylene units), and in the case of the piperidine series,
the length could be interpreted as a constrained 4-methylene unit linker. Notwithstanding this
caveat, the top-ranked hypothesis included five features which were all consistent with the broader
σ-1 literature, such as an aliphatic hydrophobic site, two aromatic hydrophobe sites, a positive
ionizable N-site, and an H-bond acceptor. Cost function analysis indicated a high confidence
in a true correlation (Pearson 𝑟 = 0.896) between predicted and experimental activities. A test
set of related benzylpiperidine-4-carboxamides and σ-1 reference ligands performed remarkably
well (Pearson 𝑟 = 0.882) when aligned to the pharmacophore model. Additionally, response
randomization suggested a statistical significance of 98% for the top-ranked hypothesis. This model
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was later used in the refinement of the first published σ-1 homology model.15
Figure 1.9: Zampieri’s 5-feature benzooxazolone-based pharmacophore65 includes an H-bond
acceptor site and diﬀerentiates between aromatic and aliphatic hydrophobic features. Reprinted
with permission from Zampieri et al. 65 Copyright (2009) American Chemical Society.
1.3.2.13 Oberdorf Quasar pseudoreceptor model
Oberdorf et al. used a congeneric series of spirocylic piperidines to develop a pseudoreceptor
model of the σ-1 receptor.66 Out of the 87 total structures analyzed, only 5 where achiral, whereas the
remainder comprised 41 enantiomeric pairs representing the racemate compounds tested in vitro.
Development of the pseudoreceptor model required the initial preparation of a pharmacophore
for structure alignment. Towards this goal, structures were protonated prior to conformational
analysis and alignment, making this study distinct with respect to the other σ-1 models. A unique
result of this study was the perception of an H-bond acceptor feature in the pharmacophore which
complemented the positive ionizable nitrogen. According to the authors, the remaining sites
presented features in line with the models of Glennon 53 and Laggner et al. 62 Unfortunately, the
authors did not disclose the coordinates or relative distances of the features in this pharmacophore
model.
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Figure 1.10: Oberdor’s Quasar pseudoreceptor model.66 Reprinted with permission from Oberdorf
et al. 66 Copyright (2010) Elsevier Science.
1.3.2.14 Rossi Galahad pharmacophore model
Rossi et al. developed a 3-feature pharmacophore model from a set of congeneric arylalke-
namines.67 The most highly ranked hypothesis, according to their heuristics, possessed two hy-
drophobic features and a positive ionizable N. While the model was found to aid in classifying
active vs inactive compounds, conventional methods of validating the model were not presented.
Model parameters such as distances and coordinates between features were also not disclosed.
1.3.3 Sigma-2 models
1.3.3.1 Cratteri GRIND-based pharmacophore model
The model presented by Cratteri et al. 68 used grid-independent descriptors69 to generate a
description of the putative environment surrounding α-tropanyl derivatives in their bioactive
conformations. Some of the derivatives were tested as racemate mixtures, and the decision was
made to develop a model based upon the (R) isomers, stemming from their modestly higher
eudismic ratio. A significant result of their analysis was a description of the putative dimensions of
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Figure 1.11: Rossi’s Galahad pharmacophore67 again proposed two hydrophobic features and a
positive ionizable nitrogen, but this pharmacophore places both of the hydrophobic groups on one
side of the nitrogen. Reprinted with permission from Rossi et al. 67 Copyright (2011) Pergamon.
three σ-2 receptor regions based on the selectivity of a subset of the data: distances between two
hydrophobic regions, and from one of these to a H-bond donor region were disclosed. This suggests
an upper limit on the total width of the binding pocket of the σ-2 receptor.
Figure 1.12: Cratteri’s GRIND-based pharmacophore68 provided a pseudoreceptor model which
places some restrictions on the overall size of the binding site. Reprinted with permission from
Cratteri et al. 68 Copyright (2004) Kluwer Academic Publishers.
1.3.3.2 Abate pharmacophore and CoMFAmodel
Abate et al. used an automated alignment of cyclohexylpiperazines and congeners to the template
molecule, 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)propyl]piperazine
((R)-PB28), in their pursuit of a predictive CoMFA model for σ-2 ligands.70 Initial CoMFA perfor-
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mance with the automated alignment was poor, so an alternative manual alignment of the dataset
to 1-Cyclohexyl-4-[3-(naphthalen-1-yl)propyl]piperazine was undertaken, with the focus not on
global alignment of all features, but rather on the overlay of the piperazine ring. To simplify the
alignment, and because of electrostatic considerations, the piperazine moieties were modeled in
their dibasic ionization state. The manual alignment led to CoMFA models with both internal
correlation and consistency, as well as external predictivity for structurally related compounds
(𝑟2 = 0.95, 𝑞2 = 0.73, 𝑄2 = 0.55; 4 PLS components).70 The final model supported a SAR interpreta-
tion of the binding requirements of cyclohexylpiperazines to σ-2 receptors. Apart from suggesting
an important σ-2 pharmacophore feature, no intersite distances between multiple features were
proposed.
1.3.3.3 Laurini Catalyst pharmacophore model
The first ligand-based pharmacophore model specifically aimed at determining the features
necessary for σ-2 aﬃnity were recently reported by Laurini et al., based on the benzooxazolone
motif.71 This set of ligands had been previously used in the development of a σ-1 pharmacophore,65
and share the same drawbacks with regard to the diversity represented in the training set. Aﬃnities
for σ-2 span amuch narrower range than for σ-1, and are not distributed evenly through the training
set.
Figure 1.13: Laurini’s 5-feature benzoxazolone-based σ-2 pharmacophore71 implicated an absolute
requirement of an aliphatic hydrophobic feature for σ-2 binding and revisits the H-bond acceptor
feature proposed by Zampieri.65 Reprinted with permission from Laurini et al. 71 Copyright (2010)
Pergamon.
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Assuming that the previous considerations do not adversely aﬀect the regression, this is a
groundbreaking pharmacophore. The model implicates an absolute requirement for an aliphatic
hydrophobic moiety for high aﬃnity, although the authors admit that σ-2 selectivity is not explained
by this feature. An aromatic hydrophobic site and a general hydrophobic feature build upon this
pharmacophore. The ubiquitous positive ionizable N is also present. Rounding out the 5-feature
pharmacophore is an H-bond acceptor complementing the carbonyl of the benzoxazolones. Re-
sponse randomization studies indicate a 95% confidence level that the hypothesis is statistically
significant, and the robustness of the model is backed by leave-one-out pharmacophores showing
no substantive diﬀerence from the best hypothesis.
1.3.4 “Sigma-3” model
Myers et al. used DISCO (as part of the Sybyl package) to develop a CoMFA model for a series
of phenylaminotetralins which displayed aﬃnity for a putative “σ-3” receptor.21 Subsequently
Bucholtz et al. determined that the predominant activity of these compounds was at histamine H1
receptors.23 Accordingly, the development of their “σ-3” model and the corresponding QSARs will
not be discussed, and is mentioned only for the edification of the curious reader.
1.3.5 Summary of pharmacophore models in the σ literature
As seen in Table 1.1, a great number of pharmacophore models have been proposed over the
years. Many of the early pharmacophores, and several of the more recent σ-2 pharmacophores
are based upon perceptions of a virtual receptor or projected points. Until the mid-nineties, these
pharmacophore models were not developed with a focus on receptor subtype selectivity. Only two
of the studies involved what would be regarded today as “diverse” structures; the majority were
focused on elaborating the SAR of a congeneric series of molecules. Aﬃnity prediction has also
become more of a focus in the past decade. The consideration of molecular alignments has been
a recurring challenge in σ pharmacophore development, requiring special consideration in many
cases. When manual superposition to a template or automated alignments of congeneric series
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are applied in CoMFA studies, there is a likelihood that spurious correlations will be found in the
SAR because the chosen alignments do not accurately reflect the conformation of the ligands to
receptor sites. Additionally, a majority of the experiments carried out with diverse scaﬀolds were
performed with only a handful of compounds. Because of the symmetric nature of many of the
3-point pharmacophores with Hydrophobe-Nitrogen-Hydrophobe features coupled with the fact
that many σ ligands possess a high degree of flexibility, the issue is raised over whether multiple
binding modes may exist. Further complicating matters is the possibility of subsites on σ receptor
subtypes. These factors all detract from the general utility of the majority of these models for
ligand-based drug design.
1.4 Overview of σ binding assay methodology
An overwhelming number of radioligands and binding assays have been developed for imaging
and competition binding studies of σ receptors.72 Despite the preponderance of radioligands, there
are few subtype selective compounds commonly used for σ-1 research, of which (+)-pentazocine is
most commonly used, and only one generally-used radioligand (DTG) for σ-2 receptor assays, which
is ordinarily accompanied by a modicum of PTZ to saturate residual σ-1 sites. Sigma receptors
are ubiquitously expressed in all tissues with minimal specificity. While cloned σ-1 receptors have
been expressed in yeast14 and HeLa cells,73 almost all competition binding experiments to date
have been performed in brain or liver tissue homogenates from guinea pig or rat. The majority of
σ-1 assays have been performed using guinea pig brain membranes, whereas rat liver membranes
are generally preferred for σ-2. The diversity of assay methodologies presents a challenge for
computational eﬀorts aimed at generating QSARs and pharmacophore models, as the variability in
assay performance under diﬀerent conditions can lead to significant diﬀerences in perceived ligand
aﬃnity. This variability carries over as uncertainty in model development and negatively aﬀects
model performance.
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Table 1.1: Overview of σ pharmacophore models
Feature count
Authors Year Receptor Ligand Lone pairs QSAR Reference
σ non-selective
Manallack et al. 1988 3 2 0 35
Gund and Shukla 1991 0 2 1 39
Gund et al. 1992 0 2 1 40
Ablordeppey et al. 1992 0 4 0 • 41
Seri-Levy et al. 1994 0 1 0 • 43
Beart et al. 1994 3 2 0 46
σ-1 selective
Carroll et al. 1992 3 2 0 47,49
Gilligan et al. 1992 0 4 0 50
Hudkins et al. 1994 3 0 0 51
Glennon et al. 1994 3 0 0 52
Ablordeppey et al. 1998 0 3 0 • 56
Huang et al. 2001 0 4 0 • 57
Cao et al. 2003 0 3 0 • 59
Gund et al. 2004 0 5 0 60
Jung et al. 2004 0 2 1 • 61
Laggner et al. 2005 0 5 0 • 62
Zampieri et al. 2009 0 5 0 • 65
Oberdorf et al. 2010 0 4 0 • 66
Rossi et al. 2011 0 3 0 • 67
σ-2 selective
Cratteri et al. 2004 3 0 0 • 68
Abate et al. 2009 2 2 0 • 70
Laurini et al. 2010 0 5 0 • 71
1.5 Research Objectives
Given the lack of selective σ-2 probes and the lack of general utility of many of the modeling
eﬀorts to date, the field of σ research remains open to new discoveries. Modeling software and
computational techniques have advanced significantly in recent years, and a fresh approach using
curated data is overdue. That being said, σ ligand design has routinely focused on highly flexible
molecules with a great degree of pharmacophore symmetry that pose challenges when there is a
lack of crystallographic information to provide target structures. Virtual screening and aﬃnity
assessments, particularly eﬀorts at identifying selective scaﬀolds, will require a more fundamental
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understanding of the general binding requirements of σ ligands. As part of these eﬀorts, the
following objectives were established:
1. Create a database of binding competition experiments to identify experimentalmethodologies
that are suﬃciently similar for dataset collection.
2. Collect and curate data from the literature which utilize the most prevalent methodologies.
3. Use a combination of scaﬀold analysis, distance measures, and hierarchical clustering to
generate representative training and test sets for classification of active and inactive molecules
towards either σ-1 or σ-2, depending upon the underlying methodology.
4. Identify the most significant conformers of the active compounds for pharmacophore devel-
opment.
5. Use these pharmacophores to clarify structural features necessary for aﬃnity and selectivity.
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2. METHODS
We have no future because our present
is too volatile. We have only risk
management. The spinning of the





Database preparation and analysis was undertaken on a 2.8 GHz Intel Core 2 Duo Mac OS
X laptop furnished with 8 GB 1067 MHz DDR3 RAM. Computational methods were performed
on the same system, or on a 2.5 GHz Intel Core i5 Mac OS X desktop furnished with 4 GB 1333
MHz DDR3 RAM. CPU and memory intensive calculations were done on a Fedora Linux cluster
comprising 8 Microway computers, four with 2.5 GHz 8-core Intel Xeon L5420 CPUs and 16 GB
667 MHz DDR2 RAM, and another four equipped with 2.27 GHz 16-core Intel Xeon L5520 CPUs
and 32 GB 1333 MHz DDR3 RAM.
2.2 Data collection and curation
Articles with competition binding data were identified from the literature using a combination
of electronic search and cross-referencing to related literature found in proceedings, books, and
patents, to a limited extent. Additional sources of binding data included data generated by our lab
and those generated by our colleagues. Bibliographic information as well as details concerning the
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radioligand, masking ligands (if present), matrix (i.e. organism and tissue preparation), as well
as PubMed ID (if available) were recorded in a PostgreSQL database (version 9.2). Records with
competition binding data were analyzed to determine which experimental methodologies were
most prevalent. An experimental methodology was defined as a combination radioligand, masking
ligand, and matrix.
Following the identification of relevant data sources, those competition experiments with the
most reliable data (e.g. 𝐾i in lieu of IC50 data) were added to a project table in Maestro (version
9.3, Schrödinger, LLC, New York, NY, 2012). Molecules were sketched using the stereochemistry
assigned in the original article, unless corrected for in an erratum, or unless there was evidence
in the experimental section that the molecule had been incorrectly sketched in the paper. Aﬃnity
data and experimental methodology were annotated along with any assay limits, if applicable. In
the case that the stereochemistry was unknown, ambiguous, or known to be tested as a racemate,
the molecule was marked as racemate. Several other properties and SMILES strings were calculated
using the Generate SMILES script in Maestro and QikProp (version 3.5, Schrödinger, LLC, New
York, NY, 2012). Once sketched, LigPrep (version 2.5, Schrödinger, LLC, New York, NY, 2012), was
used to clean up the structures and to generate relevant stereoisomers, if necessary. All molecules
were double-checked for consistent stereochemistry and accurate aﬃnity data entry. A Python
script (Appendix E.1) was written to automate the processing of PubMed IDs into SMILES strings,
but it was determined that the PubMed records were not reliable enough to identify molecules of
interest.
2.3 Dataset composition
The initial dataset was divided into subsets representing each predominant methodology. These
subsets were limited to contain molecules of unambiguous stereochemistry that were determined to
have aﬃnity within the assay limits. On occasion, a molecule would be tested more than once under
a given set of experimental conditions, and thus would be replicated in the dataset. In order to deal
with this situation, which was very common for reference compounds, themolecules were imported
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into Canvas74 (version 1.5, Schrödinger, LLC, New York, NY, 2012), duplicate identification was
performed, and statistical analysis was carried out on the duplicates. This analysis was undertaken
to determine the variability of the collated experimental data. After analysis, duplicate data points
were removed, retaining the highest aﬃnity (p𝐾i) measured in any experiment. This choice was
made deliberately because of a classification technique (vide infra) used later on in the modeling
process. Expurgated datasets were then exported as SMILES and CSV files.
2.3.1 Scaﬀold decomposition
Molecular scaﬀolds were decomposed by two methods implemented in Strip-It (version 1.0.1,
Silicos-it, Schilde, Belgium, 2012). Initially, a canonical SMILES representation of each molecule
was converted into RINGS_WITH_LINKERS_2 scaﬀolds preserving the ring structures, any linking
chains between rings, and exolinker double bonds. Aside from these linkers, all pendant groups are
eliminated in this process, which allows for a mapping of the molecule to an underlying scaﬀold that
may be shared by other analogues. All of the unique scaﬀolds were then subjected to a subsequent
decomposition into MURCKO_1 core scaﬀolds. The core scaﬀolds are similar to the former, with
the exception that all atoms are converted to C, the bond order between connected atoms is reduced
to a single bond, and exolinker double bonds are removed. This process allows for the perception
of common ring and linker systems and reduces the ambiguity presented by unsaturated systems
and heteroatoms. It should be noted that information about stereochemical configuration is lost
in the scaﬀold generation process, although this is fortuitous since it allows for molecules that
have identical atom connectivity to be clustered together and provides an avenue for investigating
eudismic analysis.
2.3.2 Core fingerprints
Ameasure of the diﬀerence between scaﬀolds was required in order to cluster similar scaﬀolds.
Dendritic and radial (extended-connectivity) fingerprints calculated by Canvas were evaluated
for this purpose based on the moderate to high number of bits typically set “on”, and on their
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performance in screening enrichment.75 Stereochemical information was ignored in the hashing of
radial fingerprints in order to be consistent with the scaﬀold generation process. Default atom typing
(Daylight invariant and Fn functional types, respectively) were used in preparing core fingerprints.
The impact of atom typing was not investigated because the core scaﬀolds do not distinguish atoms
other than carbon, and also because bond orders were reduced by the core decomposition process.
With binary bit-strings, the minimum distance provided with this metric is 0, meaning the
molecules are indistinguishable by fingerprint. The distance increases as the number of bits which
are diﬀerent in each fingerprint increases. Several distance measures are provided in Canvas, and
it was determined that the Euclidean distance measure worked very well to distinguish clusters of
molecules with similar scaﬀolds. Euclidean distance𝐷 = √𝐴 + 𝐵, where 𝐴 is the number of bits
exclusively set “on” in the bitstring of scaﬀold moleculeA, and 𝐵 is the number of bits exclusively set
“on” in the scaﬀold of molecule B. Based on the initial results (data not shown), it was determined
that radial fingerprints at the default level of 4 iterations provided a suﬃcient degree of distance to
ensure that core scaﬀolds could be distinguished from one another, whereas dendritic fingerprints
with the default 5-atom path length led to a small but significant proportion of cores that were not
distinguished.
2.3.3 Core clustering and network visualization
Following the general procedure of Guiguemde et al.,76 the McQuitty linkage method of hierar-
chical clustering was chosen in order to ensure that every core scaﬀold was connected to at least one
other core by a node. Kelley’s criterion77 was used to select an appropriate number of clusters. This
particular method is well suited for the application of common scaﬀold perception when paired
with a suitable fingerprint and distance metric. Structures and clusters are paired based on the
minimizing the average distance between members, and as clustering progresses, more distant
candidates are paired incrementally in such a manner to ensure that the largest clusters of similar
cores are produced. The end product of clustering is a dendrogram relating successive nodes to leaf
core scaﬀolds and child nodes.
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The visualization method of Guiguemde et al. 76 was implemented with slight modifications
using custom scripts to process the scaﬀolds generated by Strip-It and the cluster dendrograms
produced by Canvas. An edge network consisting of molecule to scaﬀold, and scaﬀold to core
relationships was supplemented by core to node, and node to node edge relationships from the
dendrogram. When singleton molecule to scaﬀold relationships were identified, they were replaced
by molecule to core relationships and the original molecule to scaﬀold relationships were deleted
from the network. No attempt was made to identify common child scaﬀolds. The resulting network
was visualized using the yFiles circular network layout in Cytoscape78 (version 2.8.3, Cytoscape
Consortium). Binding aﬃnity data formolecules were imported from the CSVfile as node attributes.
By applying node size and color mappings based upon binding aﬃnity, clusters with a suﬃciently
large number of members and a suitable spread of aﬃnity data could be selected and assigned
cluster membership for pharmacophore and QSAR development in Phase. Suitable values for
core-node distance for cluster discrimination were found at a Euclidean distance of ~10–12, based
on the classical benzomorphan and morphinan scaﬀolds. Scripts for scaﬀold decomposition, core
fingerprinting, and core clustering may be found in Appendix A.
2.3.4 Selection of classification model training and test sets
Using the range of aﬃnity values determined from the duplicate experimental points within each
individual methodology, it was possible to define a range of aﬃnity values to classify set members
as active, not determined, or inactive. The choice of selecting the highest aﬃnity value for each
molecule biases the selection of the inactive set towards truly inactive compounds while placing
a handful of compounds that would have been indeterminate for classification purposes into the
active set. Once suitable aﬃnity ranges were selected, the inactive and active members of each
cluster were identified, and up to three members were selected from each cluster to achieve an
acceptable level of diversity among scaﬀold classes for training and test sets. Class membership
and cluster information was exported from Cytoscape to Canvas as a CSV file, so that the original
datafile could be used to generate the classification model sets.
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2.4 Generation of conformers
All pharmacophore modeling approaches require a set of ligand conformations to be gener-
ated either before or during the pharmacophore elucidation step. For a useful model, the set of
ligand conformers must contain conformations very near to those found in the target–ligand com-
plex. ConfGen79 (version 2.3, Schrödinger, LLC, New York, NY, 2012.) is a tool included in the
Schrödinger Suite that is integrated in pharmacophore and docking protocols. Chen and Foloppe
developed an optimized set of parameters for ConfGen that more frequently identifies conformers
close to established bioactive states of two sets of ligands extracted from crystal structures.80 These
modifications have since been incorporated into the standard protocols, with the exception of
two modifications to the CGO6 and CHYD parameters which control elimination of “compact”
structures and hydrogen-bonding electrostatics, respectively. To this end, the CGO6 opcodes in the
Macromodel file were deleted, CHYD was added and the first argument in the opcode string was
set to -1. These additional “compactness-allowed” modifications were utilized because the impact
on the total number of conformers generated is minimal and also because of the extension of the
conformational sampling to potentially important conformations of highly-flexible ligands, which
are frequently presented in the σ-literature.
2.5 Model development
2.5.1 Classification models
Multiple Instance Learning via Embedded instance Selection (MILES) is a supervised learning
technique proposed by Chen et al. 81 and extended by Fu et al. 82 in the context of drug activity
prediction. MILES, as applied to bags of conformers and their relationships to individual conformers,
is particularly useful as a means of associating the activity of a molecule to individual conformers
across a set of training molecules.
We used this technique, with a fewmodifications, to develop classification models for σ receptor
ligands, using prototype conformational instances to generate more robust pharmacophore models.
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This is particularly important for σ-1 and σ-2 ligands, as very few are rigid enough to provide
simple solutions, i.e., the vast majority of active and inactive compounds are highly symmetric,
flexible ligands, with little bulk or chirality to assist in interpreting how pharmacophore features
might correspond to one another. Another issue with σ ligands is that no crystallographic infor-
mation is presently available that might allow for structure-based perception of multiple binding
modes. MILES assists in overcoming this problem by allowing for the selection of multiple signifi-
cant pharmacophore configurations which can be used in traditional pharmacophore modeling
applications.
2.5.2 Pharmacophore fingerprints
Pharmacophore fingerprints are a useful means of encoding the distances between potential
pharmacophore features into a string of bits that represent the presence or absence of some particular
combination of features. A variety of general molecular features such as hydrophobic, aromatic,
positive, negative, and hydrogen bond donor or acceptor sites is typically used in tandem with
binned distances to generate a hashed fingerprint. Although it is possible to calculate fingerprint data
based on 3-point pharmacophores, 4-point pharmacophores, or a combination of both, only 4-point
pharmacophores were used in this work. Among the reasons for selecting 4-point pharmacophores
are the ability to infer the presence of chirality,83 and by not combining them with 3-point features
the impact of correlated descriptors is reduced.84 Four-point pharmacophore fingerprints were
generated using the default features defined by Phase85 (version 3.4, Schrödinger, LLC, New York,
NY, 2012), along with a custom feature matching the centroid of piperidine and piperazine moieties.
In some cases, no four-point pharmacophores could be generated for a structure, and these were
removed from the 1n-SVM classification modeling process. Several hundred thousand fingerprint
bits are typically calculated during this process, which leads to additional computational expense
when similarity measurements are calculated directly within Canvas. Given a large number of
conformers and fingerprint bits, the memory and computational cost can exceed the limits of
contemporary workstations.
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Canvas provides several options to pre-filter fingerprints after their calculation, among them
the ability to discard bits that are set by less than a certain percentage of conformers, or alternatively
the most informative bits can be retained. Informative bits are decided by calculating the frequency
with which each bit is turned “on” based on the total number of molecules in the collection. For
classification purposes, optimally informative bits in a well constructed collection will trend towards
a frequency of 50%, and thus the ranking
𝑟inf = |𝑓bit − 0.5|,
where 𝑟inf is the informative bit ranking given the bit frequency 𝑓bit. After the bits are ranked,
informative bits are retained based on those with the least deviation from optimal. The original
Significance Analysis of Pharmacophores (SAP) method described by Fu et al. 82 implemented a
pre-filtering cutoﬀ of 5% bit frequency, which can result in fingerprint lengths of several tens of
thousands. Hence the option to retain informative bits was investigated to compare the utility
of each approach for activity classification. One immediate benefit of the latter option is that an
optimal fingerprint of arbitrary length can be determined heuristically to reduce computational
overhead when applying the SAP filtering method. For comparison of fingerprint lengths and to
assess the impact of SAP on the performance ofMILES, a variety of fingerprint lengths were selected,
including unfiltered fingerprints, those filtered by eliminating the least significant 5% of bits, and a
range of informative bit string lengths from 256 to 16,384.
2.5.3 Implementation of SAP
SAPwas implemented using the samr package86 in R,87 closely following themethods described
by Li et al. 88 and Fu et al. 82 Fingerprint data were read into a data table and transposed to create an
appropriately formatted matrix. The “two class unpaired” response model was selected, and activity
classificationswere used as outcomemeasurements, with 500 permutations of the activity class labels
used as a control. AΔ table was computed from the data and divided into 100 intervals. Significance
analysis was performed with the Δ corresponding to an estimated false positive rate (FPR) of zero
at the 90th percentile. As shown in Figure 2.1, a sizable number of pharmacophore features can be
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Figure 2.1: The results of SAP analysis provide two sets of bits representing pharmacophore features
which are either significant (red) or insignificant (yellow) for the appropriate classification of binding
activity. Insignificant bits are removed from the fingerprint and used in subsequent similarity
calculations.
identified as lacking significance for accurate activity classification. In the initial experiments, care
was taken to ensure that the fingerprints chosen for significance analysis were only selected from the
conformers corresponding to training set molecules. Model sets were stratified between training
and test in a 2:1 ratio on the complete dataset after sorting by activity. Further experiments were
conducted with the inclusion of all fingerprints without regard to training or test set assignment.
All pharmacophore fingerprint bits having a non-negative correlation to activity were retained for
the entire set of conformers. Code detailing the SAP process is included in Appendix B.
2.5.4 Instance-based similarity mapping
In the MILES formulation, feature mapping can be described in terms of either a distance or a








where each moleculeM𝑖 is evaluated against every conformer C
𝑟 in the embedded feature space as
themaximum similarity of any individual conformerC𝑖𝑗 in each bag to each individual conformer in
every bag. By using a similarity measure, it is possible to avoid a troublesome hurdle when it comes
to ranking conformers, namely that distance measures trend towards 0 if there is no perceivable
diﬀerence in the pharmacophore fingerprints. When this occurs, the ranking algorithm will be
unlikely to predict that the top-ranked conformations are mapped as the most active conformer,
even though the weight of the support vectors may otherwise be high. This happens because the
most likely conformations of an active molecule will have solutions equal to zero when mapped
from their own bag. On the other hand, similarity measures trend towards higher values as the
molecules share more pharmacophore fingerprint bits, even if not normalized by design or coercion,
and thus the solutions have a positive correlation to the inputs in the feature mapping.
The Kulczynski similarity measure (see Table 2.1), was initially investigated as a way to en-
sure that the support-vector machine (SVM) correctly mapped active conformers to their parent
molecules (vide infra), and to average out the similarity of each conformer to the shared phar-
macophore features of both partners. This measure benefits from omitting the bits from each
pharmacophore fingerprint that are set “oﬀ”, which is problematic in that activity prediction based
on pharmacophore fingerprints is not formulated in amanner consistent with having any knowledge
of what it means for a bit to be “oﬀ” when making comparisons between molecular conformers.89
Cosine, Dice, McConnaughey, Petke, Simpson, Tanimoto, and Tversky similarity metrics were also
investigated for their performance in the MILES context for similar reasons. Training and external
test sets were assigned using the same stratified 2:1 approach described in 2.5.5. Conformations rep-
resenting the test set were removed from the instance-based embedding. Code for instance-based
similarity mapping is included in Appendix C.
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Table 2.1: Measures of similarity. Canvas provides the following similarity metrics that lack an


























𝑎 + 𝑏 − 𝑐
Tversky
𝑐
𝛼(𝑎 − 𝑐) + 𝛽(𝑏 − 𝑐) + 𝑐
aFor binary fingerprints F1 and F2, a bit is set “on” and given the value “1” if
the feature represented by that bit is present in the fingerprint; otherwise, the
bit is given the value “0.” 𝑎 is the count of bits set on in F1, 𝑏 is the count of
bits set on in F2, and 𝑐 is the count of bits that are set on in both fingerprints.
In the Tversky metric 𝛼 and 𝛽 are parameters used to scale the count of bits
that are exclusively set on in F1 and F2, respectively.
2.5.5 Implementation of 1-norm SVM
Support vector machines are commonly used for classification purposes, and can be useful for
evaluating novel compounds as “active” or “inactive” based on competition binding data. Phar-
macophore fingerprints which are derived from multiple conformations of chemical entities are
prone to have common spurious configurations that provide no productive information about their
complexes with biological targets. In this context, 1-norm SVMs are particularly useful because
they are less susceptible to over-fitting the input data, and tend to eliminate noise resulting from
common but meaningless pharmacophore configurations. Linear programming (LP) techniques
have previously been formulated to solve 1n-SVMs,90–92 and have been used in the context of
pharmacological classification.81
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subject to Az = b
z ≥ 0,
along with the following definitions:
z ≡ ( 𝛽+0 𝛽
−
0 (𝛽
+)′ (𝛽−)′ (𝜁+)′ (𝜁−)′ )′
c ≡ ( 0 0 0′ 0′ 1′ 0′ )′
a ≡ ( 0 0 1′ 1′ 0′ 0′ )′
A ≡ ( 𝑌 −𝑌 diag(𝑌)X −diag(𝑌)X I′ −I′ )′
b ≡ 1.
The solution, z,minimizes the distance of support vectors from the hyperplane given the objective
function. Here c is a vector of normalized indices of the slack variables used as part of calculating
the objective function, b is a vector representing the right-hand side of the constraint constants, a is a
vector used to implement the objective function, 𝑌 are the class labels, X is the feature matrix in the
context of the MILES81 formulation, and 𝜆 is a tunable control parameter of the objective function.
An optimal hyperplane 𝛽0 + 𝛽X is then solved subject to the non-separable case of a 1n-SVM
classifier by the introduction of the slack variable 𝜁 that allows for some points to be misclassified.
Classification of activity is based on the sign of the output, sgn(𝛽0 + 𝛽X).
Tuning of the 1n-SVM (as illustrated in Figure 2.2) was accomplished using the perry package93
of R, with 5-fold cross-validation using random splits of the data for a total of 15 replicates. The
𝜆 parameter was initially chosen by validations over the range of 10−12–104 at each power of 10.
Prediction error was assessed as the misclassification error rate. After narrowing down the range
for 𝜆, a second cross-validation was undertaken at 21 points ranging from the nearest lower power
of 10 to the higher, spaced at arithmetic intervals between each order of magnitude. An optimal
tuning parameter corresponding to the least mean cross-validation prediction error was then used
to generate the 1n-SVM slack and penalty values that are necessary to calculate the accuracy of the



















Figure 2.2: Tuning of the 1-norm SVM.The control parameter 𝜆 is selected as the minimum value
(red point) at which the mean cross-validation prediction error (PE, misclassification error rate) is
also minimized. The first round of tuning covers a wide order of magnitudes. A second round of
tuning is performed to optimize this parameter.
using the caret package of R.The code used to implement this 1-norm SVM is included in Appendix
D.
2.5.6 Selection of prototype conformers
Non-zero elements of 𝛽 correspond to prototype conformers for which molecular similarity
measures contribute positively or negatively to the classification of molecular activity. Many of
the conformations will have no impact on classification, and can be removed from the cohort of
conformers taken on to traditional pharmacophore development. In practice, the indices of training
set conformations from the original collection are congruent with the 𝛽 so that the non-zero
elements can be collected to generate a substantially smaller subset of conformers. Ranking of
all conformers could be performed at this point, but the prototype conformers are suﬃcient for
pharmacophore model development given that there are no known crystal structures for complexes
of σ receptors and their ligands. After the prototype conformers are retrieved from the full set, the
corresponding fingerprints for active ligands are used to generate a substantially smaller similarity
matrix. This matrix is visualized as a clustered heat map to determine a practical number of active
ligands that are needed to generate common pharmacophore hypotheses.
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2.5.7 Pharmacophore modeling
Phase providesmeans for bothmanual and automated pharmacophore development. Individual
hypotheses can be generated from each prototype conformer manually, but the development of
common pharmacophore hypotheses from the entire set of prototype conformers allows for the
perception of features common to subsets of entire cohort of selected conformers. Common
pharmacophore hypotheses are generated and evaluated in a five-step process: generating ligand
conformations, identification of pharmacophore sites, perception of common pharmacophore
hypotheses, scoring of hypotheses, and building atom- or pharmacophore-based 3D QSAR models.
In structure-based pharmacophore development, the conformations of ligands are known with
a high degree of certainty. Without such information, ligand-like conformations must be selected
through other means, such as through the use of the ConfGen application. Highly flexible ligands,
such as those found frequently in the σ literature are problematic because the number of potential
common pharmacophore hypotheses rapidly becomes too great to discern any statistically signifi-
cant hypotheses after the scoring step. In preliminary studies, it was not infrequent to generate tens
of thousands of common 5-point hypotheses; analyzing the resulting QSAR models became an in-
tractable task. By utilizing the prototype active and inactive conformers that were identified through
MILES, the number of common pharmacophores is reduced by several orders of magnitude.
Phase provides a default set of pharmacophore sites including hydrogen bond acceptors (A),
hydrogen bond donors (D), positive ionizable (P), negative ionizable (N), hydrophobic (H), and
aromatic rings (R). This set was extended to include piperazine and piperidine rings (X) as group
features, as was performed during the pharmacophore fingerprinting steps. After editing the feature
definitions, sites were generated for all the input conformers. The prototype conformers that share
a high pharmacophore fingerprint similarity will likely share many of the same features. Common
pharmacophores were identified by determining an reasonable number of each type of feature, an
optimal number of site points (from3–7), and requiringmatches to the number of active compounds
identified from the heat map of active prototype conformers. Scoring of hypotheses was performed
with the default settings in Phase, and the hypotheses that survived the initial scoring process were
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taken on to pharmacophore screening and QSAR development without regard to score.
Typically atom- or pharmacophore-based QSAR models would be generated at this point. How-
ever, the common pharmacophore workflow makes it diﬃcult to generate these models if the
conformations of all other ligands in the database are not carried throughout the process. Atom-
basedmodels are best performed on cohorts of structures of limited diversity, and are not well suited
to molecules with a high degree of rotational freedom. Pharmacophore-based models are more
appropriate under these circumstances, but the resulting models cannot be used to infer activity
when steric clashes are important to binding aﬃnity, and there is no way to run this application
outside of the common pharmacophore hypothesis workflow. On the other hand, the surviving
hypotheses can be used outside of the workflow to screen through databases of ligands with known
activity to retrieve cohorts of ligands which can then be utilized for QSAR development using
alternative methodologies.
2.5.8 Database screening
ThePhase Advanced Pharmacophore Screening applicationwas used to retrieve pharmacophore
hits from the database of all ligands. Decoy sets of 1000 drug-like ligands94 were combined with the
curated sigma database ligands and inactive ligands from the superset for calculation of enrichment.
For these purposes, an aﬃnity at 10,000 micromolar or better was considered “active”. In the case
of σ-2 ligands, a set with an average molecular weight of 400 was utilized, whereas the σ-1 database
was more matched to the decoy set having an average molecular weight of 360. Databases were
created using the same ConfGen parameters as were used in the fingerprinting and pharmacophore
modeling steps. Searching of the database was performed using the existing conformers without
refinement. Default matching criteria were used, with the exception that only 4 sites out of the total
were required to match, and preference was given to conformers matching more sites. Four-site
matches are optimal under these circumstances, as they naturally allow alignments based on chirality,
but are not overly aggressive at screening out matches that contribute valuable QSAR information.
Hits were scored based on default scoring fitness, but were rejected if vector features diverged at
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an angle of 90∘ or more, or if the volume score was less than 0.3. These limits were determined
heuristically to generate reasonable alignmentswithout rejecting toomany ligands from the database.
Compound aﬃnities were ranked according to a field-based QSAR, described below.
2.5.9 Field-based QSAR
Field-based QSAR based on the CoMFA (Force Field) and CoMSIA (Gaussian) approaches was
recently incorporated into the Schrödinger software suite. Both of these approaches evaluate fields
based on a rectangular grid encompassing the training set molecules. However, the Force Field
method involves a Partial Least Squares (PLS) regression based on the fields evaluated at each grid
point, and is very sensitive to the alignment of ligands. The Gaussian method evaluates fields based
on a weighted function dependent upon the distance of atoms from the grid points, and is less
sensitive to alignment artifacts. Given the diverse nature of scaﬀolds retrieved during the database
screening steps, the Gaussian approach was used for QSAR analysis.
Each set of aligned ligands was used to develop independent QSAR models. A random split of
the dataset into 50% training to test set was applied to the ligands. This ratio was chosen as it was
the default for Phase, and ideally should be set high enough to generate a predictive model with a
representative external test set. These sets are automatically distributed in a relatively even manner
across the range of activities present in the dataset. A maximum of 3 PLS factors at a grid spacing
of 1Å were used in the regression. The grid was extended 3Å beyond training set limits, and force
fields within 2Å of any training set atom were ignored. Steric and electrostatic fields were truncated
at 30 kcal/mol. Variables with a standard deviation of less than 0.01, or with |t-value| less than




We’ve learned from experience that
the truth will come out. Other
experimenters will repeat your
experiment and find out whether you
were wrong or right. Nature’s
phenomena will agree or they’ll
disagree with your theory. And,
although you may gain some
temporary fame and excitement, you
will not gain a good reputation as a
scientist if you haven’t tried to be very
careful in this kind of work. And it’s
this type of integrity, this kind of care
not to fool yourself, that is missing to a




3.1 Competition Binding Database
A total of 1,208 articles representing the σ literature covering the years 1981–2011 were identi-
fied as potential sources of competition binding data, which was confirmed for 564 articles. After
characterizing the nature of the competition binding assay methodology, it was possible to identify
the most prevalent combinations of hot ligands and masking agents as shown in Table 3.1. Further-
more, 7-OH-DPAT,7-OH-PIPAT, DTG or HAL (without a masking ligand), ifenprodil, NANM and
PPP are not suﬃciently target or subtype selective for the purposes of pharmacophore development.
We chose to collect structural and binding data for articles containing DTG with a masking agent
as σ-2 selective methodology or PTZ as a σ-1 selective ligand. In order to confidently combine
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Table 3.1: Breakdown of σ research articles providing competition binding data. The following hot
ligand/masking ligand combinations were only represented by a single article: 2-IPB, 4-IBP, 4-IPBS,
DuP734, I-benzamide, IPAB, IPEMP, ANSTO-14, clonidine, DTG/DuP734, DTG/AC915, DTG/car-
betapentane, DTG/DXM, FPS, HAL/l-sulpiride, HAL/spiroperidol/BIMU-8, IPIPAG,MS377, azido-
DTG, NANM/dizoclipine, NANM/etorphine, PB28/PTZ, PPP/DXL, progesterone, PTZ/Lu28-179,
SA4503, SN56, and SW120. Several of the hot ligands are now known to more eﬀectively target
other receptors.




















data from diﬀerent articles into sets of compounds for quantitative computational experiments, the
methodologies should be as practically identical as possible. To this end, the matrix used in the σ
assay is a very important consideration, so we further limited our investigations to those articles in
Table 3.2 which were most widely used for competition binding experiments. Of the combinations
investigated, σ-1 assays performed with PTZ on guinea pig brain tissue homogenates, and σ-2 assays
run with DTG using PTZ as a masking agent on rat liver homogenates, were found to represent
a suﬃcient number of active and inactive compounds for our computational requirements. The
curated datasets included 723 unique σ-2 ligands and 1,396 curated σ-1 ligands.
41
Table 3.2: Breakdown of assay methodology for selective σ competition binding experiments.
Hot ligand Masking ligand Organism Tissue No. articles
DTG DXL rat brain 3
DTG DXL rat liver 44
DTG NANM guinea pig brain 18
DTG NANM rat brain 5
DTG NANM rat liver 2
DTG PTZ guinea pig brain 33
DTG PTZ guinea pig brain plus cerebellum 1
DTG PTZ human MCF-7 ADR cells 3
DTG PTZ rat brain 32
DTG PTZ rat brain minus cerebellum 2
DTG PTZ rat liver 111
PTZ guinea pig brain 212
PTZ guinea pig brain minus cerebellum 17
PTZ guinea pig brain plus cerebellum 2
PTZ guinea pig clone in E. Coli 3
PTZ guinea pig clone in S. Cerevisiae 2
PTZ guinea pig liver 9
PTZ human MCF-7 cells 2
PTZ human brain 2
PTZ human jurkat cells 5
PTZ mouse brain 2
PTZ rat C6 cells 2
PTZ rat brain 55
PTZ rat brain minus cerebellum 7
PTZ rat liver 9
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3.2 Impact of Fingerprint Length
Fingerprints of various lengths were calculated using the options available in Canvas. A σ-2
rat liver/DTG data set (Table 3.3 and Figure 3.1) was processed with the following treatments:
no bit filtering, filtering out bits that are present in less than 5% of the conformers, or retaining
informative bits with fingerprint lengths of 256, 512, 1,024, 2,048, 4,096, 8,192, and 16,384 bits.
Table 3.3: Statistics of the initial σ-2 classificationmodel data set. The active and inactive compounds
were selected from the curated dataset containing 723 ligands, using p𝐾i cutoﬀs of 6.0 and 8.301
for inactive and active molecules, respectively.
No. of molecules
Training set Test Set
Active Inactive Active Inactive Total Total no. of conformers
14 22 6 12 54 5,634
To determine the extent to which SAP methodology improved the calculations, each treatment
was performed without SAP. SAP methodology was then used to determine a subset of significant
bits, as shown in Table 3.4. Initial experiments were conducted by holding out the fingerprints
from the test set, except in the case of unfiltered fingerprints. Unfiltered fingerprints could not be
treated to SAP because of excessive memory resource requirements. The ratio of retained bits to
informative/frequent bits following significance analysis decreases steadily from 95% down to 84%
when 8,192 ormore post-filtered bits are used. Retained bits alsomake up a very small percentage of
the pre-filtered bits, ranging from 0.03% up to 2.41%. Threshold cutoﬀs for removal of insignificant
bits tended to increase with increasing fingerprint length. Notably, repeated runs of SAP on the same
fingerprints tended to generate diﬀerent selections of significant bits as the fingerprint length rose
above 1,024 bits (data not shown). One likely explanation for this phenomenon is that the number
of random permutations of the data is fixed at 500, whereas the number of potential significant bits
rises with fingerprint length. If may therefore be possible to resolve a reproducible SAP fingerprint
by increasing the number of permutations if the computational cost is justifiable.
A similarity matrix using the Kulczynski metric was calculated for each treatment, and MILES
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Figure 3.1: Clustered σ-2 scaﬀold data. Molecules classified as inactive are in blue and active
molecules are colored orange; the remaining unclassifiedmolecules are in gray. Fifty-fourmolecules
(larger hexagons) were selected from this set for SAP and MILES performance analysis. Solid lines
connect molecules and scaﬀolds to their cores. A clustering cutoﬀ at a Euclidean distance of 10-12 is
indicated by dashed lines. The dotted lines demonstrate the connectivity between cores and nodes
in the dendrogram beyond the clustering cutoﬀ distance.
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was used to develop classification models. Confusion matrices, internal validation statistics, and
cross-validation statistics were used to characterize the impact of fingerprint length on the quality
of the final classification models. In order that cross-validation results remained matched across
treatments, the same selection of splitting replicates were used.
Table 3.4: Significance analysis parameters after Canvas filtering and SAP: the total number of bits











5% (19805) 16,794 3.108
aNumber of informative bits, or % bits
filtered by minimum frequency; bbits re-
maining after SAP; cselected threshold for
elimination of insignificant bits
As shown in Table 3.5, regardless of whether or not SAP was performed, there was no obvious
trend in 𝜆 parameter or the cross-validation prediction error. Internal accuracy of the non-SAP
models was 100% (except for the 256 bit fingerprint). External accuracy and MCC were adversely
aﬀected with every treatment compared to the unfiltered fingerprint. Filtering by SAP slightly
degraded internal accuracy, particularly at shorter fingerprint lengths. The external accuracy and
Matthews Correlation Coeﬃcient (MCC) measures were inconsistent, with no obvious trend to-
wards better performance with increasing fingerprint length. At 8,192 bits with SAP filtering, the
MILES classification performance was essentially identical to using raw fingerprints.
Confusion matrices and cross-validation statistics for the non- and SAP-filtered sets are pre-
sented in Tables 3.6 and 3.7, respectively. Classification of true negatives performed more poorly
than that of the unfiltered fingerprint for all of the informative bit fingerprints, whereas true positive
classification performed identically when the fingerprint length was set at 2,048 bits or longer. In
the case of the traditional SAP method, or with a pre-filtered 8,192 bit fingerprint, the classification
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Table 3.5: Tuning parameters and MILES results vary depending on the fingerprint length chosen
and the application of SAP.
Pre-filtering treatment 𝜆a PEb IAc EAd MCCe
no SAP treatment
256 8e-01 0.163 0.972 0.772 0.351
512 1e-05 0.150 1.000 0.611 0.088
1,024 2e-05 0.207 1.000 0.722 0.351
2,048 7e-06 0.191 1.000 0.611 0.236
4,096 5e-05 0.196 1.000 0.722 0.403
8,192 8e-06 0.156 1.000 0.722 0.403
16,384 2e-06 0.123 1.000 0.722 0.403
5% 7e-06 0.135 1.000 0.778 0.472
raw 2e-06 0.196 1.000 0.833 0.614
processed with SAP
256 1e02 0.144 0.944 0.667 0.316
512 1e02 0.137 0.917 0.667 0.25
1,024 9e01 0.209 0.944 0.778 0.5
2,048 1e02 0.226 0.944 0.611 0.161
4,096 1e02 0.254 0.944 0.667 0.316
8,192 9e-05 0.250 1.000 0.833 0.614
16,384 3e-02 0.252 1.000 0.778 0.472
5% 5e-05 0.265 1.000 0.833 0.614
aoptimal tuning parameter; bcross-validation prediction error; cinternal accuracy of prediction;
dexternal test set accuracy; eMatthews Correlation Coeﬃcient
performance was identical that of the unfiltered fingerprint. The use of SAP therefore allows the
use of far fewer bits to achieve MILES classification results comparable to those found with raw
fingerprints. Unfortunately there is no way to know in advance how many fingerprint bits to retain
in the pre-filtering step. Some caveats with this interpretation are that only the Kulczynski metric
was used in the MILES formulation for these experiments, and that the dataset was biased towards
more inactive compounds. In this case, at least, the bias can be resolved by selecting fewer inactives,
or by broadening the criteria for the inclusion of active compounds from the scaﬀold perception
step.
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Table 3.6: Confusion matrices of models at various fingerprint lengths without SAP filtering.
Unfiltered 5% Cutoﬀ 256 bits
Reference F T F T F T
Prediction F 11 2 11 3 10 3
T 1 4 1 3 2 3
512 bits 1,024 bits 2,048 bits
Reference F T F T F T
Prediction F 9 4 10 3 7 2
T 3 2 2 3 5 4
4,096 bits 8,192 bits 16,384 bits
Reference F T F T F T
Prediction F 9 2 9 2 9 2
T 3 4 3 4 3 4
Table 3.7: Confusion matrices at various fingerprint lengths in tandem with SAP filtering.
5% Cutoﬀ 256 bits
Reference F T F T
Prediction F 11 2 8 2
T 1 4 4 4
512 bits 1,024 bits 2,048 bits
Reference F T F T F T
Prediction F 9 3 10 2 8 3
T 3 3 2 4 4 3
4,096 bits 8,192 bits 16,384 bits
Reference F T F T F T
Prediction F 8 2 11 2 11 3
T 4 4 1 4 1 3
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3.3 Comparison of Similarity Metrics
Given the mixed results using the Kulczynski metric, several other metrics were investigated
in the MILES formulation. SAP-filtered fingerprints calculated previously using the 1,024 and
4,096 most informative bits were utilized in this approach. Similarity metrics were calculated using
those available in Canvas that do not explicitly include the shared number of bits turned “oﬀ”.
Thus cosine, Dice, McConnaughey, Petke, Simpson, Tanimoto, and Tversky metrics were used to
calculate similarity matrices for feature mapping. Internal validation accuracy, confusion matrices,
and external test set prediction statistics were used to characterize the impact of fingerprint metric,
as well as to investigate the impact of fingerprint length using these metrics.
As shown in Table 3.8, every similarity measure performed better than the original Kulcznski
metric in terms of internal accuracy. Interestingly, shorter fingerprint lengths were better or equiva-
lent to the unfiltered fingerprint at classification of the external test set with every metric except
McConnaughey and Simpson. Longer fingerprints led to poorer external classification results for
cosine, Petke, and Simpson metrics, but better results for the McConnaughey metric. The mean
cross-validation prediction error increased with the use of longer fingerprints. Matthews Corre-
lation Coeﬃcients indicate performance on par with the unfiltered fingerprints using the Cosine
and Petke metrics, and slightly better performance using Dice, Tanimoto, or Tversky metrics. The
Dice, Tanimoto, and Tversky metrics appear to perform very well and are less sensitive to changes
in fingerprint length.
3.4 Impact of training and test set size
Given the previous results, it was worthwhile to investigate the performance of SAP and MILES
with a more balanced dataset. A library of 130 molecules (Table 3.11 and Figure 3.2) was assembled
using all of the active ligands from every possible cluster, along with inactive molecules sampled
from the remaining clusters. In many projects, it is likely that there will be many more inactive
molecules than active ones. Additionally, there are some clusters which simply do not possess active
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Figure 3.2: Clustered σ-2 scaﬀold data for the balanced dataset. Visualization details are the same
as in Figure 3.1. One hundred and thirty molecules (larger hexagons) were selected from this set
for SAP and MILES performance analysis. All molecules classified as active were included from all
available clusters. Inactive compounds were added to roughly approximate the number of actives
by selecting poor aﬃnity ligands as evenly as possible, cluster by cluster.
49
Table 3.8: Stability of MILES performance utilizing alternative similarity metrics. Lower stability is
associated with denominators in the similarity calculations that involve products or minimum/max-
imum functions.
Pre-filtering treatment 𝜆a PEb IAc EAd MCCe
1,024 bit fingerprint
Cosine 2e-07 0.185 1.000 0.833 0.614
Dice 8e-04 0.169 1.000 0.889 0.756
McConnaughey 9e-06 0.313 1.000 0.611 0.161
Petke 9e-04 0.185 1.000 0.889 0.756
Simpson 1e02 0.263 1.000 0.778 0.5
Tanimoto 1e-04 0.185 1.000 0.889 0.756
Tversky 8e-04 0.169 1.000 0.889 0.756
4,096 bit fingerprint
Cosine 2e-03 0.209 1.000 0.778 0.5
Dice 4e-06 0.194 1.000 0.889 0.756
McConnaughey 2e-02 0.370 1.000 0.722 0.403
Petke 3e-03 0.219 1.000 0.833 0.632
Simpson 5e-03 0.287 1.000 0.556 0.
Tanimoto 4e-06 0.248 1.000 0.889 0.756
Tversky 4e-06 0.194 1.000 0.889 0.756
aoptimal tuning parameter; bcross-validation prediction error; cinternal accuracy of prediction;
dexternal test set accuracy; eMatthews Correlation Coeﬃcient
molecules, yet it is important that the pharmacophore information in these molecules is not lost. It
is noteworthy that some molecules, particularly flexible ones, will generate many more conformers
than other molecules, so while the number of compounds may be balanced, it is possible for the
number of conformers to remain unbalanced.
As part of this investigation, pharmacophore fingerprints from all molecules were utilized in
the significance analysis. This allows a less biased comparison to the performance of the metrics
with respect to raw fingerprints, since similarity metrics calculated with Canvas will use all available
bits. Experiments were run using raw fingerprints, or the 1,024 or 16,384 most informative bits.
A summary of the latter fingerprints is provided in Table 3.12. The Dice, Petke, Tanimoto, and
Tversky metrics were chosen because of their superior performance in the prior experiments.
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Table 3.9: Confusion matrices for diverse similarity metrics using 1,024–bit fingerprints in tandem
with SAP filtering. The McConnaughey metric performed notably poorer than all other metrics.
Cosine Dice Kulczynski
Reference F T F T F T
Prediction F 11 2 12 2 10 2
T 1 4 0 4 2 4
McConnaughey Petke Simpson
Reference F T F T F T
Prediction F 8 3 12 2 10 2
T 4 3 0 4 2 4
Tanimoto Tversky
Reference F T F T
Prediction F 12 2 12 2
T 0 4 0 4
Table 3.10: Confusion matrices for diverse similarity metrics using 4,096–bit fingerprints and SAP
filtering. With longer fingerprint lengths, the Kulczynski and McConnaughey metrics performed
better. The Simpson metric performed notably poorer at this length.
Cosine Dice Kulczynski
Reference F T F T F T
Prediction F 10 2 12 2 11 2
T 2 4 0 4 1 4
McConnaughey Petke Simpson
Reference F T F T F T
Prediction F 9 2 12 3 8 4
T 3 4 0 3 4 2
Tanimoto Tversky
Reference F T F T
Prediction F 12 2 12 2
T 0 4 0 4
51
Table 3.11: Statistics of the balanced σ-2 classification model data set.
No. of molecules
Training set Test Set
Active Inactive Active Inactive Total Total no. of conformers
43 44 21 22 130 8,576
Table 3.12: Significance analysis parameters after Canvas filtering and SAP with a more balanced






aNumber of informative bits; bbits re-
maining after SAP; cselected threshold for
elimination of insignificant bits
Table 3.13: Comparison of metric performance with a more balanced molecular library. Classi-
fication of the external dataset improved with larger training and test sets, but only with larger
fingerprints. SAP-filtered fingerprints at 16,384 bits were comparable to the performance with raw
fingerprints.
Pre-filtering treatment 𝜆a PEb IAc EAd MCCe
unfiltered fingerprint
Dice 1e-06 0.129 1.000 0.930 0.868
Petke 9e-07 0.138 1.000 0.884 0.774
Tanimoto 8e-07 0.181 1.000 0.884 0.788
Tversky 1e-06 0.129 1.000 0.930 0.868
1,024 bit fingerprint
Dice 3e-06 0.221 1.000 0.767 0.542
Petke 9e-07 0.138 1.000 0.884 0.774
Tanimoto 4e-05 0.211 1.000 0.791 0.612
Tversky 3e-06 0.221 1.000 0.767 0.542
16,384 bit fingerprint
Dice 9e-04 0.194 1.000 0.884 0.788
Petke 2e-06 0.188 1.000 0.884 0.788
Tanimoto 4e-06 0.182 1.000 0.907 0.828
Tversky 8e-04 0.194 1.000 0.884 0.788
aoptimal tuning parameter; bcross-validation prediction error; cinternal accuracy of prediction;
dexternal test set accuracy; eMatthews Correlation Coeﬃcient
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3.5 Development of σ-2 pharmacophore models and QSAR
Prototype conformers discovered in the “balanced” 16,384 bit experiment using Tanimoto
similarity metrics were taken through the Develop Pharmacophore Hypothesis workflow in Phase.
The heat map of active conformers indicates several clusters containing 3 distinct ligands. Matching
on 6 sites with a minimum of 3 ligands allowed for up to 3 hydrogen bond acceptor moieties,
and some of the most similar conformers had pairs of acceptors in close proximity, so the feature
frequency of acceptors was reduced to 1. After scoring, the complete linkage clustering method was
used to select representative pharmacophores with a minimum similarity of 0.9 based on survival
scores. Thirty-four hypotheses were retained and used for screening the complete conformer
database.
A Gaussian Field-based QSAR analysis was performed on the subsequent alignments. Two
compounds 3.4 were removed from each alignment, if present, as they consistently caused problems.
Compound 1 fromChoi et al. 95 would occasionally pass the volume filter of the database screen, but
was too large when assigned to the training set for the QSAR to run because points only associated
with this compound fell far away from all other training set compounds, requiring more PLS factors
than Phase was designed to accommodate. Compound 5 from Fontanilla et al. was always predicted
to have a much higher aﬃnity than observed by the original authors, at times up to 4 orders of
magnitude greater.
Statistical results from these calculations are presented in Table 3.14. Standard deviations of
regression were less than the average standard deviation of activity values under all circumstances,
which suggests that these models are not over-fit. Higher 𝑅2 and 𝑄2 statistics are preferred, as
long as the RMSE is not too much greater than the SD. High leave-one-out cross-validated 𝑅2 is
no guarantee of a predictive model, although an old rule of thumb is that a model is generally
only useful if 𝑅2 CV is at least 0.5.97 The Stability metric more precisely estimates the eﬀect of
removing molecules from the training set. In Phase, random subsets of 10% are left out and the
predictions (not the observed activities) are compared to the full model; the higher this value, the
less sensitive the model to changes in the training set. Very few of the resulting models show
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Figure 3.3: Sigma-2 prototype conformer heat map
Figure 3.4: Problem compounds for development of Gaussian QSAR from aligned datasets
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appreciable sensitivity when increasing the number of PLS factors. Scrambling of activity labels
should also not produce a coeﬃcient of determination comparable to 𝑅2, as that would indicate
that the model is no better than one generated at random. Pearson-𝑟 is a measure of the ability of
the model to predict the relative rank correctly in the external test set.
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Table 3.14: Sigma-2 pharmacophore hypotheses and related statistics for regressions of 1–3 PLS fac-
tors. Each hypothesis is label with the nature of the pharmacophore features (A = H-bond acceptor,
D = H-bond donor, H = hydrophobic, R = aromatic, N = negative ionizable, P = positive ionizable).
The number of database screening matches within the σ-2 database is shown in parentheses. A total
of 723 ligands representing the curated σ-2 data were screened.
No. Factors SDa 𝑅2b 𝑅2 CVc 𝑅2 Scrambled Stabilitye Ff Pg RMSEh 𝑄2i Pearson-rj
ADHHPR.15 (470)
1 0.8564 0.4186 0.2916 0.1568 0.971 167.1 3.82e-29 0.96 0.2381 0.5076
2 0.7584 0.5460 0.3484 0.2855 0.944 138.9 2.45e-40 0.91 0.3160 0.5809
3 0.6570 0.6608 0.3636 0.4169 0.879 149.3 9.98e-54 0.88 0.3484 0.6149
ADHHPR.17 (472)
1 0.8098 0.4337 0.3308 0.1207 0.983 178.5 1.33e-30 0.98 0.2110 0.4782
2 0.7284 0.5439 0.3846 0.2306 0.962 138.3 2.83e-40 0.94 0.2807 0.5409
3 0.6342 0.6557 0.4180 0.3365 0.908 146.7 3.23e-53 0.92 0.3010 0.5576
ADHHPR.28 (471)
1 0.8405 0.4074 0.2708 0.1333 0.971 160.2 2.75e-28 0.87 0.3334 0.5785
2 0.7271 0.5584 0.3541 0.2572 0.941 146.7 6.66e-42 0.84 0.3737 0.6131
3 0.6124 0.6881 0.3937 0.3486 0.872 169.9 3.68e-58 0.84 0.3819 0.6248
ADHHPR.3 (485)
1 0.8033 0.4425 0.3035 0.1265 0.969 191.3 2.05e-32 0.91 0.2355 0.5100
2 0.7120 0.5639 0.3709 0.2309 0.949 155.1 5.68e-44 0.87 0.3012 0.5732
3 0.6227 0.6678 0.4260 0.3391 0.909 160.1 6.51e-57 0.84 0.3575 0.6055
ADHHPR.39 (483)
1 0.7866 0.4560 0.3574 0.1346 0.983 200.3 1.94e-33 0.87 0.2942 0.5509
2 0.6899 0.5833 0.4188 0.2671 0.96 166.6 5.77e-46 0.83 0.3590 0.6158
3 0.6093 0.6764 0.4312 0.3741 0.909 165.1 8.89e-58 0.81 0.3835 0.6356
ADHHPR.43 (509)
1 0.8055 0.4300 0.3095 0.1276 0.979 190.1 1.33e-32 0.89 0.2983 0.5477
2 0.6872 0.5868 0.3740 0.2553 0.94 178.2 6.78e-49 0.93 0.2409 0.5140
3 0.6081 0.6777 0.4157 0.3623 0.896 175.3 3.49e-61 0.92 0.2605 0.5363
ADHHPR.57 (482)
1 0.7906 0.4654 0.3419 0.1351 0.976 208.1 2.35e-34 0.88 0.3031 0.5721
2 0.6836 0.6020 0.3891 0.2575 0.938 180.0 2.41e-48 0.81 0.4080 0.6483
3 0.6100 0.6844 0.3729 0.3630 0.863 171.3 4.48e-59 0.82 0.3893 0.6395
ADHHPR.83 (555)
1 0.8241 0.4213 0.3240 0.1268 0.985 200.9 1.21e-34 0.88 0.3026 0.5531
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2 0.7482 0.5247 0.3578 0.2477 0.964 151.8 3.83e-45 0.86 0.3253 0.5785
3 0.6656 0.6252 0.3567 0.3436 0.903 152.4 4.21e-58 0.80 0.4181 0.6492
ADHHPR.87 (490)
1 0.7962 0.4861 0.3848 0.1306 0.983 229.8 5.45e-37 0.86 0.3519 0.5958
2 0.6884 0.6174 0.4596 0.2716 0.962 195.2 3.26e-51 0.76 0.4979 0.7060
3 0.6085 0.7023 0.4735 0.3702 0.925 189.5 4.07e-63 0.76 0.5058 0.7126
ADHPRR.30 (483)
1 0.8250 0.3970 0.2357 0.1570 0.961 158.0 3.56e-28 0.97 0.1038 0.4020
2 0.7062 0.5601 0.3278 0.2785 0.925 152.1 2.43e-43 0.92 0.2054 0.4853
3 0.6346 0.6462 0.3239 0.3638 0.866 144.9 2.01e-53 0.88 0.2735 0.5474
ADHPRR.34 (469)
1 0.8177 0.4255 0.3110 0.1264 0.979 172.6 7.21e-30 0.90 0.2531 0.5136
2 0.7206 0.5557 0.3631 0.2715 0.948 145.1 1.34e-41 0.85 0.3470 0.5995
3 0.6277 0.6644 0.3867 0.3716 0.887 152.4 1.71e-54 0.83 0.3677 0.6229
ADHPRR.36 (485)
1 0.8527 0.3627 0.2797 0.1378 0.988 140.0 7.18e-26 0.96 0.1851 0.4455
2 0.7131 0.5561 0.4011 0.2385 0.965 153.5 6.22e-44 0.90 0.2767 0.5458
3 0.6237 0.6619 0.4524 0.3412 0.936 159.2 3.62e-57 0.86 0.3342 0.5881
ADHPRR.38 (494)
1 0.8519 0.3378 0.2691 0.1345 0.991 124.4 1.27e-23 0.92 0.2700 0.5197
2 0.6968 0.5587 0.4061 0.2333 0.957 153.8 6.85e-44 0.90 0.2938 0.5583
3 0.5909 0.6840 0.4550 0.3385 0.911 174.6 3.02e-60 0.89 0.3088 0.5789
ADHPRR.40 (499)
1 0.8094 0.4487 0.3511 0.1398 0.983 201.0 8.73e-34 0.93 0.2372 0.5107
2 0.7405 0.5404 0.3925 0.2712 0.97 144.6 2.96e-42 0.92 0.2562 0.5250
3 0.6506 0.6467 0.3703 0.3711 0.903 149.5 4.49e-55 0.89 0.2999 0.5654
ADHPRR.41 (506)
1 0.8684 0.3677 0.2640 0.1164 0.98 146.0 8.51e-27 0.93 0.2383 0.4939
2 0.7713 0.5032 0.3323 0.2436 0.958 126.6 1.05e-38 0.90 0.2854 0.5438
3 0.6787 0.6169 0.3573 0.3404 0.911 133.6 1.33e-51 0.87 0.3373 0.5850
AHHHPR.109 (485)
1 0.8807 0.3760 0.2821 0.1540 0.984 144.6 2.22e-26 0.93 0.2702 0.5201
2 0.7654 0.5306 0.3470 0.2704 0.951 135.1 5.63e-40 0.91 0.3036 0.5559
3 0.6580 0.6545 0.3831 0.3686 0.895 150.3 1.18e-54 0.83 0.4205 0.6485
AHHHPR.111 (482)
1 0.8684 0.3986 0.3088 0.1335 0.986 158.4 3.31e-28 0.94 0.2609 0.5198
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2 0.7702 0.5289 0.3619 0.2694 0.961 133.6 1.26e-39 0.91 0.3132 0.5752
3 0.6472 0.6687 0.4091 0.3602 0.901 159.5 1.4e-56 0.85 0.3924 0.6441
AHHHPR.113 (574)
1 0.8764 0.3373 0.2245 0.1272 0.98 145.1 2.78e-27 0.96 0.1525 0.4349
2 0.7838 0.4717 0.3109 0.2363 0.963 126.8 4.45e-40 0.94 0.1936 0.4903
3 0.6485 0.6396 0.3853 0.3530 0.909 167.4 2.07e-62 0.88 0.3008 0.5741
AHHHPR.114 (575)
1 0.8061 0.4241 0.2603 0.1274 0.96 210.6 3.9e-36 0.87 0.3084 0.5633
2 0.7414 0.5146 0.3224 0.2276 0.951 151.1 1.86e-45 0.85 0.3264 0.5778
3 0.6687 0.6065 0.3603 0.3276 0.923 145.9 3.25e-57 0.81 0.3891 0.6305
AHHHPR.46 (546)
1 0.8127 0.4173 0.2958 0.1397 0.977 193.3 1.63e-33 0.89 0.2708 0.5285
2 0.6899 0.5816 0.3799 0.2482 0.945 187.0 1.27e-51 0.82 0.3821 0.6269
3 0.5596 0.7258 0.4567 0.3516 0.883 236.5 5.6e-75 0.84 0.3485 0.6236
AHHHPR.51 (538)
1 0.8486 0.3625 0.2867 0.1268 0.99 151.2 8.07e-28 0.95 0.2298 0.4843
2 0.7565 0.4952 0.3078 0.2515 0.951 130.0 4.62e-40 0.95 0.2235 0.4880
3 0.6589 0.6185 0.3396 0.3372 0.884 142.6 5.95e-55 0.93 0.2706 0.5391
AHHHPR.53 (571)
1 0.8344 0.3880 0.2941 0.1206 0.987 179.4 5.07e-32 0.91 0.2397 0.5051
2 0.7453 0.5135 0.3628 0.2205 0.969 148.8 7.61e-45 0.90 0.2663 0.5447
3 0.6105 0.6747 0.4098 0.3182 0.895 194.3 3.33e-68 0.87 0.3030 0.5836
AHHHPR.90 (584)
1 0.8362 0.3927 0.3097 0.1301 0.989 186.9 3.72e-33 0.97 0.2044 0.4688
2 0.7405 0.5254 0.3587 0.2499 0.964 159.4 2.45e-47 0.92 0.2883 0.5492
3 0.6531 0.6321 0.3793 0.3546 0.912 164.4 5.15e-62 0.91 0.3010 0.5746
AHHPRR.48 (588)
1 0.7977 0.4207 0.3186 0.1338 0.98 211.4 2.26e-36 0.96 0.1798 0.4468
2 0.7291 0.5178 0.3739 0.2216 0.967 155.7 1.17e-46 0.94 0.2261 0.4890
3 0.6018 0.6726 0.4553 0.3286 0.927 197.9 9.5e-70 0.87 0.3275 0.5808
AHHPRR.49 (584)
1 0.8112 0.3999 0.2979 0.1074 0.983 192.6 6.64e-34 0.93 0.2246 0.4829
2 0.7324 0.5125 0.3743 0.2069 0.972 151.4 1.18e-45 0.93 0.2312 0.5031
3 0.6483 0.6193 0.4111 0.3108 0.942 155.6 6.94e-60 0.91 0.2628 0.5358
AHHPRR.50 (579)
1 0.8690 0.3173 0.2414 0.1330 0.99 133.4 1.36e-25 1.02 0.0990 0.3498
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2 0.7513 0.4915 0.3575 0.2337 0.972 138.2 9.87e-43 0.95 0.2168 0.4783
3 0.6119 0.6638 0.4187 0.3286 0.911 187.6 3.8e-67 0.93 0.2439 0.5172
AHHPRR.54 (618)
1 0.9070 0.2783 0.2250 0.1168 0.995 118.0 1.82e-23 0.93 0.2711 0.5214
2 0.7586 0.4968 0.3613 0.2134 0.974 150.5 3.31e-46 0.85 0.3804 0.6172
3 0.6252 0.6592 0.4302 0.3069 0.924 196.0 9.66e-71 0.79 0.4642 0.6818
AHHPRR.55 (623)
1 0.9338 0.2729 0.2197 0.1073 0.995 116.3 3.05e-23 0.97 0.1672 0.4226
2 0.7792 0.4954 0.3601 0.2035 0.972 151.7 1.28e-46 0.94 0.2209 0.5057
3 0.6848 0.6115 0.3724 0.3144 0.929 161.6 6.52e-63 0.91 0.2657 0.5515
AHHPRR.61 (414)
1 0.8200 0.4307 0.3573 0.1587 0.991 155.1 7.08e-27 1.02 0.0551 0.3543
2 0.6735 0.6178 0.4198 0.2760 0.94 164.8 2.5e-43 0.98 0.1263 0.4496
3 0.5777 0.7202 0.4620 0.3813 0.89 174.1 7.05e-56 0.98 0.1208 0.4656
AHHPRR.62 (411)
1 0.7923 0.4314 0.3427 0.1304 0.987 154.0 1.09e-26 0.92 0.2729 0.5237
2 0.6740 0.5906 0.4379 0.2531 0.967 145.7 6.76e-40 0.91 0.2914 0.5427
3 0.6138 0.6621 0.4400 0.3653 0.938 131.3 4.02e-47 0.89 0.3253 0.5723
AHHPRR.63 (406)
1 0.8221 0.3896 0.2747 0.1600 0.979 127.7 3.26e-23 0.91 0.2838 0.5344
2 0.7077 0.5500 0.3558 0.2834 0.948 121.6 3.1e-35 0.88 0.3295 0.5788
3 0.5995 0.6787 0.3835 0.3854 0.888 139.4 1.43e-48 0.87 0.3442 0.6088
HHHPRR.4 (559)
1 0.8985 0.2975 0.2088 0.1162 0.987 117.8 4.16e-23 0.98 0.1176 0.3704
2 0.7198 0.5508 0.3758 0.2340 0.954 169.8 7.24e-49 0.90 0.2626 0.5267
3 0.6119 0.6766 0.4459 0.3547 0.919 192.4 2.46e-67 0.87 0.3173 0.5746
HHHPRR.5 (562)
1 0.9323 0.2411 0.1670 0.1360 0.99 88.3 2.15e-18 0.97 0.1366 0.3781
2 0.7843 0.4649 0.2634 0.2576 0.946 120.3 2.46e-38 0.88 0.2836 0.5347
3 0.6650 0.6166 0.2712 0.3687 0.862 148.0 3.66e-57 0.83 0.3629 0.6087
HHHPRR.6 (561)
1 0.8535 0.3443 0.2547 0.1175 0.987 146.0 2.7e-27 0.97 0.1534 0.4115
2 0.7553 0.4883 0.3412 0.2285 0.971 132.2 4.95e-41 0.99 0.1137 0.3932
3 0.6312 0.6440 0.3795 0.3440 0.905 166.4 1.34e-61 0.96 0.1787 0.4606
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astandard deviation of the regression; bcoeﬃcient of determination; cleave-one-out cross-validated coeﬃcient of regression; dcoeﬃcient
of determination using scrambled activity data; estability of the model to changes in training set composition; f ratio of model variance to
activity variance; gsignificance level of F; hRoot-Mean-Square Error in test set predictions; icoeﬃcient of determination for the external
test set, jcorrelation between predicted and observed external test set activity.
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Figure 3.5: Sigma-2 training and test set regressions for the 3PLS-factor QSAR model.
Based on the battery of statistics, QSAR model ADHHPR.87 comprising either 2- or 3-PLS
factors performed significantly better than the remainingmodels. Plots of the regression for training
and tests sets are provided in Figure 3.5. This pharmacophore corresponded to a conformer of a
molecule developed byMach et al. (see Figure 3.6).98 ThePearson-𝑟 of the 3-PLS factor QSARmodel
indicates modest relative accuracy, and the remaining statistics are acceptable. Virtual screening
of the curated dataset spiked with known inactives and the set of 1,000 drug-like decoys led to a
recovery of 57.6% of known active compounds. Receiver-operator characteristic and performance
as percentage of the database screened are provided in Figure 3.7. After ranking based on the QSAR,
enrichment factors EF1, EF*1, and EF′1 were determined to be 2.6, 42, and 65, respectively. The
latter two measures indicate a robust early enrichment despite the inability to recover all known
actives.
Field fractions from the 2- and 3-PLS regressions (Figure 3.15) indicate a considerable amount
of steric (bulk) and hydrophobic (grease) contributions to the QSAR, followed by hydrogen bond
acceptor contributions. Electronic and hydrogen bond donor contributions were minimal.
Visualization of the Gaussian fields superimposed on the pharmacophore and representative
ligand are provided in Figures 3.8–3.12. Positive steric eﬀects are indicated at the hydrophobic and
ring aromatic sites on the east and west ends of the ligand, respectively. The impact of negative
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Table 3.15: Gaussian field fractions of hypothesis ADHHPR.87
No. Factors Steric Electrostatic Hydrophobic Hbond Acceptor Hbond Donor
1 0.407 0.054 0.314 0.177 0.047
2 0.390 0.069 0.306 0.168 0.068
3 0.328 0.081 0.309 0.190 0.091
steric contributions is negligible. An interesting combination of negative and positive electrostatic
contributions demonstrates unfavorable interactions with positive partial charge surrounding the
aromatic ring and continuing towards the the linker oxygen presented by the carbamate. Another
unfavorable electrostatic positive partial charge field is present over the tertiary amine. Favorable
positive electrostatics extend over the top of the aromatic ring and through the carbonyl of the
carbamate and around the amine in a snake-like manner. Positive hydrophobic contours are present
throughout themajority of the scaﬀold with the exception of the tertiary amine, and a small portions
of the chain at the east end. Positive hydrogen bond acceptor projected point fields are expressed at
the back of the aromatic ring and nestled between the amide and ester linkages of the carbamate,
whereas negative contributions are made around the carbonyl and at the east end in the linker chain
near the amine. Hydrogen bond donor projected point fields have an almost exclusively negative
impact on theQSARmodelwith the exception of the back side of the 9-azabicyclo[3.3.1]nonan-3α-yl
moiety.
Additional visualizations of the best alignment of one of our laboratory’s active and nonselective
benzo[d]thiazol-2(3H)ones99 is provided for context of how this particular QSAR model could be
used for ligand-based drug development. Due to the bent alignment, this particular conformation
of RB8 is well superimposed on the positive steric and hydrophobic fields. The thiazolone moiety
is also well situated within the positive electrostatic region, whereas the tertiary amine is located
within the negative electrostatic region. This agrees with the relative partial charges assigned by the
OPLS_2005 force field. The thiazolone carbonyl nestles a region of slightly negative hydrogen bond
acceptor contours, yet the second, and particularly third carbon down the linker from the thiazolone
seem particularly suited for replacement with an acceptor moiety. While RB8, aligned in this way
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does not suﬀer from the negative hydrogen bond donor fields, one hypothetical improvement to
σ-2 aﬃnity would to be to place a donor at the pro-S hydrogen 2 carbons away from the amine on
the internal linker.
3.5.1 Development of σ-1 pharmacophore models and QSAR
The σ-1 database of 1396 compounds was treated to the same workflow as described for σ-2
ligands. A subset of active and inactive compounds (Table 3.16 and Figure 3.18) was selected using
up to 3 active compounds from each cluster along with suﬃcient inactives (3 or more) to balance
the classification set. SAP was performed using 16,384 informative fingerprints bits. The Δ cutoﬀ
Table 3.16: Statistics of the balanced σ-1 classification model data set.
No. of molecules
Training set Test Set
Active Inactive Active Inactive Total Total no. of conformers
39 44 19 22 124 10,409
was determined to be 0.761, resulting in a fingerprint length of 13,334. The Tanimoto metric was
used to generate a fingerprint matrix from this file for instance-based feature mapping. An optimal
λ tuning parameter of 0.006, corresponding to a prediction error of 0.224 was used to train the
SVM. An internal accuracy of 1 was found, with external accuracy and an MCC of 0.732 and 0.460,
respectively. In total, 52 prototype conformers were found, comprising 30 active and 22 inactive
conformers.
These conformers were taken through the develop common pharmacophore process, using
feature definitions including the piperidine and piperazinemoieties. Amaximumof 6 sitesmatching
a minimum of three ligands, based on the heat map (Figure 3.19), produced 4 representative
common pharmacophores which were used to screen the entire database of σ-1 conformers.
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Figure 3.6: Prototype ligand for the pharmacophore alignment ADHHPR.87
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Figure 3.7: Sigma-2 virtual screening performance. Receiver-operator characteristic and screening
performance as percentage of the database screened. The 45∘ line corresponds to the expected
performance if the screening were no better than random.
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Figure 3.8: Gaussian steric fields presented by QSAR of ADHHPR.87. Positive steric field contours
are shown in dark green. Negative contours are shown in yellow.
Figure 3.9: Gaussian electrostatic fields presented by QSAR of ADHHPR.87. Positive electrostatic
field contours are shown in blue. Negative contours are shown in red.
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Figure 3.10: Gaussian hydrophobic fields presented byQSARofADHHPR.87. Positive hydrophobic
field contours are shown in yellow. Negative contours are shown in white.
Figure 3.11: Gaussian hydrogen bond acceptor fields presented by QSAR of ADHHPR.87. Positive
H-bond acceptor field contours are shown in red. Negative contours are shown in magenta.
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Figure 3.12: Gaussian hydrogen bond donor fields presented by QSAR of ADHHPR.87. Positive
H-bond donor field contours are shown in blue-violet. Negative contours are shown in cyan.
Figure 3.13: Positive steric field contours are shown in dark green. Negative contours are shown in
yellow.
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Figure 3.14: Positive electrostatic field contours are shown in blue. Negative contours are shown in
red.
Figure 3.15: Positive hydrophobic field contours are shown in yellow. Negative contours are shown
in white.
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Figure 3.16: Positive H-bond acceptor field contours are shown in red. Negative contours are shown
in magenta.
Figure 3.17: Positive H-bond donor field contours are shown in blue-violet. Negative contours are
shown in cyan.
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Figure 3.18: Clustered σ-2 scaﬀold data for the balanced dataset. Visualization details are the same
as in Figure 3.1. One hundred and thirty molecules (larger hexagons) were selected from this set
for SAP and MILES performance analysis.
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Figure 3.19: Sigma-1 prototype conformer heat map
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Table 3.17: Sigma-1 pharmacophore hypotheses and related statistics for regressions of 1–3 PLS fac-
tors. Each hypothesis is label with the nature of the pharmacophore features (A = H-bond acceptor,
D = H-bond donor, H = hydrophobic, R = aromatic, N = negative ionizable, P = positive ionizable).
The number of database screening matches within the σ-1 database is shown in parentheses. A total
of 1396 ligands representing the curated σ-1 data were screened.
No. Factors SDa 𝑅2b 𝑅2 CVc 𝑅2 Scrambled Stabilitye Ff Pg RMSEh 𝑄2i Pearson-rj
AAHHPR.12 (758)
1 1.0369 0.3573 0.2807 0.1096 0.988 209.6 4.37e-38 1.13 0.2357 0.4949
2 0.8772 0.5412 0.4082 0.2175 0.97 221.8 2.41e-64 1.08 0.3065 0.5672
3 0.7703 0.6472 0.4555 0.3127 0.942 229.3 1.84e-84 1.01 0.3876 0.6298
AAHHPR.16 (680)
1 0.9336 0.4356 0.3491 0.1246 0.984 250.9 2.83e-42 1.10 0.2056 0.4692
2 0.8293 0.5561 0.4319 0.2421 0.974 202.9 7.38e-58 1.06 0.2622 0.5262
3 0.7484 0.6396 0.4404 0.3456 0.943 191.1 3.04e-71 1.02 0.3124 0.5715
AAHHPR.4 (795)
1 0.9810 0.3996 0.3106 0.1081 0.986 255.5 1.87e-44 1.09 0.2405 0.5036
2 0.8617 0.5379 0.4003 0.2185 0.972 222.9 6.23e-65 1.00 0.3620 0.6080
3 0.7738 0.6283 0.4467 0.2978 0.951 215.2 1e-81 1.01 0.3439 0.6015
AAHHPR.8 (757)
1 1.0347 0.3422 0.2501 0.1087 0.982 196.1 3.6e-36 1.12 0.2246 0.4897
2 0.9197 0.4817 0.3326 0.2367 0.964 174.7 2.21e-54 1.08 0.2777 0.5506
3 0.8125 0.5965 0.3842 0.3171 0.928 184.8 1.51e-73 1.01 0.3654 0.6178
astandard deviation of the regression; bcoeﬃcient of determination; cleave-one-out cross-validated coeﬃcient of regression; dcoeﬃcient
of determination using scrambled activity data; estability of the model to changes in training set composition; f ratio of model variance to
activity variance; gsignificance level of F; hRoot-Mean-Square Error in test set predictions; icoeﬃcient of determination for the external
test set, jcorrelation between predicted and observed external test set activity.
Gaussian field-based QSARs were developed for alignments to all hypotheses, and statistics for
the chosen 3 PLS-factor model are given in Table 3.17. Plots of the regression for training and tests
sets are provided in Figure 3.20.
Hypothesis AAHHPR.12 performed slightly better than the remaining hypotheses, all of which
shared the same number of features. The Gaussian field fractions (Table 3.18), much like those of
the the σ-2 QSAR, indicate a high level of steric, hydrophobic character, although the hydrogen
bond field fraction is noticeably more predominant. Virtual screening of the curated dataset spiked
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Figure 3.20: Sigma-1 training and test set regressions for the 3PLS-factor QSAR model.
with known inactives and the set of 1,000 drug-like decoys led to a recovery of 54.4% of known
active compounds. After ranking based on the QSAR, enrichment factors EF1, EF*1, and EF′1
were determined to be 1.8, 12, and 23, respectively. The latter two measures indicate a robust early
enrichment despite the inability to recover all known actives. Receiver-operator characteristic and
performance as percentage of the database screened are provided in Figure 3.21.
Table 3.18: Gaussian field fractions of hypothesis AAHHPR.12
No. Factors Steric Electrostatic Hydrophobic Hbond Acceptor Hbond Donor
1 0.399 0.042 0.229 0.252 0.079
2 0.401 0.045 0.276 0.208 0.069
3 0.377 0.054 0.265 0.215 0.090
Visualization of the Gaussian fields superimposed on the pharmacophore and representative
ligand are provided in Figures 3.23–3.27. Interestingly, although the feature types of the underlying
pharmacophore are very similar to the σ-2 pharmacophore, there are some important diﬀerences
in the Gaussian fields. Sterically, the only favorable interaction is located very near to the positive
ionizable feature. The remaining steric interactions form a pocket around the reference ligand of
Hudkins et al. 51 (see Figure 3.22). Again, negative electrostatics are favored around the positive
ionizable feature. Hydrophobic features extend through much of the scaﬀold except for the location
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Figure 3.21: Sigma-1 virtual screening performance. Receiver-operator characteristic and screening
performance as percentage of the database screened.
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of the positive ionizable feature and the ring aromatic at the west end. Acceptor fields are favored
near the ester oxygens, in the same areas which are disfavored sterically. Donor contours show a
strong unfavorable interaction on the west end in the vicinity of the ring aromatic pharmacophore
site.
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Figure 3.22: Prototype ligand for the pharmacophore alignment AAHHPR.12
Figure 3.23: Gaussian steric fields presented by QSAR of AAHHPR.12. Positive steric field contours
are shown in dark green. Negative contours are shown in yellow.
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Figure 3.24: Gaussian electrostatic fields presented by QSAR of AAHHPR.12. Positive electrostatic
field contours are shown in blue. Negative contours are shown in red.
Figure 3.25: Gaussian hydrophobic fields presented byQSARofAAHHPR.12. Positive hydrophobic
field contours are shown in yellow. Negative contours are shown in white.
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Figure 3.26: Gaussian hydrogen bond acceptor fields presented by QSAR of AAHHPR.12. Positive
H-bond acceptor field contours are shown in red. Negative contours are shown in magenta.
Figure 3.27: Gaussian hydrogen bond donor fields presented by QSAR of AAHHPR.12. Positive
H-bond donor field contours are shown in blue-violet. Negative contours are shown in cyan.
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4. CONCLUSIONS AND FUTUREWORK





Computational techniques for ligand-based drug design based on pharmacophore modeling,
virtual screening, and QSARs have met with many challenges over the years when applied to σ
receptor targets. One of the major hurdles, having a database of the extensive number of ligands
presented in the literature since σ research began, will undoubtably help to overcome the cause of
many inconsistencies in computational analyses, namely, data heterogeneity. Curated set of σ data,
based on𝐾i values, and using comparable analytical methods is now available.
Clustering of the datasets by scaﬀold allowed for a sensible way of generating diverse training
and test sets of active and inactive compounds in an eﬃcient manner. This technique, pioneered by
Guiguemde et al. 76 has the advantage of hierarchically assembling a dendrogram of structures by
related scaﬀold, and provides an intuitive way of visualizing properties associated with structural
changes at the core of a database of ligands.
The modeling approach described here has met with a modicum of success, particularly for
σ-2 classification techniques. Pharmacophore fingerprints performed very well when used for
the classification of active and inactive compounds through the Multiple-instance learning via
embedded subset selection protocol. Significance Analysis of Pharmacophores has the potential to
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allow for a greatly reduced fingerprint bit length, although care must be taken to pick an appropriate
metric, whether it be a distance or similarity measure. In particular, implementing MILES with
measures which use products of bits from each instance or that use a maximum or minimum
similarity are problematic if SAP has been utilized to reduce the fingerprint length. While the
pharmacophore features which lead to better SAP classification accuracy can readily be calculated
at some computational expense, the original implementation was designed for microarray data.
The number of wells in a microarray is much smaller than the number of instances in a SAP analysis,
and the SAMmethod which SAP is based upon uses the Γ function for permutation analysis. As
the number of instances grows, this function causes an overflow and triggers an error, calling some
question into the validity of the statistical analysis.
Aggressive reduction in fingerprint length tends to reduce classification accuracy, particularly
with larger numbers of instances. A cursory analysis of the results of this research suggests that
no fewer “informative bits” are used than the total number of conformers. The elimination of bits
with a frequency of less than 5%, as implemented by Fu et al. 82 produced slightly more bits than
the levels we investigated. This may partially explain the comparable classification performance
with the 54-molecule dataset used at higher fingerprint lengths.
An issue with purely ligand-based design projects is how to identify active conformers of lig-
ands for pharmacophore development, shape-screening, virtual screening, and other methods that
depend on good knowledge of the 3D coordinates of active molecules at the biomolecular target.
In preliminary experiments using a complete set of conformers, the number of pharmacophores
surviving the common pharmacophore perception step was overwhelming, and model assessment
at this point was unjustifiable. The MILES method, as implemented here, provided a set of proto-
type conformers that was useful in reducing the overhead of pharmacophore generation with very
flexible molecules. Consequentially, number of common pharmacophores generated incorporating
theMILES approach was orders of magnitude smaller than when using a complete set of conformers.
Virtual screening of with the surviving pharmacophore hypotheses allowed for the retrieval of much
of the original datasets, indicating a general utility for screening σ-like molecules. Quantitative
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structure-activity relationships built upon the aligned hits provided provided virtual screening
rankings that retrieved over 50% of the known actives for both σ-1 and σ-2 targets. While this level
of performance is not ideal, it does suggest that multiple binding modes or binding sites are present
on both receptors. It may be possible to eliminate the retrieved actives from the pharmacophore
modeling process and build new models which capture the pharmacophore features of these alter-
nate binding sites. These pharmacophore models and their related QSARs will be useful tools for
further virtual screening projects targeted at discovering more diverse scaﬀolds from which to build
upon.
4.2 Future Work
Identification of alternative pharmacophore models based on the set of ligands not retrieved
with the current pharmacophore models is needed for a comprehensive description of the σ binding
motifs. As it stands, the virtual screening performance is suitable for screening a large database of
commercially available compounds. Careful consideration of the hits retrieved in such a screen
will be useful for identifying more diverse scaﬀolds for the exploration of σ site probes. Small
modifications of the procedures used in this work will also be useful for developing selectivity-
rather than aﬃnity-based models. It will also be interesting to expand this work to identify binding
requirements of agonists versus antagonists, although the existing literature is sometimes vague or
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APPENDIX A. HIERARCHICAL CLUSTERING SCRIPTS
The following directory listings, Makefile, and python files implement hierarchical clustering.
Prerequisites for this process are Canvas, Strip-It, Python, and Make. A SMILES input file named
SMILES.smi which contains only unique structures is required. An output file cytoscape.net
that contains the requisite network table data for visualization with Cytoscape is generated by the
Makefile.
A.1 hcviz directory listing
xibalba:hcviz dewatson$ ls -lR
total 8
-rw-r--r-- 1 dewatson staff 1567 Jun 22 15:25 Makefile
drwxr-xr-x 6 dewatson staff 204 Sep 12 19:47 bin
drwxr-xr-x 4 dewatson staff 136 Jun 22 14:15 lib
./bin:
total 32
-rwxr-xr-x 1 dewatson staff 1378 Jun 22 13:04 network_cores.py
-rwxr-xr-x 1 dewatson staff 1341 Jun 22 13:52 network_linkage.py
-rwxr-xr-x 1 dewatson staff 1826 Jun 22 14:43 network_scaffolds.py
-rwxr-xr-x 1 dewatson staff 1414 Jun 22 13:04 singletons.py
./lib:
total 16
-rw-r--r-- 1 dewatson staff 9 Jun 22 13:02 MURCKO1.def





# Driver to control the processing of molecular SMILES into
# a complete edge network
#
# author David Watson
# email dewatson@icloud.com
# copyright Copyright (c) 2013, David Watson
##
all: stripit canvas network
stripit:
@echo Running Strip-It and creating scaffold files
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strip-it --input SMILES.smi --output RWL2.strip \
--scaffolds ./lib/RWL2.def
grep -v -e ”-$$” RWL2.strip > RWL2.scaf
awk ’{ print $$3 ” ” $$3 }’ RWL2.scaf | grep -v ”RINGS” | \
sort -u > MURCKO1.smi
strip-it --input MURCKO1.smi --output MURCKO1.scaf \
--scaffolds ./lib/MURCKO1.def
awk ’{ print $$3 ” ” $$3 }’ MURCKO1.scaf | grep -v ”MURCKO” | \
sort -u > RADIAL.smi
network:
./bin/network_scaffolds.py -i RWL2.scaf -o radial.net
strip-it --input singletons.smi --output singletons.scaf \
--scaffolds ./lib/MURCKO1.def
./bin/network_cores.py -i MURCKO1.scaf -o radial.net
./bin/network_linkage.py -i radial.tree -o radial.net
./bin/singletons.py -i singletons.scaf -o radial.net
sed ’s/\[/\\[/g’ singletons.sed | sed ’s/\]/\\]/g’ > singletons.grep
grep -v -f singletons.grep radial.net > cytoscape.net
canvas:
$$SCHRODINGER/utilities/canvasFPGen -ismi RADIAL.smi -o radial.fp \
-fptype radial -nostereo
$$SCHRODINGER/utilities/canvasFPMatrix -ifp radial.fp \
-ocsv radial.csv -metric euclidean
$$SCHRODINGER/utilities/canvasHC -im radial.csv -linkage mcquitty \
-ot radial.tree -kelley
mostly-clean: stripit-clean network-clean canvas-clean
stripit-clean:
-rm -f RWL2.strip RWL2.scaf MURCKO1.smi MURCKO1.scaf RADIAL.smi
network-clean:
-rm -f radial.net singletons.smi singletons.sed singletons.scaf \
singletons.grep
canvas-clean:








Creates network core node entries based on a Strip-it scaffold file
author David Watson
email dewatson@icloud.com




parser = argparse.ArgumentParser(description =
’Create a hierarchy of RWL2_Murcko1 interactions from a murko_1 strip-it’ \
’ file.’)
parser.add_argument(’-i’, metavar = ’infile’, type = argparse.FileType(’r’),
help = ’Strip-It murcko1 file’, required = True,
dest = ’murcko’)
parser.add_argument(’-o’, metavar = ’outfile’, type = argparse.FileType(’a’),










sys.exit(’Strip-it file appears empty’)
if not stripped.startswith(’NAME’):













for smiles in murcko.keys():
for molecule in range(0, len(murcko[smiles]), 1):






Converts a Canvas dendrogram to a Cytoscape edge network
author David Watson
email dewatson@icloud.com




parser = argparse.ArgumentParser(description =
’Create dendrogram leaf-node and node-node linkages from a Canvas tree ’ \
’file.’)
parser.add_argument(’-i’, metavar = ’infile’, type = argparse.FileType(’r’),
help = ’Canvas tree file’, required = True, dest = ’tree’)
parser.add_argument(’-o’, metavar = ’outfile’, type = argparse.FileType(’a’),










sys.exit(’Tree file appears empty’)
if not stripped.startswith(’0’):








node = ’N’ + nodeline[0]
weight = nodeline[1].rstrip()












Create Cytoscape network node entries based on scaffolds
author David Watson
email dewatson@icloud.com





description = ’Creates an edge network of molecule-scaffold from ’ \
’ Strip-It RINGS_WITH_LINKERS_2 output.’)
parser.add_argument(’-i’, metavar = ’infile’, type = argparse.FileType(’r’),
help = ’Strip-It rwl2 file’, required = True, dest = ’rwl’)
parser.add_argument(’-o’, metavar = ’outfile’, type = argparse.FileType(’w’),






cytoscape = ’%s %s %s %s\n’
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singletons = open(’singletons.smi’, ’w’)




sys.exit(”Strip-it file appears empty”)
if not stripped.startswith(’NAME’):
sys.exit(”Strip-it file appears to be invalid”)
rings_with_linkers = {}











for smiles in rings_with_linkers.keys():
for molecule in range(0, len(rings_with_linkers[smiles]), 1):
if len(rings_with_linkers[smiles]) == 1:
singletons.write(”%s %s\n” % (smiles,
rings_with_linkers[smiles][0]))








Replace molecule-scaffold and scaffold-core mappings when there









description = ’Create an edge network of molecule-core interactions ’ \
’from a Strip-It MURCKO_1 file containing singletons.’)
parser.add_argument(’-i’, metavar = ’infile’, type = argparse.FileType(’r’),
help = ’Strip-It MURCKO_1 file’, required = True,
dest = ’murcko’)
parser.add_argument(’-o’, metavar = ’outfile’, type = argparse.FileType(’a’),










sys.exit(”Strip-it file appears empty”)
if not stripped.startswith(’NAME’):












for smiles in murcko.keys():
for molecule in range(0,len(murcko[smiles]),1):




Configuration file for Strip-it
MURCKO_1
A.8 RWL2.def
Configuration file for Strip-it
RINGS_WITH_LINKERS_2
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APPENDIX B. SAP IMPLEMENTATION
B.1 Makefile
Given a set of conformations produced by ConfGen, the following Makefile will attempt to gen-





# Prepare Canvas fingerprints for SAP analysis
#
# author David Watson
# email dewatson@icloud.com





-fp sigmaPforeFeatures.def -imae superset.maegz \
-odata conformers.fp -4pt -mostSig 16384 1>&2 2> pharmFPerrors.txt
$$SCHRODINGER/utilities/canvasFPBinary2CSV \
-i conformers.fp -o conformers.csv -off 0 -notot
-grep index pharmFPerrors.txt >duds.txt
-awk ’{ print $$9 }’ duds.txt >duds.conformers
$$SCHRODINGER/utilities/proplister -c -noheader -p s_m_title \
-p i_user_model_set -p i_user_activity_class superset.maegz -o props.csv
python bin/strip_3pt_pfores.py
B.2 bin/strip_3pt_pfores.py




Removes property information from the property file if Canvas is unable
to generate a fingerprint for some reason
author David Watson
email dewatson@icloud.com




# The following function was contributed by Olafur Waage to the website
# http://stackoverflow.com/questions/845058/how-to-get-line-count-cheaply-in-python
# This uses a subprocess to execute the Unix command ”wc -l” to determine
# the file length
def file_len(fname):
p = subprocess.Popen([’wc’, ’-l’, fname], stdout=subprocess.PIPE,
stderr=subprocess.PIPE)
result, err = p.communicate()





totalRange = range(1, totallength + 1)
duds = [int(line.rstrip()) for line in open(”duds.conformers”, ”r”)]
for myDud in duds:
totalRange.remove(myDud)
propsFile = open(”propsSubset.csv”, ”w”)
props = [line for line in open(’props.csv’, ’r’)]









# Implements SAP as described by Fu, et al. in BMC Bioinformatics 13, S3
#
# author David Watson
# email dewatson@icloud.com
# copyright Copyright (c) 2013, David Watson
#
##
# begin with a set of fingerprints and properties extracted from the superset
# load the SAP driver code
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source(”bin/sap.R”)
# read in the raw fingerprints
FPs <- read.csv(”conformers.csv”,header=TRUE)
# read in the activity assignments: 1 := active, 2 := inactive
ACs <- read.csv(”props.csv”)
colnames(ACs) <- c(”s_m_title”, ”i_user_model_set”, ”i_user_activity_class”)
# determine the indices of the training set
attach(ACs)
modelSets <- 1:length(i_user_model_set) * (i_user_model_set != 2)
detach(ACs)
# generate a table containing the bags
uniqueActivities <- unique(ACs)
# classify bags as active and inactive
acActivity <- assignActivities(uniqueActivities)
# divide up the bags
intTrainClass <- acActivity[uniqueActivities$i_user_model_set == 1]
extTestClass <- acActivity[uniqueActivities$i_user_model_set == 2]






# Implements SAP as described by Fu, et al. in BMC Bioinformatics 13, S3
#
# author David Watson
# email dewatson@icloud.com





determineSAP <- function(rawFPs, ACs) {
# transpose the fingerprint
tFPs <- as.matrix(t(subset(rawFPs,select=-name)))
attach(ACs)
SAPFdata <- list(x = tFPs, y = i_user_activity_class,
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geneid = as.character(1:nrow(tFPs)),




resp.type = ”Two class unpaired”,
nperms = 500)
save(SAP, file = ”SAP.RData”)
DELTAs <-samr.compute.delta.table(SAP, nvals = 100)
save(DELTAs, file = ”DELTAs.RData”)
DELTArow <- sum(DELTAs[1:nrow(DELTAs), 3] != 0) + 1
DELTA <- DELTAs[DELTArow, 1]
write.csv(DELTA, file = ”DELTA.csv”,
quote = FALSE, row.names = FALSE)
par(pch = ”.”)
# Be sure a proper graphics terminal is open or comment the next line
samr.plot(SAP, DELTA)
SAPresults <- samr.compute.siggenes.table(SAP, DELTA, SAPFdata, DELTAs)
keepbits <- !colnames(FPs) %in% SAPresults$genes.lo[,2]
sigFPs <- subset(FPs, select=colnames(FPs[keepbits == TRUE]))
write.csv(sigFPs, file = ”sigFPs.csv”, quote = FALSE,row.names = FALSE)
cat(”Significant fingerprint bits were saved to sigFPs.csv”)
}
assignActivities <- function (acTable) {
attach(acTable)
activeBits <- 1*s_m_title %in% s_m_title[i_user_activity_class == 1]
inactiveBits <- -1*!s_m_title %in% s_m_title[i_user_activity_class == 1]
detach(acTable)







APPENDIX C. FEATUREMAPPING IMPLEMENTATION
C.1 Makefile
Canvas is used to convert the significant fingerprints in CSV form into a native format, and
then a fingerprint matrix is generated. Suitable metrics are cosine, dice, kulczynski, mcconnaughey,
petke, simpson, tanimoto, and tversky. When working from unfiltered fingerprints, only the matrix




# Convert fingerprints into binary form and calculate similarity matrix
#
# author David Watson
# email dewatson@icloud.com




$$SCHRODINGER/utilities/canvasCSV2FPBinary -icsv sigFPs.csv -o sigFPs.fp
$$SCHRODINGER/utilities/canvasFPMatrix \





# Map bags to instances and return a feature matrix
#
# author David Watson
# email dewatson@icloud.com
# copyright Copyright (c) 2013, David Watson
#
##
featureMap <- function(FPmatrix, activityClasses) {
trainSet <-
unique(subset(activityClasses, i_user_model_set == 1, select=s_m_title))
featureVector <-





for ( i in unique(canvas)) {
moleculeCount <- moleculeCount + 1
message(”Evaluating molecule ”, moleculeCount)
for ( j in 1:nrow(activityClasses)) {
count <- count + 1
featureVector[count] <-




matrix(featureVector, nrow = length(unique(canvas)),
ncol = length(canvas),
dimnames = list(unique(canvas),canvas), byrow = TRUE)
keepFeatures <- colnames(interimMatrix) %in% trainSet$s_m_title
subset(interimMatrix, select=keepFeatures)
}
conformerMap <- function(FPmatrix, activityClasses) {
trainSet <- unique(subset(activityClasses,
i_user_model_set == 1, select = s_m_title))
conformerCount <- 0
count <- 0
featureVector <- vector(mode = ”numeric”, length = (nrow(activityClasses)^2))
for ( i in 1:nrow(FPmatrix)) {
conformerCount <- conformerCount + 1
message(”Evaluating conformer ”, conformerCount)
for ( j in 1:nrow(activityClasses)) {
count <- count + 1




matrix(featureVector, nrow = nrow(activityClasses), ncol = nrow(activityClasses),
dimnames = list(FPmatrix$canvas, FPmatrix$canvas), byrow = TRUE)
keepFeatures <- colnames(interimMatrix) %in% trainSet$s_m_title
subset(interimMatrix, select = keepFeatures)
}
C.3 mapping.R




# Interactive workflow for feature mapping
#
# author David Watson
126
# email dewatson@icloud.com
# copyright Copyright (c) 2013, David Watson
#
##
# read in the fingerprint similarity matrix and should be run directly after the SAP
# code otherwise read in the properties as in the SAP driver
FPmatrix <- read.csv(”FPmatrix.csv”, header = TRUE)
attach(FPmatrix)
# perform the instance-based feature mapping
FPfeatures <- featureMap(FPmatrix, ACs)
detach(FPmatrix)
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IMPLEMENTATION
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# Implementation of Yao and Lee’s parametric 1-norm SVM as an LP
# Another Look at Linear Programming for Feature Selection
# via Methods of Regularization, Technical Report No. 800r,
# Department of Statistics, Ohio State University, 2010.
#
# See section 4.2, equation 17
#
# author David Watson
# email dewatson@icloud.com






oneNormSVM <- function (trialMatrix, activityAssignment, lambda) {
trialRows <- nrow(trialMatrix)
trialCols <- ncol(trialMatrix)
cost <- c(rep(0, 2), rep(0, trialCols*2),
rep(1/trialRows, trialRows), rep(0, trialRows))
a <- c(rep(0, 2), rep(1, trialCols*2), rep(0, trialRows), rep(0, trialRows))
A <- cbind(activityAssignment, -activityAssignment,
activityAssignment*trialMatrix, -activityAssignment*trialMatrix,
diag(rep(1, trialRows)), -diag(rep(1, trialRows)))
b <- c(rep(1, trialRows))
oFx <- cost + (lambda*a/trialCols)
dir <- c(rep(”==”, trialRows))
ulbounds <- list(lower = list(ind = c(1L, 2L), val=c(-Inf, -Inf)))
onensvm <- Rglpk_solve_LP(oFx, A, dir, b, bounds = ulbounds)
solution <- list()
solution$hyperplane <- onensvm$solution[3:(trialCols+2)] -
onensvm$solution[(3 + trialCols):(2 * trialCols + 2)]
solution$margin <- onensvm$solution[1] - onensvm$solution[2]
solution$error <-
onensvm$solution[(2 * trialCols + 3):(2 * trialCols + trialRows + 2)] -
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onensvm$solution[(3 + 2 * trialCols + trialRows):




# Prediction method for class 1nsvm
predict.1nsvm <- function (object, testSet) {
hyperplane <- object$hyperplane
margin <- object$margin
as.vector(sign(margin + testSet %*% hyperplane))
}
# Internal accuracy calculation for a tuned 1-norm SVM
internalAccuracy <- function (internalTest, internalAssignment) {
validSet <- vector(mode=”numeric”)
for (itSol in rownames(internalTest)) {
tempSol <- sign(mySlack + internalTest[as.character(itSol),] %*% myPenalty)
validSet <- append(validSet, tempSol)
}
cat(validSet)
# The following will calculate the percent of correctly assigned activities
classificationAccuracy <- sum((validSet * internalAssignment) == 1) /
nrow(internalTest)
}
# cost function for SVM tuning
svmCost <- function(true,predicted) {
(length(predicted)-sum(diag(table(true,predicted))))/length(predicted)
}
# Matthews Correlation Coefficient for balanced measure of classification
# performance




This is the driver for the 1-norm SVM. It should be run immediately after the SAP and instance-





# Interactive workflow for tuning 1-norm SVM
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#
# author David Watson
# email dewatson@icloud.com
# copyright Copyright (c) 2013, David Watson
#
##
# divide the feature space between training and test sets
InternalMatrix <- subset(FPfeatures, subset = uniqueActivities$i_user_model_set == 1)
ExtTesting <- subset(FPfeatures, subset = uniqueActivities$i_user_model_set == 2)
# generate random splits of for 5-fold cross-validation
mySplits <- cvFolds(n = nrow(InternalMatrix), K = 5, R = 15, type = ”random”)
# perform initial tuning of the SVM
tuning <- list(lambda = c(10^(-12:4)))
# the tuning process may be split among multiple cores on SMP systems
firstTuning <- perryTuning(oneNormSVM, x = InternalMatrix,
y = intTrainClass, tuning = tuning, cost = svmCost, splits = mySplits,
names = c(”trialMatrix”, ”activityAssignment”), ncores = 2)
# examine the tuning parameter
tuning
# perform the second round of tuning
# note that this is an interactive process and the next line must be edited
tuning <- list(lambda = unique(c(seq(from = 1e-7, to = 1e-6, by = (1e-6 - 1e-7)/9),
seq(from = 1e-6, to = 1e-5, by = (1e-5 - 1e-6)/9))))
secondTuning <- perryTuning(oneNormSVM, x = InternalMatrix,
y = intTrainClass, tuning = tuning, cost = svmCost, splits = mySplits,
names = c(”trialMatrix”, ”activityAssignment”), ncores = 2)
# inspect the tuning parameter
secondTuning
# note that the following is interactive and the lambda parameter must be edited
tunedSVM <- oneNormSVM(InternalMatrix, intTrainClass, 7e-07)
mySlack <- tunedSVM$margin
myPenalty <- tunedSVM$hyperplane
tunedAccuracy <- internalAccuracy(InternalMatrix, intTrainClass)
tunedAccuracy
# perform external accuracy calculation
extPrediction <- predict(tunedSVM, ExtTesting)
131
confusionMatrix(extPrediction, extTestClass, positive = ”1”)
# calculate Matthews Correlation Coefficient
# note that this is interactive, replace with values from the confusion matrix
MCC(8,2,4,5)
# retrieve the model set compound indices
subsetRange <- seq(from = 1, to = nrow(Acs))
subsetSelect <- subsetRange[modelSets != 0]
# retrieve the prototype conformers
conformerRange <- subsetSelect[myPenalty != 0]
# write to a file for retrieval
write.csv(conformerRange, file=”prototypes.csv”, quote = FALSE,row.names = FALSE)
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APPENDIX E. ADDITIONAL SCRIPTS
E.1 pubmed_cids.py
The following script was developed to retrieve a SMILES file containing known PubChem




Retrieves a SMILES file containing known PubChem compounds
referenced back to a PubMed ID.
author David Watson
email dewatson@icloud.com










description=’Resolves compound lists in SMILES format based
upon associated PubMed IDs through PubChem.’)
parser.add_argument(’-i’, metavar=’infile’, type=argparse.FileType(’r’),


















































for pmid in args.pmid.readlines():
print ”Processing ” + pmid
cids = getCIDsFromUID(pmid.strip())
if len(cids) > 0:
processCids(pmid, cids)
except StopIteration:
sys.exit(”PubMed UID file appears to be empty”)
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def getCIDsFromUID(UID):
params = urllib.urlencode({’Db’: ’pccompound’,
’DbFrom’: ’pubmed’, ’Cmd’: ’Link’,
’LinkName’: ’pubmed_pccompound_mesh’, ’format’: ’text’,
’report’: ’uilist’, ’IdsFromResult’: UID})






for cid in cidlist:
querystring += ” <PCT-ID-List_uids_E>”
+ cid + ”</PCT-ID-List_uids_E>\n”
pubquery = PUG_DL_HEAD + querystring + PUG_DL_TAIL





for node in nodelist:
if node.nodeType == node.TEXT_NODE:




if waitingXml.length > 0:





print ”Received download URL for ” + smilesName
processDownload(smilesName, downloadXml)
def handleWait(smilesName, waitReq):
print ”Waiting on response for job ” + smilesName
waitquery = ” <PCT-Request_reqid>”
+ waitReq + ”</PCT-Request_reqid>\n”
PCT_QUERY = PUG_WAITING_HEAD + waitquery + PUG_WAITING_TAIL
time.sleep(3)






for node in downloadXml:
dlurl = getText(node.childNodes)




The following script clusters compounds based on a user-specified Tanimoto similarity cutoﬀ. A
Canvas distancematrix file is required, which should have been generated using Tanimoto similarity





Cluster compounds based on a specified Tanimoto similarity cutoff
author David Watson
email dewatson@icloud.com





description=’Convert a Canvas distance matrix
to Cytoscape network.’)
parser.add_argument(’-i’, metavar=’infile’, type=argparse.FileType(’r’),
help=’Canvas distance matrix’, required=True, dest=’canvas’)
parser.add_argument(’-o’, metavar=’outfile’, type=argparse.FileType(’w’),
help=’Cytoscape network’, required=True, dest=’cytoscape’)
parser.add_argument(’-s’, metavar=’similarity’, type=float,
help=’Tanimoto similarity cutoff (default: 0.70)’,
dest=’similarity’, default=0.70)
args=parser.parse_args()




sys.exit(”Canvas input file does not contain header information”)
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if len(compounds) <= 1 or compounds[0] != ’canvas’:











sys.exit(”The input file appears corrupt”)
while compound_index < len(compounds):
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APPENDIX F. BINDING AFFINITY DATA SETS
Table F.1: Sigma 1: PTZ guinea pig brain dataset
SMILES Name p𝐾i Ref.
c1cc(I)ccc1C[C@@H](C)NCCCc2ccccc2 2 7.745 56
c1ccccc1CCCCNCc2ccccc2 4 8.013 56
c1ccccc1CCCNCCc2ccccc2 7 7.959 56
c1ccccc1C[C@@H](C)[N+](C)(C)CCCc2ccccc2 14 6.873 56
CN(C)CCCCCc1ccccc1 16 9.237 56
c1ccccc1C[C@H](C)N(Cc2ccccc2)CCCc3ccccc3 17 6.893 56
c1ccccc1C[C@H](C)NCCCCc2ccccc2 22 7.721 56
c1ccccc1C[C@H](C)NCCCc2ccccc2 23 7.292 56
c1ccccc1CCCNCCCc2ccccc2 24 7.959 56
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 8.796 56
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-pentazocine 6.943 56
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.387 56
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 9.328 56
c1cc(O)ccc1[C@@H](O)[C@@H](C)N(CC2)CCC2Cc3ccccc3 Ifenprodil 8.237 56
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 6.282 56
CC(C)(C)[C@@](C1)(O)CCN([C@H]1c2c34)C[C@@H]4c5c(cccc5)CCc3ccc2 R-Butaclamol 7.161 56
CC(C)(C)[C@](C1)(O)CCN([C@@H]1c2c34)C[C@H]4c5c(cccc5)CCc3ccc2 S-Butaclamol 6.234 56
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-NANM 6.830 56
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-NANM 5.439 56
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 R-3PPP 7.319 56
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 S-3PPP 6.506 56
OCCN(CC1)CCN1CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4 Perphenazine 7.602 56
CCN(CC)CCCN1c(cccc2)c2Sc(c13)cccc3 Chlorpromazine 6.474 56
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 Rimcazole 5.937 56
c1ccccc1CCCN(CC2)CCC2(O)c3cc(Cl)ccc3 42 7.824 56
CCCN1CCN(CC1)c2ccccc2 43 7.086 56
c1ccccc1CCCCCN(CC2)CCC2Cc3ccccc3 44 9.237 56
c1ccccc1C[C@@H](C)[N+](C)(C)CCCc(c2)ccc(c23)cccc3 46 8.569 56
C1CCCCN1CCCc2ccccc2 47 7.310 56
CCCCCNCCc1ccccc1 49 7.930 56
c1ccccc1CCCCCN(C)CCc2ccccc2 51 9.690 56
CNCCCCc1ccccc1 52 7.380 56
c1ccc(Cl)cc1C(=O)CCCCN(CC2)CCC2c3ccccc3 53 8.110 56
c1ccc(Cl)cc1C(=O)CCCCN2CCCCC2 54 9.660 56
c1ccccc1C(=O)CCCCN(CC2)CCC2c3ccccc3 55 10.050 56
c1cc(Cl)ccc1CCCCCN(CC2)CCC2c3ccccc3 56 9.820 56
c1cc(Cl)ccc1C(=O)CCCCN(CC2)CCC2c3ccccc3 57 9.920 56
c1cc(Cl)ccc1C(=O)CCCCN2CCCCC2 58 9.740 56
c1ccccc1CCCN(CC2)CCC2c3ccccc3 59 9.520 56
c1ccccc1CCCCN(CC2)CCC2c3ccccc3 60 9.660 56
c1ccccc1CCCN2CCN(CC2)c3ccccc3 62 7.990 56
c1ccccc1CCCCN2CCN(CC2)Cc3ccccc3 3 9.699 100
c1ccccc1C(=O)N2CCN(CC2)CCCCc3ccccc3 4 6.903 100
c1ccccc1CCCCN(CC2)CCC2Cc3ccccc3 5 9.097 100
c1ccccc1CCCCCN2CCN(CC2)Cc3ccccc3 6 9.398 100
C1CN(C)CCN1CCCCCc2ccccc2 8 8.854 100
CC1CCN(CC1)CCCCCc2ccccc2 9 10.155 100
C1CN(C)CCC1CCCCCc2ccccc2 10 8.886 100
C1CCCCN1CCCCCc2ccc(N)cc2 13 7.420 100
C1CCCCN1C\C=C\C=C\c(c2)ccc(c23)OCO3 14 9.066 100
C1CCCCN1CCCCCc(c2)ccc(c23)OCO3 15 9.495 100
c1ccccc1CCCCC[N@@+]2(C)CC[C@@H](CC2)Cc3ccccc3 16 8.569 100
[C@H]12CC[C@H](CC1)CN(C2)CCCCCc3ccccc3 2 9.000 101
CCN(CC)CCCCCc1ccccc1 4 8.222 101
CCCN(C)CCCCCc1ccccc1 5 9.602 101
CN(C)CCCCCc1ccccc1 6b 7.854 101
c1ccccc1CCCCCNCc2ccccc2 8a 9.770 101
c1ccccc1CCCCCN(C)CCCc2ccccc2 10b 9.444 101
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c1ccccc1CCCCCN(CC2)CCC2c3ccccc3 14 9.796 101
c1ccccc1CCCN(CC2)CCC2Cc3ccccc3 21 9.398 101
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC 1 6.458 102
CC(C)(C)OC(=O)COc(c1)ccc(C=C[C@H]2CCCC3)c1[C@@]23CCN(C)C(=O)OC(C)(C)C 5 7.854 102
CC(C)(C)OC(=O)CN(C)CC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6a 7.432 102
CN(C)CC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6b 6.611 102
C=CCN(C)CC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6c 7.310 102
COCCN(C)CC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6d 7.310 102
C1CCC[C@@H]2C=Cc(ccc(c3)OC)c3[C@]12CCN(C)CCOCc4ccccc4 6e 6.618 102
CNCC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6g 6.341 102
OCCN(C)CC[C@]12c3c(ccc(c3)OC)C=C[C@H]1CCCC2 6i 6.793 102
CC(C)(C)OC(=O)CN(C)CC[C@]12c3c(ccc(c3)OC)CC[C@H]1CCCC2 6j 6.428 102
CC(C)(C)OC(=O)COc(c1)ccc(C=C[C@@H]2CCCC3)c1[C@]23CCN(C)C(=O)OC(C)(C)C 6k 6.939 102
c1ccccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 9 5.839 103
c1ccc(F)cc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 10 6.064 103
c1cc(F)ccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 11 6.187 103
c1ccc(OC)cc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 12 5.710 103
COc(cc1)ccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 13 5.907 103
c1ccc(F)cc1CCN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 14 6.631 103
c1cc(F)ccc1CCN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 15 6.609 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccccc4 23 7.538 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4cc(F)ccc4 24 7.658 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccc(F)cc4 25 7.921 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4cc(OC)ccc4 26 6.622 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccc(cc4)OC 27 7.907 103
c1ccc(F)cc1CCN([C@@H](C2)C3)[C@H](C4)C[C@@H]3C[C@@H]24 28 8.081 103
c1cc(F)ccc1CCN([C@@H](C2)C3)[C@H](C4)C[C@@H]3C[C@@H]24 29 7.893 103
CC(=O)Nc1ccc(cc1)N(CC2)CCN2CCCCNS(=O)(=O)CC3CCCCC3 20m 7.000 104
CCCCN(C1)CCN([C@H]12)C(=O)CC2 14b 6.462 105
C1CN(C)[C@@H](C2)CC(=O)C[C@]12c3cc(O)ccc3 (+)-(1S,5S)-4 6.118 106
C1CN(C)[C@H](C2)CC(=O)C[C@@]12c3cc(O)ccc3 (-)-(1R,5R)-4 4.498 106
c1ccccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-(1R,5R)-5 8.027 106
c1ccccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-(1R,5R)-5 5.886 106
c1cc(Cl)c(Cl)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-(1R,5R)-6 7.495 106
c1cc(Cl)c(Cl)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-(1R,5R)-6 5.495 106
c1ccccc1/C=C([C@H](C2)[N+](C)(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-(1R,5R)-7 5.268 106
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O SKF10047 7.658 107
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 6.438 107
c1ccccc1C2(CCCC2)C(=O)OCCOCCN(CC)CC Carbetapentane 7.125 107
c1ccccc1C2(CCCCC2)C(=O)OCCN3CCOCC3 PRE-084 8.046 107
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)C BD1047 8.812 107
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.987 108
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 8.592 108
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)C BD1047 8.276 108
CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 7.897 108
c1cc(Cl)c(Cl)cc1CCN2CCN(C)CC2 BD1063 7.786 108
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.192 108
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 7.125 108
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O SKF-10,047 6.824 108
c1ccccc1C2(CCCCC2)C(=O)OCCN3CCOCC3 PRE-084 6.821 108
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC dextromethorphan 6.643 108
CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4 progesterone 5.841 108
N#Cc1ccc(cc1)OCC2CCN(CC2)CCCF 2 8.367 109
CC(C)(C)[C@@](C1)(O)CCN([C@H]1c2c34)C[C@@H]4c5c(cccc5)CCc3ccc2 (-)-Butaclamol 7.377 110
CC(C)(C)[C@](C1)(O)CCN([C@@H]1c2c34)C[C@H]4c5c(cccc5)CCc3ccc2 (+)-Butaclamol 6.321 110
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 6.642 110
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)O Dextrorphan 6.387 110
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 6.971 110
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 9.252 110
c1cc(F)ccc1C(=O)CCCN2CCN(CC2)c(c3)ncc(c34)cccc4 HR-375 7.495 110
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 7.097 110
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 (-)-3-PPP 6.133 110
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 Rimcazole 6.078 110
CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3 Amitryptiline 5.792 110
CCN(CC)CCCN1c(cccc2)c2Sc(c13)cccc3 Chlorpromazine 6.379 110
CN(C)CCCN(c(c12)cccc1)c3c(CC2)cccc3 Imipramine 6.491 110
OCCN(CC1)CCN1CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4 Perphenazine 7.481 110
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(C)CC4 Trifluoperazine 6.662 110
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FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN(C)C Trifluopromazine 6.110 110
C1CC1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-alpha-Cyclazocine 7.721 110
C1CC1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-alpha-Cyclazocine 5.994 110
C1CC1CN(CC2)[C@H]([C@@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-beta-Cyclazocine 5.131 110
C1CC1CN(CC2)[C@@H]([C@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-beta-Cyclazocine 4.544 110
CC[C@@]12c3c(ccc(c3)O)C(=O)[C@@H]([C@H]1C)N(CC2)CC4CC4 (+)ethylketocyclazocine 6.686 110
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-alpha-Pentazocine 8.678 110
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-alpha-Pentazocine 6.951 110
CC(C)=CCN(CC1)[C@H]([C@@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-beta-Pentazocine 6.108 110
CC(C)=CCN(CC1)[C@@H]([C@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-beta-Pentazocine 5.157 110
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF-10,047 6.740 110
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF-10,047 5.325 110
CCCCCC(=O)CC[C@@]1(C)[C@@H](N(C)CC2)Cc(c3[C@]12C)ccc(c3)O (+)-Tonazocine 5.582 110
CCCCCC(=O)CC[C@]1(C)[C@H](N(C)CC2)Cc(c3[C@@]12C)ccc(c3)O (-)-Tonazocine 4.571 110
CC(C)CCC(=O)CC[C@@]1(C)[C@@H](N(C)CC2)Cc(c3[C@]12C)ccc(c3)O (+)-Zenazocine 5.484 110
c1cc(F)ccc1C(c2ccc(F)cc2)OCCN(CC3)CCN3CCCc4ccccc4 GBR-12909 7.658 110
C1CN(C)CCC1(C(=O)OCC)c2ccccc2 Meperidine 5.763 110
O1[C@H]2[C@@H](O)C=C[C@H]3[C@H](N(C)CC4)Cc5ccc(O)c1c5[C@@]234 Morphine 5.004 110
c1ccccc1C2(CCCCC2)N3CCCCC3 Phencyclidine 5.857 110
c1cc(Cl)c(Cl)cc1CC(=O)N(C)[C@@H]2[C@H](CCCC2)N3CCCC3 U-50,488H 5.730 110
CCN(CC)CCOC(=O)C1(CCCC1)c2ccc(N)cc2 Aminocaramiphen 7.167 111
CCN(CC)CCOC(=O)C1(CCCC1)c2ccc(I)cc2 Iodocaramiphen 8.750 111
CCN(CC)CCOC(=O)C1(CCCC1)c2ccc(cc2)N3CCCC3 4 6.939 111
CCN(CC)CC#CCOC(=O)C1(CCCC1)c2ccccc2 7 7.108 111
c1ccccc1C2(CCCC2)C(=O)OCCCN(CC)CC 8 8.437 111
C1CN(C)CCC1OC(=O)C2(CCCC2)c3ccccc3 9 6.100 111
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C2)Cc(c23)cc(OC)c(c3)OC 3 5.841 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)CCc(c23)cc(OC)c(c3)OC 4 5.295 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)c(c23)cc(OC)c(c3)OC 5 5.345 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCC2)Cc(c23)cc(OC)c(c3)OC 6 5.684 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCCC2)c(c23)cc(OC)c(c3)OC 7 5.591 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCC2)c(c23)cc(OC)c(c3)OC 8 5.347 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C)CCc2cc(OC)c(cc2)OC 9 6.234 112
c1ccccc1C[C@@H](C)NCCc2ccccc2 (-)4 7.360 52
c1ccccc1C[C@H](C)NCCc2ccccc2 (+)4 7.866 52
c1ccccc1C[C@@H](C)N(C)CCc2ccccc2 (-)5 7.785 52
c1ccccc1C[C@H](C)N(C)CCc2ccccc2 (+)5 8.237 52
c1ccccc1C[C@@H](C)NCCCc2ccccc2 (-)3 7.967 52
c1ccccc1C[C@H](C)NCCCc2ccccc2 (+)3 7.409 52
c1ccccc1C[C@H](C)N(C)CCCc2ccccc2 (+)6 8.886 52
c1ccccc1C[C@H](C)N(Cc2ccccc2)CCCc3ccccc3 (+)7 6.886 52
c1ccccc1C[C@@H](C)[N+](C)(C)CCCc2ccccc2 (-)8 6.870 52
c1cc(I)ccc1C[C@@H](C)NCCCc2ccccc2 (-)11 7.752 52
c1ccccc1C[C@@H](C)NCCCCc2ccccc2 (-)16 8.131 52
c1ccccc1C[C@H](C)NCCCCc2ccccc2 (+)16 7.712 52
c1ccccc1C[C@@H](C)NCCCCCc2ccccc2 (-)18 9.301 52
c1ccccc1C[C@H](C)NCCCCCc2ccccc2 (+)18 9.046 52
c1cccc(c12)ccc(c2)CCCN(C)CCCc(c3)ccc(c34)cccc4 21 7.523 52
c1ccccc1C[C@@H](C)NCCCc2cccc(c23)cccc3 (-)22 8.066 52
c1ccccc1C[C@@H](C)NCCCc(c2)ccc(c23)cccc3 (-)23 8.244 52
c1ccccc1CCCNCCc2ccccc2 24 7.947 52
c1ccccc1CCCNCCCc2ccccc2 25 7.943 52
c1ccccc1CCCCNCc2ccccc2 26 8.018 52
c1ccccc1CCCCNCCc2ccccc2 27 8.585 52
c1ccccc1CCCCCNCc2ccccc2 28 9.495 52
c1ccccc1CCCCCN(C)Cc2ccccc2 29 9.721 52
c1ccccc1CCCCCNCCc2ccccc2 30 9.770 52
c1ccccc1CCCCCN(C)CCc2ccccc2 31 9.602 52
c1ccccc1CCCCCNCCCc2ccccc2 32 9.553 52
c1ccccc1CCCCCN(C)CCCc2ccccc2 33 9.420 52
c1ccccc1CCCCCNCCCCc2ccccc2 34 9.319 52
c1ccccc1CCCCCCCNCc2ccccc2 35 8.638 52
c1ccccc1CCCCCCCNCCc2ccccc2 36 8.824 52
CCCCCNCCc1ccccc1 37 7.317 52
CCCN(C)CCCCCc1ccccc1 38 9.538 52
CN(C)CCCCCc1ccccc1 39 7.932 52
CNCCCCCc1ccccc1 40 6.379 52
C1CCCN1CCCCCc2ccccc2 41 9.119 52
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C1CCCCN1CCCCCc2ccccc2 42 9.319 52
c1ccccc1CCNCCN2CCCC2 45 7.081 52
C1CCCCC1CCCCCNCc2ccccc2 46 9.092 52
CN(C)CCCCCC1CCCCC1 47 9.585 52
CNCCCCCC1CCCCC1 48 8.167 52
NCCCCCC1CCCCC1 49 6.721 52
c1cccc(c12)sc(c2)C3(N)CCCCC3 4 5.499 113
c1cccc(c12)sc(c2)C3(CCCCC3)N4CCCC4 7 6.775 113
c1cccc(c12)sc(c2)C3(CCCCC3)N4CCCCCC4 8 6.171 113
c1cccc(c12)sc(c2)C3(CCCC3)N4CCCC4 9 6.903 113
c1cccc(c12)sc(c2)C3(CCCC3)N4CCCCC4 10 5.959 113
c1cccc(c12)sc(c2)C3(CCCC3)N4CCCCCC4 11 5.539 113
c1cccc(c12)sc(c2)C3(N4CCCC4)CCCCCC3 12 6.143 113
c1cccc(c12)sc(c2)C3(CCCCCC3)N4CCCCC4 13 5.652 113
c1cccc(c12)sc(c2)C3(CCCCCC3)N4CCCCCC4 14 5.567 113
c1cccc(c12)sc(c2)C3(N)CCCC3 17 5.762 113
c1cccc(c12)sc(c2)C3(N)CCCCCC3 20 5.038 113
c1ccccc1C2(CCCC2)C(=O)OCCOCCN(CC)CC Carbetapentane 7.495 114
c1ccccc1C(C)(c2ccccc2)C(=O)CCN(CC3)CCC3c4ccccc4 7 8.102 115
c1ccccc1C(C)(c2ccccc2)C(=O)CCCN(CC3)CCC3c4ccccc4 8 8.585 115
c1ccccc1C(C)(c2ccccc2)C(=O)CCCCN(CC3)CCC3c4ccccc4 9 9.018 115
C1CCCCC1C2(CCCCC2)C(=O)CCN(CC3)CCC3c4ccccc4 10 7.921 115
C1CCCCC1C2(CCCCC2)C(=O)CCCN(CC3)CCC3c4ccccc4 11 8.174 115
C1CCCCC1C2(CCCCC2)C(=O)CCCCN(CC3)CCC3c4ccccc4 12 8.387 115
CCN(CC)CCC(=O)C(C)(c1ccccc1)c2ccccc2 Aprophen 7.585 115
CCN(CC)CCC(=O)C1(CCCCC1)C2CCCCC2 Dicyclomine 7.921 115
c1ccccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 14 8.403 51
c1cc([N+]([O-])=O)ccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 15 10.301 51
c1cc(I)ccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 16 8.842 51
N#Cc1ccc(cc1)C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 17 8.886 51
c1cc(Cl)ccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 18 8.873 51
COc(cc1)ccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 19 8.991 51
c1ccccc1C2(CCCC2)C(=O)OCCN3CCN(CC3)c4ccccc4 20 7.202 51
c1cc([N+]([O-])=O)ccc1C2(CCCC2)C(=O)OCCN3CCN(CC3)c4ccccc4 21 8.556 51
c1cc(I)ccc1C2(CCCC2)C(=O)OCCN3CCN(CC3)c4ccccc4 22 7.642 51
c1cc(Cl)ccc1C2(CCCC2)C(=O)OCCN3CCN(CC3)c4ccccc4 23 7.114 51
c1ccccc1C2(CCCC2)C(=O)OCCCN(CC3)CCC3c4ccccc4 24 9.301 51
c1cc([N+]([O-])=O)ccc1C2(CCCC2)C(=O)OCCCN(CC3)CCC3c4ccccc4 25 9.569 51
c1cc(Cl)ccc1C2(CCCC2)C(=O)OCCCN(CC3)CCC3c4ccccc4 26 8.821 51
c1cc(I)ccc1C2(CCCC2)C(=O)OCCCN(CC3)CCC3c4ccccc4 27 9.056 51
COc(cc1)ccc1C2(CCCC2)C(=O)OCCCN(CC3)CCC3c4ccccc4 28 9.187 51
c1ccccc1C2(CCCC2)C(=O)OCCCCN(CC3)CCC3c4ccccc4 32 9.292 51
c1ccccc1C2(CCCC2)C(=O)OCCCCCN(CC3)CCC3c4ccccc4 33 9.215 51
c1ccccc1C2(CCCC2)C(=O)OCCCCCCN(CC3)CCC3c4ccccc4 33 8.917 51
CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2 caramiphen 7.585 51
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCN(CC4)CCC4c5ccccc5 9 7.770 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCN(CC4)CCC4c5ccccc5 10 7.658 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCN(CC4)CCC4c5ccccc5 11 8.000 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCCN(CC4)CCC4c5ccccc5 12 9.155 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCCCN(CC4)CCC4c5ccccc5 13 9.229 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCN4CCN(CC4)c5ccccc5 14 6.178 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCN4CCN(CC4)c5ccccc5 15 6.484 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCCN4CCN(CC4)c5ccccc5 16 7.721 116
c1ccccc1C2(c3ccccc3)C(=O)N(C(=O)N2)CCCCCCN4CCN(CC4)c5ccccc5 17 7.886 116
O=C(O)/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O Crocetin 5.796 117
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 8.721 117
c1cc(O)ccc1[C@@H](O)[C@@H](C)N(CC2)CCC2Cc3ccccc3 Ifenprodil 7.972 118
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 9.046 118
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.450 118
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 8.334 118
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OCCF FE-SA4503 8.095 118
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 8.790 118
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CCc5c[nH]c(c56)cccc6 GA 1-69 6.367 119
CC(C)[C@@H](N)CN1[C@@H](CC[C@@H]12)C[C@H](C2)OC(c3ccc(F)cc3)c4ccc(F)cc4 GA 2-50 7.917 119
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CCN GA 2-99 6.889 119
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CC5CC5 JWH 013 8.161 119
c1cccc(c1[C@]23C)[C@H](N3)Cc4c2cccc4 (+)-3 4.228 120
S=C=Nc(cc1)cc2c1C[C@@H](N3)c(c4[C@]23C)cccc4 (+)-8a 5.317 120
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c1ncc(I)cc1C(=O)NCCN(CC)CC 1 5.509 121
c1nc(I)ccc1C(=O)NCCN(CC)CC 2 6.328 121
c1ncc(I)cc1C(=O)NCCCCN(CC)CC 3 6.201 121
c1ncc(I)cc1C(=O)N2CCN(CC2)Cc3ccccc3 4 6.538 121
c1cccc(c12)ncc(c2)C(=O)N3CCN(CC3)Cc4ccc(I)cc4 5 6.481 121
c1ccccc1[C@@]2(CO)[C@@H](C2)CN(C)C34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (+)-18 8.900 122
c1ccccc1[C@]2(CO)[C@H](C2)CN(C)C34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (-)-18 8.857 122
c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CN(C)C34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (+)-4 7.410 123
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN(C)C34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (-)-4 8.678 123
c1ccccc1[C@@]2(CO)[C@@H](C2)CNC34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (+)-5 7.936 123
c1ccccc1[C@]2(CO)[C@H](C2)CNC34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (-)-5 8.187 123
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3 9.174 25
c1cc(F)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 5 9.013 25
c1cccc(F)c1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 6 8.839 25
N#Cc1ccc(cc1)CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 7 8.815 25
c1cc(C)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 8 8.682 25
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 9 8.660 25
c1cc(Cl)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 10 8.625 25
COc(cc1)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 11 8.539 25
c1cc(Br)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 12 8.507 25
c1cccc(C)c1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 13 7.892 25
c1cc(I)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 14 7.782 25
c1cc(N)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 15 7.776 25
FC(F)(F)c1ccc(cc1)CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 16 7.688 25
c1ccc(I)cc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 17 7.565 25
CC(=O)Nc(cc1)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 18 7.328 25
CN(C)c(cc1)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 19 6.993 25
c1cc(I)c([N+]([O-])=O)cc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 20 6.413 25
c1cccc(I)c1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 21 6.032 25
CC(C)(C)c1ccc(cc1)CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 22 5.972 25
c1c(O)ccc(c1[C@]23C)C[C@@H]([C@H]2C)NCC3 1l 5.563 124
c1c(O)ccc(c1[C@]23C)C[C@@H]([C@H]2C)N(C)CC3 1m 5.876 124
CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1n 5.963 124
CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1o 7.367 124
CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1p 8.222 124
CCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1q 8.420 124
CCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1r 8.638 124
CCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1s 8.721 124
CCCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1t 8.553 124
CCCCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1u 7.921 124
CCCCCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 1v 7.161 124
c1c(O)ccc(c1[C@@]23C)C[C@H]([C@@H]2C)NCC3 1a 5.171 124
c1c(O)ccc(c1[C@@]23C)C[C@H]([C@@H]2C)N(C)CC3 1b 4.742 124
CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1c 4.780 124
CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1d 6.131 124
CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1e 6.983 124
CCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1f 7.347 124
CCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1g 7.398 124
CCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1h 7.310 124
CCCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1i 7.456 124
CCCCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1j 7.495 124
CCCCCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 1k 7.420 124
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.921 125
c1ccccc1CCCN2CCN(CC2)Cc3ccccc3 3a 9.180 34
c1ccccc1CCCN2CCN(CC2)Cc3c(Br)cccc3 3b 9.222 34
c1ccccc1CCCN2CCN(CC2)Cc3c([N+]([O-])=O)cccc3 3c 8.553 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(I)ccc3 3d 9.409 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(F)ccc3 3e 8.866 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(OC)ccc3 3f 9.060 34
c1ccccc1CCCN2CCN(CC2)Cc3cc([N+]([O-])=O)ccc3 3g 9.032 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc(cc3)OC 3h 9.119 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 3i 9.432 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc(C)cc3 3j 8.932 34
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 9.081 34
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 8.363 34
c1cc(Cl)ccc1[C@]2(C(=O)OC)[C@H](C2)CN(CC3)[C@@H]([C@@H]4C)Cc(c5[C@]34C)ccc(c5)O CCB 5.979 126
O=C1CCCc(c12)cc(cc2)CC(=O)N3CCCC[C@H]3CN(C)C BRL 53001 5.916 126
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN(CC3)[C@H]([C@H]4C)Cc(c5[C@@]34C)ccc(c5)O (1R,2S)-6a 7.176 127
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c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CN(CC3)[C@H]([C@H]4C)Cc(c5[C@@]34C)ccc(c5)O (1S,2R)-6a 5.860 127
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)–SKF10047 6.772 127
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 6.801 127
c1cccc([N+]([O-])=O)c1C(=O)NC2CCN(CC2)Cc3ccccc3 1 7.876 128
c1cc([N+]([O-])=O)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 2 8.408 128
c1cccc(F)c1C(=O)NC2CCN(CC2)Cc3ccccc3 3 8.470 128
c1cc(F)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 4 8.588 128
c1cc(Cl)c(Cl)cc1CC(=O)N2CCN(CCCC)C[C@@H]2[C@H](C)N3CCCC3 (R,S)-22 7.396 129
c1cc(Cl)c(Cl)cc1CC(=O)N2CCN(CCCC)C[C@H]2[C@@H](C)N3CCCC3 (S,R)-22 7.092 129
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.658 129
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)–pentazocine 8.446 129
c1cc(F)ccc1C(=O)C[C@@H]2CCCN([C@@H]23)CCCC3 8alpha-b 6.582 130
c1cc(F)ccc1C(=O)C[C@H]2CCCN([C@@H]23)CCCC3 8beta-b 6.119 130
c1ccccc1/C=C/[C@@H]2CCCN([C@@H]23)CCCC3 9alpha-a 6.893 130
c1ccccc1/C=C/[C@H]2CCCN([C@@H]23)CCCC3 9beta-a 7.387 130
c1ccccc1CC[C@@H]2CCCN([C@@H]23)CCCC3 10alpha-a 7.420 130
c1cc(F)ccc1CC[C@@H]2CCCN([C@@H]23)CCCC3 10alpha-b 8.180 130
COc(cc1)ccc1CC[C@@H]2CCCN([C@@H]23)CCCC3 10alpha-c 7.553 130
c1ccccc1CC[C@H]2CCCN([C@@H]23)CCCC3 10beta-a 8.187 130
c1cc(F)ccc1CC[C@H]2CCCN([C@@H]23)CCCC3 10beta-b 8.432 130
COc(cc1)ccc1CC[C@H]2CCCN([C@@H]23)CCCC3 10beta-c 7.854 130
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.439 130
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.097 130
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.697 130
c1ccccc1C[C@@H]2CCCN([C@@H]23)CCCC3 1 7.453 131
c1ccccc1CCC[C@@H]2CCCN([C@@H]23)CCCC3 4 8.377 131
c1ccccc1SC[C@@H]2CCCN([C@@H]23)CCCC3 5 7.051 131
Fc1ccc(cc1)SC[C@@H]2CCCN([C@@H]23)CCCC3 6 7.879 131
c1ccccc1CSC[C@@H]2CCCN([C@@H]23)CCCC3 7 8.495 131
c1cc(Cl)ccc1CSC[C@@H]2CCCN([C@@H]23)CCCC3 8 9.000 131
c1ccccc1CCSC[C@@H]2CCCN([C@@H]23)CCCC3 9 9.201 131
c1cc(F)ccc1CCSC[C@@H]2CCCN([C@@H]23)CCCC3 10 9.201 131
c1ccccc1SC[C@H]2CCCN([C@@H]23)CCCC3 14 8.000 131
Fc1ccc(cc1)SC[C@H]2CCCN([C@@H]23)CCCC3 15 8.357 131
c1ccccc1CSC[C@H]2CCCN([C@@H]23)CCCC3 16 9.284 131
c1cc(Cl)ccc1CSC[C@H]2CCCN([C@@H]23)CCCC3 17 9.638 131
c1ccccc1CCSC[C@H]2CCCN([C@@H]23)CCCC3 18 9.420 131
c1ccccc1CC(=O)C[C@@H]2CCCN([C@@H]23)CCCC3 19 7.991 131
c1cc(F)ccc1C(=O)CSC[C@@H]2CCCN([C@@H]23)CCCC3 20 8.046 131
c1cc(Cl)ccc1OCC(=O)OC[C@@H]2CCCN([C@@H]23)CCCC3 22 7.433 131
c1cc(Cl)ccc1SCC(=O)OC[C@@H]2CCCN([C@@H]23)CCCC3 23 7.616 131
c1cc(F)ccc1C(c2ccc(F)cc2)C[C@@H]3CCCN([C@@H]34)CCCC4 24 7.310 131
c1cc(F)ccc1C(c2ccc(F)cc2)SC[C@@H]3CCCN([C@@H]34)CCCC4 25 8.194 131
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.357 131
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.839 131
COCCN1CCN(CC1)C[C@H](C2=O)CCN2c3ccc(Cl)cc3 MS-377 7.137 132
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.481 132
C1CCCn(c12)c(=O)c(c(n2)C)CCN(CC3)CCC3c4noc(c45)cc(F)cc5 Risperidone 4.886 132
CC(C)NC[C@H](O)COc1cccc(c12)ccc(C)c2 (+-)-Propranolol 6.149 133
CC(C)NC[C@@H](O)COc1cccc(c12)ccc(C)c2 (+-)-Propranolol 6.149 133
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.553 133
OCCN(CC1)CCC1COc2ccc(I)cc2 3 8.638 134
N#Cc1ccc(cc1)CN(CC2)CCC2COC/C=C/I 1 9.420 135
N#Cc1ccc(cc1)OCC2CCN(CC2)C/C=C/I 2 9.174 136
c1cc(I)ccc1C(=O)OC2CCN(CC2)CCCF 4 8.914 136
N#Cc1ccc(cc1)OCC2CCN(CCF)CC2 1 7.614 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3ccc(F)cc3 3 9.119 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3c(Br)cccc3 5 8.695 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3c(I)cccc3 6 8.034 137
c1cc(F)ccc1CN(CC2)CCC2COc(cc3)ccc3[N+]([O-])=O 7 8.921 137
FCCN(CC1)CCC1COc2ccc(I)cc2 8 9.076 137
C1CC1CN(CC2)CCC2COc3ccc(I)cc3 10 9.301 137
N#Cc1cc(ccc1)CN(CC2)CCC2COc3ccc(I)cc3 11 8.538 137
c1cccc(c1C#N)CN(CC2)CCC2COc3ccc(I)cc3 12 7.979 137
FCCCN(CC1)CCC1COc2ccc(Br)cc2 13 9.420 137
C1CC1CN(CC2)CCC2COc3ccc(Br)cc3 14 9.222 137
C1CC1CN(CC2)CCC2COc3cc(Br)ccc3 15 9.056 137
FCCCN(CC1)CCC1COc2c(F)c(F)c(F)c(F)c2F 16 8.770 137
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c1cc(F)ccc1CN(CC2)CCC2COc3c(F)c(F)c(F)c(F)c3F 17 8.444 137
c1ccc(F)cc1CN(CC2)CCC2COc3c(F)c(F)c(F)c(F)c3F 18 8.481 137
FCCC[C@H](O1)c(cccc2)c2C13CCN(CC3)Cc4ccccc4 S-2 9.229 138
FCCC[C@@H](O1)c(cccc2)c2C13CCN(CC3)Cc4ccccc4 R-2 8.745 138
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCCCNc4ccc([N+]([O-])=O)c(c45)non5 K05-138 5.959 139
c1cc(Cl)c(Cl)cc1CCN(C)[C@@H]2[C@@H](CCCC2)N3CCCC3 (-)-2 8.109 140
c1cc(Cl)c(Cl)cc1CCN(C)[C@H]2[C@H](CCCC2)N3CCCC3 (+)-2 7.729 140
c1cc(Cl)c(Cl)cc1CCN(C)[C@@H]2[C@H](CCCC2)N3CCCC3 (+)-4 6.370 140
c1cc(Cl)c(Cl)cc1CCN(C)[C@H]2[C@@H](CCCC2)N3CCCC3 (-)-4 6.342 140
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCC2 1 8.678 140
c1cc(Cl)c(Cl)cc1CCN2CCC[C@H]2CN3CCCC3 (-)-8 8.757 140
c1cc(Cl)c(Cl)cc1CCN2CCC[C@@H]2CN3CCCC3 (+)-8 8.363 140
C1CCCN1CCN(CC2)Cc(c23)cc(Cl)c(Cl)c3 12 8.873 140
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 8.509 140
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 1,3-di-o-tolylguanidine 7.558 140
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.432 140
c1ccccc1C2(CCCCC2)N3CCCCC3 1 5.963 141
C1CCCCN1[C@](C2)(C[C@@H]([C@@H]23)C3)c4ccccc4 6 5.429 141
C1CCCCN1[C@@](C2)(C[C@@H]([C@@H]23)C3)c4ccccc4 7 4.788 141
C1CCCCN1[C@]2(CC[C@@H]([C@@H]23)C3)c4ccccc4 (+)-8 5.138 141
C1CCCCN1[C@@]2(CC[C@H]([C@H]23)C3)c4ccccc4 (-)-8 5.947 141
c1cc(Cl)c(Cl)cc1CCN2CCNCC2 3 6.924 142
c1cc(Cl)c(Cl)cc1CCN2CCN(C)CC2 4 8.039 142
c1cc(Cl)c(Cl)cc1CCN2CCN(CC)CC2 5 8.796 142
CCCN1CCN(CC1)CCc2cc(Cl)c(Cl)cc2 6 8.921 142
CCCCN1CCN(CC1)CCc2cc(Cl)c(Cl)cc2 7 9.260 142
CCCCCN1CCN(CC1)CCc2cc(Cl)c(Cl)cc2 8 8.770 142
c1cc(Cl)c(Cl)cc1CCN2CCN(CC2)CCc3cc(Cl)c(Cl)cc3 9 8.770 142
c1cc(Cl)c(Cl)cc1CCN2CCCNCC2 10 6.812 142
c1cc(Cl)c(Cl)cc1CCN2CCCN(C)CC2 11 6.759 142
c1cc(Cl)c(Cl)cc1CCN(C2)CCN([C@H]23)CCC3 (-)-12 8.268 142
c1cc(Cl)c(Cl)cc1CCN(C2)CCN([C@@H]23)CCC3 (+)-12 8.854 142
c1cc(Cl)c(Cl)cc1CCN2CCN(CC3)CCC23 16 6.184 142
c1cc(Cl)c(Cl)cc1CCNCC2(CCCCC2)N3CCCCC3 17 7.788 142
c1cc(Cl)c(Cl)cc1CCN(C)CC2(CCCCC2)N3CCCCC3 18 7.108 142
c1ccccc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-7 10.377 143
c1ccccc1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-7 10.347 143
COc(cc1)ccc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-8 9.092 143
COc(cc1)ccc1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-8 9.638 143
c1ccc(OC)cc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-9 9.301 143
c1ccc(OC)cc1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-9 10.000 143
c1cccc(OC)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-10 9.523 143
c1cccc(OC)c1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-10 8.389 143
COc1cccc(OC)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-11 9.585 143
COc1cccc(OC)c1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-11 9.495 143
Fc1cccc(F)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-12 9.201 143
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.548 143
COc1cccc(c12)[C@@H](CCC2)NC(=O)CN3CCN(CC3)C4CCCCC4 R-9 7.690 144
COc1cccc(c12)[C@H](CCC2)NC(=O)CN3CCN(CC3)C4CCCCC4 S-9 7.024 144
COc1cccc(c12)[C@@H](CCC2)NCCN3CCN(CC3)C4CCCCC4 R-11 7.866 144
COc1cccc(c12)[C@H](CCC2)NCCN3CCN(CC3)C4CCCCC4 S-11 7.633 144
C1CCCCC1N(CC2)CCN2CCO[C@H](CCC3)c(c34)cccc4OC R-14 8.664 144
C1CCCCC1N(CC2)CCN2CCO[C@@H](CCC3)c(c34)cccc4OC S-14 8.489 144
c1ccc(OC)c(c12)cccc2NC(=O)CN3CCN(CC3)C4CCCCC4 20 7.371 144
c1ccc(OC)c(c12)cccc2NCCN3CCN(CC3)C4CCCCC4 21 8.264 144
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.523 144
Cc(c1)ccc(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 2 5.668 145
Cc(c1)ccc(OC)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 11a 6.272 145
Cc(c1)ccc(OC)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 11b 7.342 145
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 12a 5.357 145
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 12b 7.588 145
COc(c1)c(OC)cc(Br)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 13a 5.590 145
COc(c1)c(OC)cc(Br)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 13b 6.572 145
c1cccc(c12)CCN(C2=O)CCCN(CC3)Cc(c34)cc(OC)c(c4)OC 15a 6.149 145
c1cccc(c12)CCN(C2=O)CCCN3CCN(CC3)C4CCCCC4 15b 7.607 145
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.510 145
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.582 146
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CCCN(C1)CCC=C1c(on2)cc2-c(cc3)ccc3C PD 144418 10.097 147
c1ccccc1CC/C(=N\O)C2=CCCN(C2)CCC PD 128298 9.137 147
c1cc(F)ccc1C(=O)CC2CCN(CC2)CC3CC3 DuP 734 9.041 147
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.921 147
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 8.237 147
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 7.625 147
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.582 147
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF10047 7.445 147
OC1CCN(CC1)CCCCCCOc2cccc(c23)oc(cc3=O)-c4ccccc4 NPC 16377 7.294 147
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 7.254 147
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-Pentazocine 7.092 147
CC(C)(C)[C@@](C1)(O)CCN([C@H]1c2c34)C[C@@H]4c5c(cccc5)CCc3ccc2 (-)-Butaclamol 7.019 147
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 (-)-3-PPP 6.532 147
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF10047 6.098 147
CC(C)(C)[C@](C1)(O)CCN([C@@H]1c2c34)C[C@H]4c5c(cccc5)CCc3ccc2 (+)-Butaclamol 6.097 147
c1ccccc1C2(CCCCC2)N3CCCCC3 PCP 5.841 147
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23C(=O)NCN3c4ccccc4 Spiperone 5.644 147
Fc1ccc(cc1)SC[C@H]2CCCN([C@@H]23)CCCC3 ANS-4 8.222 148
Fc1ccc(cc1)SC[C@@H]2CCCN([C@@H]23)CCCC3 ANS-5 7.721 148
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.444 148
CCCCN(C[C@@H]1O)CCN1Cc2ccccc2 3b 6.529 149
c1ccccc1CN2CCN(C[C@@H]2O)Cc3ccccc3 3c 7.417 149
c1ccccc1CN2CCN(C[C@@H]2O)Cc3ccc(cc3)OC 3d 7.907 149
c1ccccc1CCN(C[C@@H]2O)CCN2Cc3ccccc3 3e 7.434 149
c1ccccc1CN2CCN(C[C@@H]2O)C3CCCCC3 3f 7.236 149
CCC(=O)CN(C[C@@H]1O)CCN1Cc2ccccc2 3n 5.802 149
c1cc(Cl)c(Cl)cc1CC(=O)NC[C@H]2CN(CC(=O)OCC)CCN2Cc3ccccc3 17a 5.873 150
c1cc(Cl)c(Cl)cc1CC(=O)N(C)C[C@H]2CN(CC(=O)OCC)CCN2Cc3ccccc3 17b 6.742 150
c1cc(Cl)c(Cl)cc1CC(=O)N(C2)CN([C@@H]23)CCN(C3)CC(=O)OCC 19 6.042 150
c1ccccc1CN2CCCN(C[C@@H]2CO)Cc3ccccc3 4a 8.131 151
COC(OC)CN(C[C@@H]1CO)CCCN1Cc2ccccc2 4b 6.495 151
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.963 152
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.719 152
CC1(C)CCCN(C1)CCC[C@H](CCC2)c(c23)cccc3OC S-39 7.936 152
CC1(C)CCCN(C1)CCC[C@@H](CCC2)c(c23)cccc3OC R-39 7.479 152
CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 8.987 152
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCC2 BD1008 8.764 152
CC1(C)CCCN(C1)CCCC2=CCc(c23)cccc3 23 7.636 152
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.569 153
c1cc(Cl)c(Cl)cc1CC(=O)OCCN2CCCC2 AC915 8.600 153
CC1CCN(CC1)CCOc2ccc(Cl)cc2 12 9.066 153
CC1CCN(CC1)C[C@@H](C)Oc2ccc(Cl)cc2 R-13 7.900 153
CC1CCN(CC1)C[C@H](C)Oc2ccc(Cl)cc2 S-13 8.742 153
c1cc(Cl)ccc1O[C@H](C)CCN(CC2)CCC2C R-14 8.738 153
c1cc(Cl)ccc1O[C@@H](C)CCN(CC2)CCC2C S-14 8.854 153
CC1CCN(CC1)CCCOc2ccc(Cl)cc2 15 8.750 153
CC1CCN(CC1)C[C@@H](C)COc2ccc(Cl)cc2 R-16 8.963 153
CC1CCN(CC1)C[C@H](C)COc2ccc(Cl)cc2 S-16 8.770 153
CC1CCN(CC1)[C@H](C)COc2ccc(Cl)cc2 R-17 8.928 153
CC1CCN(CC1)[C@@H](C)COc2ccc(Cl)cc2 S-17 9.469 153
CC1CCN(CC1)[C@H](C)CCOc2ccc(Cl)cc2 R-18 8.656 153
CC1CCN(CC1)[C@@H](C)CCOc2ccc(Cl)cc2 S-18 8.570 153
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.516 154
c1ccccc1CCN2CCCCC2 AC927 6.510 154
COc1cccc(c12)[C@@H](CCC2)CCCN3CCN(CC3)C4CCCCC4 S-33 8.611 154
COc1cccc(c12)[C@H](CCC2)CCCN3CCN(CC3)C4CCCCC4 R-33 8.256 154
c1cccc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 43 8.666 154
c1ccc(OC)c(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 44 8.804 154
c1cccc(c12)cccc2CCCCN3CCN(CC3)C4CCCCC4 45 9.658 154
c1cccc(c12)cccc2CCCCCN3CCN(CC3)C4CCCCC4 46 8.620 154
C1CCCCN1CCCc2cccc(c23)cc(cc3)OC 21 8.108 155
CC1(C)CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 26 9.456 155
CC1(C)CCCCN1CCCc2cccc(c23)cc(cc3)OC 25 5.975 155
CC1CCN(CC1)CCCc2cccc(c23)cc(cc3)OC 24 8.824 155
CC1(C)CCN(CC1)CCCc2cccc(c23)cc(cc3)OC 27 8.833 155
C1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 28 8.943 155
CC1(C)CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 33 9.444 155
CC1(C)CCCCN1CCCCc2cccc(c23)cc(cc3)OC 32 7.654 155
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CC1CCN(CC1)CCCCc2cccc(c23)cc(cc3)OC 31 10.523 155
CC1(C)CCN(CC1)CCCCc2cccc(c23)cc(cc3)OC 34 8.648 155
C[C@@H]1CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 23R 8.870 155
C[C@H]1CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 23S 8.479 155
C[C@@H]1CCCCN1CCCc2cccc(c23)cc(cc3)OC 22R 8.738 155
C[C@H]1CCCCN1CCCc2cccc(c23)cc(cc3)OC 22S 8.152 155
C[C@@H]1CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 30R 9.620 155
C[C@H]1CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 30S 9.180 155
C[C@@H]1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 29R 8.845 155
C[C@H]1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 29S 9.301 155
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.553 155
n1ccccc1OCCN[C@@H](CC2)CC[C@@H]2c3ccccc3 cis-14 8.113 156
c1ccc(OC)cc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4cccc(c45)cccc5 cis-17 6.620 156
c1cccc(OC)c1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-19 6.433 156
c1ccc(OC)cc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-20 6.750 156
COc(cc1)ccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-21 6.712 156
c1ccccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-29 6.096 156
Cc1ccc(cc1)[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-30 6.000 156
c1cc(Cl)ccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-31 5.963 156
Fc1cccc(F)c1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-32 5.287 156
c1ccc(C)c(c1C)[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-34 8.199 156
c1cccc(OC)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-19 8.544 156
c1ccc(OC)cc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-20 7.606 156
COc(cc1)ccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-21 6.536 156
c1ccccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-29 6.983 156
Cc1ccc(cc1)[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-30 7.513 156
c1cc(Cl)ccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-31 6.721 156
Fc1cccc(F)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-32 6.721 156
COc1cccc(OC)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-33 6.668 156
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.618 156
c1cccc(c12)CCC[C@@H]2CCCN3CCN(CC3)C4CCCCC4 R-3 9.201 157
c1cccc(c12)CCC[C@H]2CCCN3CCN(CC3)C4CCCCC4 S-3 9.886 157
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.480 158
CCN1CCN(CC1)C2CCCCC2 55 7.205 158
C1CCCCC1N2CCN(CC2)C3CCCCC3 57 8.688 158
C1CCCCC1C(=O)N2CCN(CC2)C3CCCCC3 58 8.445 158
C1CCCCC1CCCN2CCN(CC2)C3CCCCC3 59 9.602 158
c1cc(I)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-8 5.767 159
c1ccc(I)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-9 5.790 159
c1ccccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(OC)ccc4 (+)-10 6.839 159
COc(cc1)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-4 5.719 159
c1ccc(OC)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-6 5.222 159
c1ccc(Cl)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-7 5.509 159
c1cc(Cl)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-5 6.120 159
COc(cc1)ccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-4 8.108 159
c1cc(Cl)ccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-5 7.735 159
c1ccc(OC)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-6 8.237 159
c1ccc(Cl)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-7 7.519 159
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(CC4)CCO Fluphenazine 7.587 160
CC(C)(C)[C@](C1)(O)CCN([C@@H]1c2c34)C[C@H]4c5c(cccc5)CCc3ccc2 (+)-Butaclamol 5.630 160
CC(C)(C)[C@@](C1)(O)CCN([C@H]1c2c34)C[C@@H]4c5c(cccc5)CCc3ccc2 (-)-Butaclamol 7.077 160
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-PPP 7.530 160
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 (-)-PPP 6.733 160
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-Pentazocine 7.080 160
C1CCC[C@@H]2[C@@H](N(CC3)CC=C)Cc(c4[C@]123)ccc(c4)O Dextrallorphan 7.870 160
C1CC1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-Cyclazocine 7.764 160
C1CC1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-Cyclazocine 5.577 160
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF10047 7.224 160
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF10047 5.285 160
c1ccccc1C2(CCCCC2)N3CCCCC3 PCP 5.753 160
c1ccccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 CB-64L 7.979 161
c1cc(Cl)c(Cl)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 CB-182 7.564 161
c1ccccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 CB-64D 5.514 161
c1cc(Cl)c(Cl)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 CB-184 5.129 161
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)OC Ibogaine 5.068 162
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)O O-des-methyl-Ibogaine 4.824 162
C1CNC(C)=C(C1=c23)N=c2cc(cc3)OC Harmaline 5.264 162
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4cc(cc5)OC Tabernanthine 5.542 162
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CC(C)(C)Oc(c1)ccc2[nH]c(c3c12)[C@H]4[C@H]5N(CC3)C[C@@H](C4)C[C@@H]5CC 10-t-butoxy-ibogamine 5.313 163
C[C@@H]1CN(C[C@H](C)N1)CCCN(c2ccc(F)cc2)c3ccc(F)cc3 10 6.907 59
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 11 7.955 59
c1cc(F)ccc1N(c2ccc(F)cc2)CCCN(C[C@H]3C)C[C@@H](C)N3CCc4cc(Cl)c(Cl)cc4 12 7.488 59
c1ccccc1N(c2ccccc2)CCCN(C[C@H]3C)C[C@H](C)N3CCc4cc(Cl)c(Cl)cc4 13 7.529 59
C1CNCCN1CCCN(c2ccc(F)cc2)c3ccc(F)cc3 15 5.857 59
c1ccccc1CCCN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 16 7.179 59
c1cc(F)ccc1N(c2ccc(F)cc2)CCCN3CCN(CC3)Cc4ccccc4 17 7.883 59
c1ccccc1C[C@H](O)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 6a 7.551 164
c1ccccc1C[C@@H](O)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 6b 7.476 164
c1ccccc1C[C@H](OC(=O)C)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 7a 7.125 164
c1ccccc1C[C@H](OC(=O)CC)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 7b 7.087 164
c1ccccc1C[C@H](OC(=O)CCC)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 7c 6.535 164
c1ccccc1C[C@H](OC(=O)C=C)CN2CCN(CC2)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 7d 7.342 164
c1ccccc1CC(=O)O[C@@H](Cc2ccccc2)CN3CCN(CC3)CCCN(c4ccc(F)cc4)c5ccc(F)cc5 7e 7.058 164
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.252 164
CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 8.623 164
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O l-pentazocine 7.079 164
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 rimcazole 6.049 164
c1cc(F)ccc1C(c2ccc(F)cc2)OCCN(CC3)CCN3CCCc4ccccc4 GBR12909 7.294 164
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-1d 7.081 165
c1ccccc1CN2CC[C@@H]3[C@@H](C)[C@H]2Cc(c34)cccc4 (-)-2a 9.018 165
c1ccccc1CN2CC[C@H]3[C@H](C)[C@@H]2Cc(c34)cccc4 (+)-2a 8.241 165
c1cccc(c12)C[C@@H]3[C@H](CC)[C@H]2CCN3Cc4ccccc4 (-)-2b 8.474 165
c1cccc(c12)C[C@H]3[C@@H](CC)[C@@H]2CCN3Cc4ccccc4 (+)-2b 7.573 165
c1cccc(c12)C[C@@H]3[C@H](C(C)C)[C@H]2CCN3Cc4ccccc4 (-)-2c 7.499 165
c1cccc(c12)C[C@H]3[C@@H](C(C)C)[C@@H]2CCN3Cc4ccccc4 (+)-2c 6.777 165
c1cccc(c12)[C@H]([C@H](C)C=C2)CCNCc3ccccc3 (+)-10a 7.708 165
c1cccc(c12)[C@@H]([C@@H](C)C=C2)CCNCc3ccccc3 (-)-10a 7.762 165
c1cccc(c12)[C@H]([C@H](CC)C=C2)CCNCc3ccccc3 (+)-10b 7.780 165
c1cccc(c12)[C@@H]([C@@H](CC)C=C2)CCNCc3ccccc3 (-)-10b 7.830 165
c1cccc(c12)[C@H]([C@H](C(C)C)C=C2)CCNCc3ccccc3 (+)-10c 7.921 165
c1cccc(c12)[C@@H]([C@@H](C(C)C)C=C2)CCNCc3ccccc3 (-)-10c 7.932 165
c1cc(I)ccc1CN(CC2)CCC23c4c(CO3)cccc4 Spiro-I 8.561 166
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.609 95
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.419 95
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 9.022 95
c1ccccc1C(c2ccccc2)(c3ccccc3)SCCNC(=O)CN(CCSC(c4ccccc4)(c5ccccc5)
c6ccccc6)CCCN7C(CCC8)CC(CC78)OC(=O)Nc(c(cc9)OC)cc9C 1 5.320 95
I\C=C\CN(CCC)[C@H](C1)CCc(c12)ccc(c2)O S-trans-7-OH-PIPAT 8.412 95
s1cccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12a 5.844 167
CN(C)c(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12b 5.900 167
c1nc(Cl)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12d 5.898 167
c1cccc(c12)[nH]c(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12e 5.745 167
c1cccc(c12)ncc(n2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12f 5.131 167
c1cccc(c12)oc(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12g 5.966 167
c1cccc(c12)sc(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12h 5.841 167
FCCc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12i 5.451 167
Cc(s1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12j 5.961 167
s1c(Br)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12k 6.466 167
c1cc(Cl)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13a 5.642 167
c1cc(F)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13b 6.034 167
COc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13d 5.063 167
c1cccc(c12)oc(c2)C(=O)NCCCCN3CCN(CC3)c(c4Cl)cccc4Cl 13f 5.246 167
FCCc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13g 5.057 167
Cc(s1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13h 5.847 167
s1c(Br)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13i 6.213 167
CCCCNCCCc1ccccc1 1a 7.137 168
CCCCCCCNCCCc1ccccc1 2a 7.824 168
CCCCCCCCCCCCNCCCc1ccccc1 3a 5.276 168
CCCCCCCCCCCCCCCCCCNCCCc1ccccc1 4a 4.463 168
CCCCNCCCc1ccc([N+]([O-])=O)cc1 1b 8.523 168
CCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 2b 8.000 168
CCCCCCCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 3b 5.292 168
CCCCCCCCCCCCCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 4b 4.570 168
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.903 169
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.053 169
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.939 169
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CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 8.959 169
c1cc(Cl)c(Cl)cc1CC(=O)OCCN2CCCC2 AC915 8.662 169
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC dextromethorphan 7.036 169
CN(C)C/C=C(\C)c(c1)ccc(c12)cccc2 2 7.703 64
CN(C)C/C=C(\C)c1cccc(c12)cccc2 3 6.991 64
CN(C)C/C=C(\C)c(c1)ccc(c12)cc(O)cc2 4 6.640 64
CN(C)C/C=C(\C)c(c1)ccc(c12)cc(cc2)OC 5 7.670 64
CN(C)C/C=C(\C)c1ccc(cc1)-c2ccccc2 6 8.854 64
c1cccc(c12)ccc(c2)C(\C)=C\CN(C)Cc3ccccc3 12 8.103 64
c1ccccc1-c(cc2)ccc2C(\C)=C\CN(C)Cc3ccccc3 13 8.199 64
C1CCCCN1C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17a 8.215 170
C1COCCN1C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17b 7.644 170
C1CCCCCN1C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17c 8.824 170
CC1CCN(CC1)C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17d 8.357 170
CCN(CC)C/C=C/1CCCc(c12)n(nc2)-c3ccccc3 17e 7.936 170
C1CCCCC1N(CC2)CCN2C/C=C/3CCCc(c34)n(nc4)-c5ccccc5 17f 7.955 170
C[C@@H]1CN(C[C@@H](O1)C)C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17g 7.710 170
c1ccccc1C2CCN(CC2)C/C=C/3CCCc(c34)n(nc4)-c5ccccc5 17h 8.602 170
c1ccccc1N(CC2)CCN2C/C=C/3CCCc(c34)n(nc4)-c5ccccc5 17i 7.380 170
c1cccc(CO2)c1C23CCN(CC3)C/C=C/4CCCc(c45)n(nc5)-c6ccccc6 17k 8.310 170
c1cccc(c12)CN(CC2)C/C=C/3CCCc(c34)n(nc4)-c5ccccc5 17m 7.395 170
c1ccccc1CN(C)C/C=C/2CCCc(c23)n(nc3)-c4ccccc4 17n 7.870 170
c1cccc(c12)CN(C2)C/C=C/3CCCc(c34)n(nc4)-c5ccccc5 17p 7.338 170
C1CCCCN1C/C=C/2CCCc(c23)n(nc3)-c(c4)ccc(Cl)c4Cl 17q 8.215 170
C1COCCN1C/C=C/2CCCc(c23)n(nc3)-c(c4)ccc(Cl)c4Cl 17r 7.226 170
C[C@@H]1CN(C[C@@H](O1)C)C/C=C/2CCCc(c23)n(nc3)-c(c4)ccc(Cl)c4Cl 17s 7.251 170
c1c(O)ccc(c1[C@]23C)C[C@@H]([C@H]2C)N(C)CC3 (+)-1a 5.678 26
CC(=O)Nc(c1)ccc(c1[C@]23C)C[C@@H]([C@H]2C)N(CC3)Cc4ccccc4 (+)-3a 8.246 26
c1cccc(c1[C@]23C)C[C@@H]([C@H]2C)N(C)CC3 (+)-2a 6.317 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(F)c4 (+)-3e 8.419 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)N(C)C (+)-3c 8.757 26
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cccc3 (+)-2c 7.084 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(Br)c4 (+)-3g 7.733 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)N (+)-3b 8.833 26
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cccc3 (+)-2b 8.804 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(Cl)c4 (+)-3f 8.145 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)NS(=O)(=O)C (+)-3d 7.983 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-2d 7.735 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(I)c4 (+)-3h 6.884 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(F)c4 (-)-3e 7.708 26
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cccc3 (-)-2b 7.578 26
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(F)c3 (-)-4a 7.516 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-1f 7.438 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(Cl)c4 (-)-3f 7.397 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-2d 7.232 26
CC(C)CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(F)c3 (-)-4b 8.330 26
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(F)c3 (+)-4a 8.830 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)CC(=C4[C@@]23C)CCC(=O)C4 (+)-10 7.947 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Br)c(c4Br)O (+)-2a 7.151 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4Br)O (+)-3a 8.757 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Br)c(c4)O (+)-4a 7.164 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(I)c(c4)O (+)-5a 6.636 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Cl)c(c4Cl)O (+)-6a 7.146 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4Cl)O (+)-7a 8.764 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(Br)c(c3Br)O (+)-2b 6.921 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3Br)O (+)-3b 8.604 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(Br)c(c3)O (+)-4b 6.943 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(I)c(c3)O (+)-5b 6.025 171
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cc(Br)c(c3)O (-)-4b 7.427 171
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cc(I)c(c3)O (-)-5b 7.453 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3Cl)O (+)-7b 8.582 171
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3CCF 11a 5.698 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3CC=C 11b 5.901 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccncc4 11c 5.806 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4cccnc4 11d 5.630 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(F)nc4 11e 5.600 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(cc4)SC 11f 5.694 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(cc4)OC 11g 6.490 172
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Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(cc4)OC 11h 6.350 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(CCF)cc4 11i 5.579 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(cc4)N(C)C 11j 5.728 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(cc4)N(C)C WC-26 5.843 172
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc(cc4)ccc4CCF WC-59 5.767 172
CCN(CC)CCOC(=O)C(CCC)(c1ccccc1)c2ccccc2 l-Lobeline 7.276 173
c1ccccc1C(=O)C[C@H]2CCC[C@H](N2C)C[C@H](O)c3ccccc3 Proadifen 7.523 173
C1CCCN([C@@H]1[C@@H]23)C[C@H](C2)[C@@H]4N(C3)CCCC4 (-)Sparteine 5.087 173
C=C[C@H]([C@H]12)CN(CC2)[C@H](C1)[C@@H](O)c3ccnc(c34)cccc4 Quinidine 4.780 173
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3ccc(F)cc3 2a 9.051 174
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3c(F)cccc3 2b 9.420 174
c1cc(Br)ccc1C(=O)NC2CCN(CC2)Cc3ccc(F)cc3 2c 9.076 174
c1cc(Br)ccc1C(=O)NC2CCN(CC2)Cc3c(F)cccc3 2d 9.222 174
c1cc(Br)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 1b 9.009 174
c1cc(F)ccc1C(=O)CN2[C@@H](CC[C@@H]23)C[C@@H](C3)c4ccccc4 11 6.552 175
c1cc(F)ccc1C(=O)CCCN2[C@@H](CC[C@@H]23)C[C@@H](C3)c4ccccc4 12 7.467 175
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23c4c(N(C)C3)cccc4 24a 6.957 175
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23c4c(CC3)cccc4 24b 8.745 175
c1c(Br)c(N)c(I)c(OC)c1C(=O)NCCN(CC)CC 2 6.556 176
COc(cc1)c(I)cc1C(=O)NCCN(CC)CC IMBA 6.604 176
CC(=O)Nc(c(I)c1)cc(OC)c1C(=O)NCCN(CC)CC 6 5.285 176
c1c(I)c(N)cc(OC)c1C(=O)NCCN(CC)CC 7 6.315 176
CC(=O)Nc(cc1)c(I)cc1C(=O)NCCN(CC)CC 9 5.333 176
CCN(CC)CCNC(=O)c1c(I)ccc(c1)OC 12 6.342 176
c1c(I)ccc(OC)c1C(=O)NCCN(CC)CC 15 7.036 176
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.530 176
CC1(C)CCCN(C1)CCCc2cccc(c23)c(OC)ccc3 11 7.348 177
CC1(C)CCCN(C1)CCCc2cccc(c23)ccc(c3)OC 13 6.939 177
COc(cc1)cc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 15 8.500 177
C1CCCCC1N(CC2)CCN2CCCc3cccc(c34)ccc(c4)OC 16 9.046 177
CC1(C)CCCN(C1)CCCc2cccc(c23)cc(O)cc3 17 6.469 177
CC1(C)CCCN(C1)CCCc2cccc(c23)ccc(c3)O 18 6.135 177
c1cc(O)cc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 19 8.169 177
c1c(O)ccc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 20 8.261 177
c1cccc2n(c(c3c12)cccc3)CCCN(C4)CCCC4(C)C 26 5.695 177
c1cccc2n(c(c3c12)cccc3)CCCCN(C4)CCCC4(C)C 27 6.757 177
c1cccc2n(c(c3c12)cccc3)CCCCCN(C4)CCCC4(C)C 28 6.860 177
c1cccc2n(c(c3c12)cccc3)CCCN4CCN(CC4)C5CCCCC5 29 5.462 177
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.489 177
CC1(C)CCCN(C1)CCCc2cccc(c23)occ3 16 7.197 178
CC1(C)CCCN(C1)CCCc2cccc(c23)scc3 17 7.284 178
CC1(C)CCCN(C1)Cc(c2)oc(c23)cccc3 22 5.433 178
c1cccc(c12)n(cc2)CCCN(C3)CCCC3(C)C 28 7.293 178
c1cccc(c12)n(nn2)CCCN(C3)CCCC3(C)C 29 6.470 178
c1cccc(c12)n(cc2C)CCCN(C3)CCCC3(C)C 30 7.381 178
C1CCCCC1CCCCN(C2)CCCC2(C)C 31 8.991 178
CC1(C)CCCN(C1)CCNc(n2)sc(c23)cccc3 37 6.247 178
s1ccnc1NCCN(C2)CCCC2(C)C 38 6.338 178
CC1(C)CCCN(C1)CCCCN(C2)CCCC2(C)C 41 7.851 178
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.500 178
c1ccccc1CN2CCN(CC2)Cc3ccccc3 3 8.236 179
c1ccc(OC)cc1CN2CCN(CC2)Cc3ccccc3 4 9.409 179
COc(cc1)ccc1CN2CCN(CC2)Cc3ccccc3 5 9.328 179
c1cccc(Cl)c1CN2CCN(CC2)Cc3ccccc3 6 8.276 179
c1ccc(Cl)cc1CN2CCN(CC2)Cc3ccccc3 7 9.337 179
c1cc(Cl)ccc1CN2CCN(CC2)Cc3ccccc3 8 8.854 179
c1cc(Cl)c(Cl)cc1CN2CCN(CC2)Cc3ccccc3 9 9.237 179
c1cc(Cl)cc(Cl)c1CN2CCN(CC2)Cc3ccccc3 10 8.119 179
COc(cc1)ccc1CN2C[C@@H](CC[C@@H]3O)N(C[C@H]23)Cc4ccccc4 15 8.125 180
COc(cc1)ccc1CN2C[C@H](CC[C@H]3O)N(C[C@@H]23)Cc4ccccc4 ent-15 8.187 180
COc(cc1)ccc1CN2C[C@@H](CC[C@H]3O)N(C[C@H]23)Cc4ccccc4 20 6.928 180
COc(cc1)ccc1CN2C[C@H](CC[C@@H]3O)N(C[C@@H]23)Cc4ccccc4 ent-20 6.903 180
COc(cc1)ccc1CN2C[C@@H](CC[C@@H]3OC)N(C[C@H]23)Cc4ccccc4 17 6.588 180
COc(cc1)ccc1CN2C[C@H](CC[C@H]3OC)N(C[C@@H]23)Cc4ccccc4 ent-17 7.585 180
COc(cc1)ccc1CN2C[C@@H](CC[C@H]3OC)N(C[C@H]23)Cc4ccccc4 22 6.900 180
COc(cc1)ccc1CN2C[C@H](CC[C@@H]3OC)N(C[C@@H]23)Cc4ccccc4 ent-22 7.602 180
c1cc(Cl)c(Cl)cc1CC(=O)N2C[C@H](CC[C@@H]3N4CCCC4)N(C[C@@H]23)C
c5ccccc5 19 6.364 181
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c1cc(Cl)c(Cl)cc1CC(=O)N2C[C@H](CC[C@H]3N4CCCC4)N(C[C@@H]23)C
c5ccccc5 20 6.703 181
c1cc(Cl)c(Cl)cc1CC(=O)N2C[C@@H](CC[C@@H]3N4CCCC4)N(C[C@H]23)C
c5ccccc5 ent-20 5.432 181
c1ccccc1\C=C\CCN2CCN(C)CC2 3a 7.538 182
CC1CCN(CC1)CCC=C2c(cccc3)c3Sc(c24)cccc4 5 9.097 182
c1ccccc1C(c2ccccc2)=CCCN(CC3)CCC3C 6 8.721 182
c1ccccc1C(c2ccccc2)CCCN(CC3)CCC3C 7 8.959 182
c1ccccc1C(c2ccccc2)=CCCCN(CC3)CCC3C 8 9.886 182
c1ccccc1C(c2ccccc2)CCCCN(CC3)CCC3C 9 10.046 182
CCN(CC)CCOC(=O)C(CCC)(c1ccccc1)c2ccccc2 11 7.770 182
c1ccccc1C(O)(c2ccccc2)CCCCN(CC)CC 13 7.921 182
c1ccccc1C(c2ccccc2)CCCCN(CC)CC 14 8.854 182
c1ccccc1C(c2ccccc2)=CCCCN(C)CCc3ccccc3 15a 9.051 182
c1ccccc1C(c2ccccc2)=CCCCNCCc3ccccc3 15b 8.886 182
c1ccccc1C(c2ccccc2)CCCCN(C)CCc3ccccc3 16a 9.319 182
c1ccccc1C(c2ccccc2)CCCCNCCc3ccccc3 16b 9.180 182
c1ccccc1CCCCN2CCN(C)CC2 4 7.699 182
c1ccccc1/C=C\CCN2CCN(C)CC2 3b 7.538 182
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 Ditolylguanidine 7.721 14
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextrometorphan 7.357 14
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF,10047 7.387 14
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 9.699 14
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF,10047 5.706 14
c1cc(O)ccc1[C@@H](O)[C@@H](C)N(CC2)CCC2Cc3ccccc3 Ifenprodil 8.699 14
OCCN(CC1)CCN1CCCN(c(c23)cccc2)c4c(C=C3)cccc4 Opipramol 9.699 14
c1ccccc1[C@](C#N)(C(C)C)CCCN(C)CCc2ccccc2 (+)-Emopamil 8.959 14
c1ccccc1[C@@](C#N)(C(C)C)CCCN(C)CCc2ccccc2 (-)-Emopamil 8.222 14
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(C)CC4 Trifluoperazine 7.678 14
O[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4 Testosterone 5.854 14
CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4 Progesterone 6.471 14
OCC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H]([C@H](C2)O)
[C@]4(C)C(CC3)=CC(=O)CC4 Corticosterone 4.553 14
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 8.155 14
c1ccc(I)cc1CCN(C)CCN2CCCC2 2 8.602 183
c1cc(I)ccc1CCN(C)CCN2CCCC2 3 8.602 183
C1CCCN1CCN(C)Cc2c(I)cccc2 4 7.575 183
C1CCCN1CCN(C)Cc2cc(I)ccc2 5 8.444 183
C1CCCN1CCN(C)Cc2ccc(I)cc2 6 8.699 183
c1ccc(Br)cc1CCN(C)CCN2CCCC2 9 8.367 183
c1cc(Br)ccc1CCN(C)CCN2CCCC2 10 8.538 183
C1CCCN1CCN(C)Cc2cc(Br)ccc2 11 8.051 183
c1ccc(F)cc1CCN(C)CCN2CCCC2 12 8.268 183
c1cc(F)ccc1CCN(C)CCN2CCCC2 13 8.222 183
c1ccc(Cl)cc1CCN(C)CCN2CCCC2 14 8.658 183
c1cc(Cl)ccc1CCN(C)CCN2CCCC2 15 8.620 183
C=CCN(C[C@H]12)[C@@H](CC=C1)CN2Cc3ccc(cc3)OC 2 8.036 55
C=CCN(C[C@@H]12)[C@H](CC=C1)CN2Cc3ccc(cc3)OC ent-2 6.544 55
COc(cc1)ccc1CN2C[C@H](CC=C3)N(C[C@@H]23)Cc4ccccc4 3 9.041 55
COc(cc1)ccc1CN2C[C@@H](CC=C3)N(C[C@H]23)Cc4ccccc4 ent-3 8.357 55
C=CCN1C[C@H](CCC2)N(C[C@@H]12)Cc3ccc(cc3)OC 23a 7.959 184
C=CCN1C[C@@H](CCC2)N(C[C@H]12)Cc3ccc(cc3)OC ent-23a 7.569 184
COC1(OC)CC[C@H](N(C[C@H]12)CC=C)CN2Cc3ccc(cc3)OC 11 5.903 184
COC1(OC)CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3ccc(cc3)OC ent-11 6.231 184
C=CCN(C[C@H]12)[C@@H](CCC1=O)CN2Cc3ccc(cc3)OC 12 5.796 184
C=CCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-12 6.261 184
C=CCN(C[C@H]12)[C@@H](CC[C@H]1O)CN2Cc3ccc(cc3)OC 15a 5.650 184
C=CCN(C[C@@H]12)[C@H](CC[C@@H]1O)CN2Cc3ccc(cc3)OC ent-15a 6.465 184
C=CCN(C[C@H]12)[C@@H](CC[C@H]1O)CN2Cc3c(OC)cc(cc3)OC 15b 5.039 184
C=CCN(C[C@@H]12)[C@H](CC[C@@H]1O)CN2Cc3c(OC)cc(cc3)OC ent-15b 5.015 184
CO[C@@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3ccc(cc3)OC 16a 5.395 184
CO[C@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3ccc(cc3)OC ent-16a 4.793 184
C=CCN(C[C@H]12)[C@@H](CC[C@@H]1O)CN2Cc3ccc(cc3)OC 20a 4.636 184
C=CCN(C[C@@H]12)[C@H](CC[C@H]1O)CN2Cc3ccc(cc3)OC ent-20a 4.764 184
CO[C@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3ccc(cc3)OC 21a 5.456 184
CO[C@@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3ccc(cc3)OC ent-21a 5.082 184
CO[C@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3c(OC)cc(cc3)OC 21b 5.241 184
CO[C@@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3c(OC)cc(cc3)OC ent-21b 4.975 184
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C=CCN1C[C@H](CCC2)N(C[C@@H]12)Cc3c(OC)cc(cc3)OC 23b 6.573 184
C=CCN1C[C@@H](CCC2)N(C[C@H]12)Cc3c(OC)cc(cc3)OC ent-23b 6.251 184
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.377 184
CCCN(C[C@H]12)[C@@H](CCC1=O)CN2Cc3ccc(cc3)OC 7 6.488 54
CCCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-7 7.174 54
CC(C)=CCN(C[C@H]12)[C@@H](CCC1=O)CN2Cc3ccc(cc3)OC 12 7.699 54
CC(C)=CCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-12 7.770 54
COc(cc1)ccc1CN2C[C@H](CCC3=O)N(C[C@@H]23)Cc4ccccc4 14 7.276 54
COc(cc1)ccc1CN2C[C@@H](CCC3=O)N(C[C@H]23)Cc4ccccc4 ent-14 6.876 54
COc(cc1)ccc1CN2C[C@H](CCC3=O)N(C[C@@H]23)c4ccccc4 16 5.204 54
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@H](N(C[C@H]23)CC=C)CCC\3=C\c4ccccc4 15 6.499 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3OC
c4ccccc4 12 6.609 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\
c4ccccc4 ent-15 5.348 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3OC
c4ccccc4 ent-12 5.783 185
CCN(CC)C(=O)c1ccc(cc1)[C@H](c2ccccc2)N3C[C@H](CCC4)N(C[C@@H]34)CC=C ent-25 6.607 185
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3OCc4ccccc4 8a 6.437 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3OCc4ccccc4 11a 6.812 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3Oc4ccccc4 13a 5.674 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3OC
c4ccccc4 11b 6.415 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3Oc4ccccc4 13b 5.393 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3Oc4ccccc4 15a 5.263 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3Oc4ccccc4 15b 5.801 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\c4ccccc4 17a 5.921 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\c4ccccc4 17b 6.333 186
COc(cc1)ccc1CN2C[C@H](C3)N(CC=C)C[C@@H]2c(c3c45)[nH]c4ccc(c5)OC 21a 4.979 186
COc(cc1)cc(OC)c1CN2C[C@H](C3)N(CC=C)C[C@@H]2c(c3c45)[nH]c4ccc(c5)OC 21b 5.197 186
COc(cc1)ccc1CN([C@@H]2CN3CC=C)C[C@@H]3Cc(c4C)c2nc(c45)cccc5 23a 5.788 186
COc(cc1)cc(OC)c1CN([C@@H]2CN3CC=C)C[C@@H]3Cc(c4C)c2nc(c45)cccc5 23b 5.263 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3OCc4ccccc4 ent-8a 5.983 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3OCc4ccccc4 ent-11a 7.041 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3OCc4ccccc4 ent-11b 5.896 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3Oc4ccccc4 ent-15a 5.790 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3Oc4ccccc4 ent-15b 5.547 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CCC\3=C\c4ccccc4 ent-17a 6.983 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CCC\3=C\c4ccccc4 ent-17b 6.500 186
COc(cc1)cc(OC)c1CN([C@H]2CN3CC=C)C[C@H]3Cc(c4C)c2nc(c45)cccc5 ent-23b 5.788 186
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 1 8.409 58
c1cccc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 2 8.511 58
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 3 8.854 58
c1cc(Cl)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 4 8.190 58
c1cc(Cl)c(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 5 8.282 58
c1cc(Cl)cc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 6 8.015 58
Clc1cccc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 7 8.138 58
c1cccc(Br)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 8 8.539 58
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 9 9.060 58
c1cc(Br)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 10 8.401 58
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 11 8.449 58
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 12 8.611 58
c1cc(F)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 13 8.465 58
c1cc(F)cc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 14 8.412 58
c1c(F)ccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 15 8.376 58
Fc1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 16 8.237 58
c1cc(F)c(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 17 8.499 58
c1c(F)cc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 18 8.117 58
c1cccc(c1C(F)(F)F)CC(=O)NC2CCN(CC2)Cc3ccccc3 19 8.060 58
FC(F)(F)c1cc(ccc1)CC(=O)NC2CCN(CC2)Cc3ccccc3 20 8.407 58
FC(F)(F)c1ccc(cc1)CC(=O)NC2CCN(CC2)Cc3ccccc3 21 8.007 58
c1cccc([N+]([O-])=O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 22 7.570 58
c1ccc([N+]([O-])=O)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 23 8.341 58
c1cc([N+]([O-])=O)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 24 7.745 58
c1cc([N+]([O-])=O)cc([N+]([O-])=O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 25 7.848 58
c1cccc(O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 26 7.726 58
c1ccc(O)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 27 6.959 58
c1cc(O)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 28 6.543 58
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c1cc(O)c(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 30 7.623 58
c1cccc(OC)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 31 7.511 58
c1ccc(OC)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 32 7.979 58
COc(cc1)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 33 7.178 58
COc(c1)ccc(OC)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 34 7.363 58
COc(cc1)c(OC)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 35 6.453 58
COc(c1)cc(OC)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 36 6.917 58
COc(c1)c(OC)c(OC)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 37 7.097 58
O1COc(c12)ccc(c2)CC(=O)NC3CCN(CC3)Cc4ccccc4 38 8.135 58
COc(cc1)cc(OC)c1NC(=O)NC2CCN(CC2)Cc3ccccc3 39 7.521 58
CSc(cc1)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 41 7.567 58
CSc(cc1)ccc1NC(=O)NC2CCN(CC2)Cc3ccccc3 42 7.194 58
c1cc(N)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 43 6.328 58
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.597 58
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)Cc4ccccc4 1 8.252 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCC4 2 8.921 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCCC4 3 8.959 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCCCC4 4 8.959 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 5 8.721 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 6 6.917 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)Cc4ccccc4 7 8.495 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCC4 8 8.444 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCCC4 9 8.237 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCCCC4 10 8.319 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 11 6.398 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)[C@@H]([C@@H]45)
[C@H]6C[C@@H](C5)C[C@@H](C4)C6 12 7.553 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)Cc4ccccc4 13 8.229 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCC4 14 9.155 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCCC4 15 8.921 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCCCC4 16 8.770 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 17 8.208 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)[C@@H]([C@@H]45)
[C@H]6C[C@@H](C5)C[C@@H](C4)C6 18 8.208 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3Cc4ccccc4 19 7.252 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCC4 20 8.398 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCC4 21 8.602 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCCC4 22 7.244 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCCCC4 23 7.896 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 24 7.777 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3[C@@H]([C@@H]45)
[C@H]6C[C@@H](C5)C[C@@H](C4)C6 25 7.631 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3Cc4ccccc4 26 6.638 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCC4 27 7.319 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCC4 28 7.509 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCCC4 29 7.684 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCCCC4 30 7.229 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3[C@@H]([C@@H]45)
[C@H]6C[C@@H](C5)C[C@@H](C4)C6 31 6.426 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)
C5CCCCC5 32 7.161 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)
C5CCCCCC5 33 7.018 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)
Cc5ccccc5 37 7.131 187
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.824 187
c1ccccc1CN(C)Cc2cnc([nH]2)-c3c(OC)c(OC)ccc3 5a 7.777 188
c1ccc(OC)c(OC)c1-c([nH]2)ncc2CNC3CCN(CC3)Cc4ccccc4 5c 7.474 188
c1c(Br)cc(OC)c(OC)c1-c([nH]2)ncc2CNC3CCN(CC3)Cc4ccccc4 5d 7.072 188
c1ccc(OC)c(OC)c1-c([nH]2)ncc2CN[C@@H](C[C@H]34)C[C@@H](CCC3)
N4Cc5ccccc5 5e 6.232 188
c1cc(Cl)ccc1C2(O)CCN(CC2)Cc3cnc([nH]3)-c4c(OC)c(OC)cc(Br)c4 5n 6.627 188
c1ccccc1C2CCN(CC2)Cc3cnc([nH]3)-c4c(OC)c(OC)cc(Br)c4 5l 6.266 188
c1ccccc1CN(CC2)CCC2c(on3)nc3-c4c(OC)c(OC)ccc4 7d 8.180 188
c1sccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 2 8.143 57
s1cccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 1 8.406 57
n1c[nH]cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 3 6.605 57
n1ccccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 4 6.628 57
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c1cccc(c12)[nH]cc2CC(=O)NC3CCN(CC3)Cc4ccccc4 10 7.963 57
c1ncccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 5 6.570 57
c1cnccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 6 6.525 57
c1cccc(c12)cccc2CC(=O)NC3CCN(CC3)Cc4ccccc4 7 8.333 57
c1cccc(c12)cccc2NC(=O)NC3CCN(CC3)Cc4ccccc4 8 7.645 57
c1cccc(c12)ccc(c2)CC(=O)NC3CCN(CC3)Cc4ccccc4 9 7.209 57
c1cc(I)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 16 7.859 57
c1c(Br)ccc(c12)[nH]cc2CC(=O)NC3CCN(CC3)Cc4ccccc4 11 7.284 57
COc(c1)ccc(c12)[nH]cc2CC(=O)NC3CCN(CC3)Cc4ccccc4 12 6.902 57
n1cccnc1SCC(=O)NC2CCN(CC2)Cc3ccccc3 15 6.824 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3c(F)cccc3 17 7.993 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(F)ccc3 18 8.085 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 19 8.181 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3c(I)cccc3 20 6.460 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 21 8.171 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 22 8.044 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(cc3C(F)(F)F)ccc3 24 6.850 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(cc3)ccc3C(F)(F)F 25 7.060 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 26 7.720 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(Cl)c(Cl)cc3 27 8.140 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(F)c(F)cc3 28 8.201 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(c3)ccc(c34)OCO4 29 8.401 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(c3)ccc(c34)cccc4 30 7.622 57
c1ccccc1CC(=O)NC2CCN(CC2)CCc3ccccc3 31 7.505 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 32 8.502 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 33 7.812 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 34 8.377 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 35 8.259 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 36 8.368 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 37 8.648 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 38 8.939 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 39 8.636 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 40 8.493 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 41 8.917 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 42 8.457 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 43 8.750 57
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.252 189
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.050 189
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.201 189
c1ccccc1C[C@H]2CN[C@H](C)Cc(c23)cccc3 14a 5.983 189
c1cccc(c12)C[C@@H](CCCC)NC[C@@H]2Cc3ccccc3 14c 6.539 189
c1ccccc1C[C@H]2CN[C@H](c3ccccc3)Cc(c24)cccc4 14d 5.978 189
c1ccccc1C[C@@H]2CN[C@@H](C)Cc(c23)cccc3 ent-14a 5.976 189
c1cccc(c12)C[C@H](CC)NC[C@H]2Cc3ccccc3 ent-14b 6.682 189
c1cccc(c12)C[C@H](CCCC)NC[C@H]2Cc3ccccc3 ent-14c 7.585 189
C[C@H](C1)NCCc(c12)cccc2 12a 5.435 190
C[C@@H](C1)NCCc(c12)cccc2 ent-12a 6.524 190
CCCC[C@H](C1)NCCc(c12)cccc2 12c 7.796 190
CCCC[C@@H](C1)NCCc(c12)cccc2 ent-12c 6.056 190
c1cccc(c12)CCN[C@@H](C2)c3ccccc3 12d 7.301 190
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCN(c3ccccc3)c4ccccc4 25 7.012 191
c1cc(F)ccc1C(c2ccc(F)cc2)OCCN(CC3)CCN3CCCc4ccccc4 3 6.511 191
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCn(c3cccc4)c(c5c34)cccc5 11 6.983 191
C[C@@H]1CN(C[C@H](C)N1)CCCN(c2ccccc2)c3ccccc3 24 6.860 191
CN1[C@@H](C)CN(C[C@H]1C)CCCn(c2cccc3)c(c4c23)cccc4 10 6.258 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(c3)[N+]([O-])=O)c(c4c23)cccc4 7 6.225 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 1 6.042 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(Br)c3)c(c4c23)ccc(Br)c4 5 5.355 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(c3)N)c(c4c23)cccc4 8 5.243 191
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.658 192
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.721 192
COc(cc1)ccc1N(C2=O)C[C@@H](O2)CN(CC3)CCC3(O)c(c4)ccc(c45)OCO5 panamesine 6.955 192
COc(cc1)ccc1N(C2=O)C[C@@H](O2)CN(CC3)CC[Si]3(O)c(c4)ccc(c45)OCO5 sila-panamesine 7.432 192
c1cc(I)ccc1C(=O)NCCN(CC)CC IDAB 7.959 193
c1cc(I)ccc1C(=O)NCCN2CCCCC2 IPAB 8.590 193
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 4-IBP 8.770 194
c1ccc(I)cc1C(=O)NC2CCN(CC2)Cc3ccccc3 3-IBP 8.520 194
c1cccc(I)c1C(=O)NC2CCN(CC2)Cc3ccccc3 2-IBP 8.785 194
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c1cc(Br)ccc1CCN(C)CCN2CCCCC2 BrPEMP 8.524 195
c1cc(I)ccc1CCN(C)CCN2CCCCC2 IPEMP 9.086 195
CCN(CC)CCNS(=O)(=O)c1ccc(Br)cc1 1 7.996 196
CCN(CC)CCNS(=O)(=O)c1ccc(I)cc1 2 8.304 196
C1CCCN1CCNS(=O)(=O)c2ccc(Br)cc2 3 8.177 196
C1CCCN1CCNS(=O)(=O)c2ccc(I)cc2 4 8.372 196
C1CCCCN1CCNS(=O)(=O)c2ccc(Br)cc2 5 8.812 196
C1CCCCN1CCNS(=O)(=O)c2ccc(I)cc2 6 9.337 196
C1CCCCCN1CCNS(=O)(=O)c2ccc(Br)cc2 7 9.201 196
C1CCCCCN1CCNS(=O)(=O)c2ccc(I)cc2 8 8.879 196
C1CCCCCN1CCN(C)S(=O)(=O)c2ccc(Br)cc2 9 9.745 196
C1CCCCCN1CCN(C)S(=O)(=O)c2ccc(I)cc2 10 9.854 196
C1CCCCN1CCNS(=O)(=O)c(cc2)cc(I)c2OC 11 7.379 196
C1CCCCCN1CCN(C)S(=O)(=O)c(cc2)cc(I)c2OC 12 8.507 196
COc(cc1)c(I)cc1C(=O)NCCN2CCCCC2 PIMBA 7.927 197
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 8.174 198
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.129 198
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 7.101 198
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.721 198
c1ccccc1C(\CC)=C(c2ccccc2)/c3ccc(cc3)OCCN(C)C Tamoxifen 6.572 198
C1CCCN1CCOc(cc2)ccc2Cc3ccccc3 PBPE 9.620 198
c1ccccc1C(C)(C)c2ccc(cc2)OCCN3CCCC3 PCPE 8.983 198
c1ccccc1Cc2ccc(cc2)OCCN3CCOCC3 MBPE 8.759 198
c1ccccc1C(C)(C)c2ccc(cc2)OCCN3CCOCC3 MCPE 7.832 198
CCCSc(nsn1)c1C2=CCCNC2 P-TZTP 7.730 199
FCCCSc(nsn1)c1C2=CCCNC2 FP-TZTP 7.207 199
FCCSc(nsn1)c1C2=CCCNC2 FE-TZTP 7.664 199
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.752 200
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)OC ibogaine 5.031 200
c1ccccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-Vesamicol 7.588 201
c1cc(F)ccc1CN(C2)CC[C@@H](O)[C@@H]2N(CC3)CCC3c4ccccc4 (+)-FBT 7.666 201
c1cc(F)ccc1CN(C2)CC[C@H](O)[C@H]2N(CC3)CCC3c4ccccc4 (-)-FBT 7.654 201
c1ccccc1C(c2ccccc2)O[C@@H](C3)C[C@@H](N4C)CC[C@H]34 Benztropine 6.503 202
Clc1c(Cl)ccc(c1)NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6a 6.885 203
Clc1c(Cl)ccc(c1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3a 7.275 203
COc(c(Cl)c1)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3b 7.500 203
c1cc(Cl)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3c 7.590 203
c1ccc(Br)cc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3d 7.907 203
c1cc(Br)ccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3 8.201 203
Cc1c(C)cccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3f 8.215 203
c1cc(C)cc(c1C)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3g 8.036 203
CCc1ccc(cc1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3h 7.602 203
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3i 7.842 203
[O-][N+](=O)c(c1)ccc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3
Cc4ccccc4 3j 7.421 203
c1cc([N+]([O-])=O)cc(c1C)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3
Cc4ccccc4 3n 7.780 203
CCCCc1ccc(cc1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3l 8.208 203
c1ccc(SC)cc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3m 8.167 203
c1cccc(Br)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3o 8.398 203
COc(cc1)ccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3p 7.487 203




c1ccc(Br)cc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4d 8.180 203
c1cc(Br)ccc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4e 7.889 203
Cc1c(C)cccc1NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4f 7.939 203
c1cc(C)cc(c1C)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4g 8.222 203
CCc1ccc(cc1)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4h 7.764 203
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4i 7.034 203
[O-][N+](=O)c(c1)ccc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 4j 7.169 203
c1cc([N+]([O-])=O)cc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
Cc4ccccc4 4k 7.676 203
CCCCc1ccc(cc1)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4l 7.393 203
c1ccc(SC)cc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4m 7.876 203
[O-][N+](=O)c1cccc(c1C)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
Cc4ccccc4 4n 8.523 203
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COc(c1)ccc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4o 6.483 203
CC(C)c(cc1)cc(c1CC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4p 7.606 203
c1ccc(Br)cc1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6c 7.048 203
Brc1cccc(c1OC)NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6f 6.889 203
c1cc(Br)ccc1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6d 6.421 203
c1cc([N+]([O-])=O)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3C
c4ccccc4 3k 8.102 203
CCN(CC)Cc1ccc([nH]1)-c2c(OC)c(OC)cc(Br)c2 6g 6.561 204
c1ccccc1CN(Cc2ccccc2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6h 6.866 204
C1CCCCN1Cc2ccc([nH]2)-c3c(OC)c(OC)cc(Br)c3 6i 6.780 204
c1ccccc1C2CCN(CC2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6j 6.777 204
c1ccccc1CC2CCN(CC2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6k 6.951 204
c1cccc(c12)CN(C2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6q 6.409 204
c1cccc(c12)CN(C2)Cc3ccc([nH]3)-c(c4OC)cc(Br)c(c45)cccc5 11d 6.510 204
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 1b 6.695 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccccc4 2a 7.223 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCc4ccccc4 3 7.137 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCc4ccccc4 4 7.184 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCC
c4ccccc4 5 7.762 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCC
c4ccccc4 6 6.670 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCC
c4ccccc4 7 6.638 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(F)cc4 2b 6.582 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(I)cc4 2c 6.757 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc([N+]([O-])=O)cc4 2e 6.668 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(N)cc4 2f 5.648 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4cc(F)ccc4 1d 6.492 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(I)cc4 1e 6.343 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4cc(I)ccc4 1g 5.868 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(C)cc4 1h 6.564 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc([N+]([O-])=O)cc4 1i 6.268 98
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCN(CC3)Cc(c34)cccc4 11a 7.821 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCN(CC3)Cc(c34)cc(OC)c(c4)OC 11b 6.723 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCCCN(CC3)Cc(c34)cc(OC)c(c4)OC 12 5.936 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCN(CC2)Cc(c23)cccc3 13a 6.558 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 13b 5.533 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 14 4.889 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)CCC2c(c3Cl)cccc3Cl 15 6.092 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCCCN(CC3)CCC3c(c4Cl)cccc4Cl 16 6.124 205
c1c(Br)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cccc3 17 7.662 205
c1c(Br)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 18 5.261 205
Cc(c1)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 19 4.982 205
Cc(c1)ccc(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 20 5.512 205
c1cc(F)ccc1CN(CC2)CCC23c4c(C(=O)O3)cccc4 2c 8.114 206
c1cc(F)ccc1CN(CC2)CCC23c4c(CO3)cccc4 2d 9.745 206
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.244 207
c1ccccc1CN(CC2)CCC23c4c(CC(=O)O3)cccc4 18 7.533 208
c1ccccc1CN(CC2)CCC23c4c(C=CO3)cccc4 19 8.728 208
c1ccccc1CN(CC2)CCC23c4c(CCO3)cccc4 20 9.161 208
c1ccccc1CN(CC2)CCC23c4c(C(=O)O3)cccc4 25 7.672 208
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 6.785 208
c1ccccc1[C@]23[C@H](C2)CN(C3)C4CCCCC4 (+)-(1R,2S)-14 9.041 209
c1ccccc1[C@@]23[C@@H](C2)CN(C3)C4CCCCC4 (-)-(1S,2R)-14 7.836 209
C1CCCCC1CN(C2)C[C@@H](C3)[C@]23c4ccccc4 (+)-(1R,2S)-15 8.638 209
C1CCCCC1CN(C2)C[C@H](C3)[C@@]23c4ccccc4 (-)-(1S,2R)-15 8.032 209
c1ccccc1CCN(C2)C[C@@H](C3)[C@]23c4ccccc4 (+)-(1R,2S)-18 7.260 209
c1ccccc1CCN(C2)C[C@H](C3)[C@@]23c4ccccc4 (-)-(1S,2R)-18 6.785 209
c1ccccc1CCCN(C2)C[C@@H](C3)[C@]23c4ccccc4 (+)-(1R,2S)-19 7.796 209
c1ccccc1CCCN(C2)C[C@H](C3)[C@@]23c4ccccc4 (-)-(1S,2R)-19 7.319 209
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN(CC3)CCC3(O)c4ccc(Cl)cc4 (+)-1 8.403 210
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN(CC3)CCC3(O)c4ccccc4 (+)-8 8.299 210
c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CN(CC3)CCC3(O)c4ccccc4 (-)-8 8.154 210
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN3[C@@H](CC[C@@H]34)C[C@](C4)(O)c5ccc(Cl)cc5 (+)-9 7.357 210
c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CN3[C@@H](CC[C@@H]34)C[C@](C4)(O)c5ccc(Cl)cc5 (-)-9 6.284 210
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.159 210
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)C BD1047 9.032 211
157
[C@@]123c4c5c(OC)ccc4C[C@H](NCC3)[C@H]2CCC(=O)[C@H]1O5 (+)-nordihydrocodeinone 4.777 212
c1cc(Cl)c(Cl)cc1CCN[C@H]2[C@H](CCCC2)N3CCCC3 LR132 8.699 213
c1cc(Cl)c(Cl)cc1CCNCCN2CCCC2 BD1060 8.523 214
C1CCCN1CCN(CC=C)CCc2cc(Cl)c(Cl)cc2 BD1052 8.699 214
c1cc(Cl)c(Cl)cc1CCN(CC)CCN2CCCC2 BD1067 8.699 214
c1cccc(OC)c1CCN(CC)CCN2CCCCC2 UMB98 7.602 215
c1ccc(OC)cc1CCN(CC)CCN2CCCCC2 UMB99 7.796 215
COc(cc1)ccc1CCN(CC)CCN2CCCCC2 UMB100 7.620 215
c1cccc(OC)c1CCN(C)CCN2CCCCC2 UMB101 7.495 215
c1ccc(OC)cc1CCN(C)CCN2CCCCC2 UMB102 7.602 215
COc(cc1)ccc1CCN(C)CCN2CCCCC2 UMB103 7.678 215
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccccc3 1a 9.310 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(cc3)OC 1b 8.975 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(O)cc3 1c 8.347 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(F)cc3 1d 9.143 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 1e 9.268 216
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2a 7.061 216
COc(cc1)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2b 7.003 216
c1cc(O)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2c 7.207 216
c1cc(F)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2d 7.500 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2e 7.011 216
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3a 9.237 216
COc(cc1)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3b 8.658 216
c1cc(O)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3c 7.807 216
c1cc(F)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3d 9.237 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3e 9.081 216
c1ccccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4a 7.585 216
COc(cc1)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4b 7.693 216
c1cc(O)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4c 7.678 216
c1cc(F)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4d 8.143 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4e 7.444 216
c1ccccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5a 8.921 216
COc(cc1)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5b 8.602 216
c1cc(O)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5c 7.896 216
c1cc(F)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5d 8.854 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5e 9.092 216
N#CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 2 4.886 217
N#CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 3 5.009 217
N#CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 4 5.770 217
N#CCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 5 6.310 217
N#CCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 6 6.194 217
N#CCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 7 7.097 217
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 8 4.959 217
C=CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 9 5.796 217
C=CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 10 7.301 217
C=CCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 11 7.658 217
CC#CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 12 5.009 217
C#CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 13 5.229 217
C#CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 14 6.699 217
N#CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 16 4.959 217
N#CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 17 6.602 217
N#CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 18 7.699 217
N#CCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 19 7.444 217
N#CCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 20 7.481 217
N#CCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 21 7.796 217
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 22 6.523 217
C=CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 23 7.824 217
C=CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 24 8.678 217
C=CCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 25 8.959 217
CC#CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 26 6.796 217
C#CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 27 6.959 217
C#CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 28 7.745 217
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCCCC2 LR172 9.398 218
c1cc(F)ccc1-n(c(c23)cccc2)c(=O)n3CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC CM353 5.903 219
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM398 5.821 219
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)CCC34c5c(CO4)cccc5 CM699 7.857 219
CCCCCn1c(=O)n(c(c12)cccc2)CCCCN3CCN(CC3)c4ccc(F)cc4 CM775 6.564 219
c1cccc(c12)n(CCC)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM777 6.447 219
158
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5ccccc5 3a 8.347 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5ccc(cc5)OC 3b 8.824 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c(cc5)ccc5C 3c 8.444 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5ccc([N+]([O-])=O)cc5 3d 8.770 220
N#Cc1ccc(cc1)-c(sc2)c(CCO3)c2C34CCN(CC4)Cc5ccccc5 3e 8.469 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5cccc(c56)cccc6 3f 8.398 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)csc4 5 9.456 220
c1ccccc1CN(CC2)CCC23c4c(C=CO3)csc4 14 8.721 220
c1ccccc1C(\CC)=C(c2ccccc2)/c3ccc(cc3)OCCN(C)C Tamoxifen 7.585 221
c1cccc(c12)oc(CCCC)c2C(=O)c3cc(I)c(c(I)c3)OCCN(CC)CC Amiodarone 8.678 221
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c(cc3C(F)(F)F)ccc3 Trifluperidol 8.886 221
c1cccc(Cl)c1CNC[C@H]2CC[C@@H](CC2)CNCc3c(Cl)cccc3 AY-9944 9.337 221
c1ccccc1/C(Cl)=C(c2ccccc2)\c3ccc(cc3)OCCN(CC)CC Enclomiphene 7.921 221
c1ccccc1\C(Cl)=C(c2ccccc2)\c3ccc(cc3)OCCN(CC)CC Zuclomiphene 8.260 221
CCCCN(CC1)CCC12c3c(CCC2)cccc3 L-609,404 9.222 221
Cn1c(=O)sc(c12)cc(cc2)CCN(CC3)CCC3c4ccccc4 6 7.699 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN3CCN(CC3)Cc4ccccc4 11 7.429 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN3CCN(CC3)Cc4cc(Cl)c(Cl)cc4 15 6.857 222
NC12C[C@@H]3C[C@H](C1)C[C@H](C2)C3 amantadine 4.853 223
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.469 223
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.770 223
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.886 223
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC dextromethorphan 6.569 223
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)O dextrorphan 6.408 223
C1CN(C)CCC12N=Nc3c(N2)cccc3 1 5.467 224
c1ccccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 2 8.553 224
c1cc(F)ccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 3 8.553 224
c1cc(Cl)ccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 4 8.903 224
c1cc(C)ccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 5 8.602 224
COc(cc1)ccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 6 8.398 224
c1ccccc1CCN(CC2)CCC23N=Nc4c(N3)cccc4 7 8.398 224
c1ccccc1CCCCN(CC2)CCC23N=Nc4c(N3)cccc4 8 8.420 224
c1ccccc1CCCCCN(CC2)CCC23N=Nc4c(N3)cccc4 9 9.027 224
c1ccccc1C(=O)CCCN(CC2)CCC23N=Nc4c(N3)cccc4 10 7.854 224
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23N=Nc4c(N3)cccc4 11 7.921 224
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.222 224
c1ccccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 2 9.222 224
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.215 225
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.409 225
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.928 226
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.030 226
c1cccc(O)c1C(=O)CCCCCN2CCN(CC2)c3noc(c34)cccc4 40 7.215 227
c1cccc(OC)c1C(=O)CCCCCN2CCN(CC2)c3noc(c34)cccc4 43 5.367 227
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.161 228
[C@@H]12CC[C@H](N2C)C[C@H](C1)OC(=O)[C@@H](C)Oc3ccc(F)cc3 R(+)1 6.446 228
[C@@H]12CC[C@H](N2C)C[C@H](C1)OC(=O)[C@H](C)Sc3ccc(Cl)cc3 S(-)16 6.427 228
Cc1ccc(cc1)[C@]2(C(=O)OC)[C@H](C2)CN(CC3)CCC3(O)c4ccccc4 (+)-7 8.721 229
Cc1ccc(cc1)[C@@]2(C(=O)OC)[C@@H](C2)CN(CC3)CCC3(O)c4ccccc4 (-)-7 7.886 229
c1ccccc1CN(CC2)CCC23C(=O)c4c(CC3)cccc4 1 8.854 230
c1ccccc1CN(CC2)CCC23CCc4c(S3)cccc4 2 9.301 230
c1ccccc1CN(CC2)CCC23CCc4c(S3(=O)=O)cccc4 4 7.699 230
c1ccccc1CN(CC2)CCC23CCc4c(O3)cccc4 5 9.208 230
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 8.495 230
CN1CCN(CC1)C2=Nc(cc(Cl)cc3)c3Nc(c24)cccc4 clozapine 5.071 230
c1cc(F)ccc1C(=O)NCCN(CC)CC F-FBZA 5.051 231
C1CCCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 1a 8.018 232
C1COCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 2a 7.873 232
C1CCCCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3a 7.697 232
C1CCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 4a 8.131 232
CCN(CC)CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 5a 7.818 232
CN(C)CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 6a 7.703 232
C1CCCCC1NCCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 7c 7.381 232
c1ccccc1NCCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 8c 8.229 232
c1ccccc1N(C)CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 9c 8.252 232
c1ccccc1N(CC)CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 10c 7.375 232
c1ccccc1CNCCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 11c 7.529 232
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.796 232
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 8.215 232
159
c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CNC34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (-)-cis-18 8.398 233
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CNC34C[C@@H]5C[C@H](C3)C[C@H](C4)C5 (+)-cis-18 6.631 233
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.229 233
C1CCCCN1CCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-1a 5.342 234
C1CCCN1CCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-1b 5.143 234
C1CCCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-3a 7.699 234
C1CCCCN1CCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-3a 7.495 234
C1CCCN1CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-3b 7.469 234
C1CCCN1CCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-3b 6.599 234
c1ccccc1NCCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)7a 5.648 234
c1ccccc1NCCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-8a 7.678 234
c1ccccc1NCCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-8a 7.237 234
c1ccccc1N(C)CCN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-8b 7.041 234
c1ccccc1N(C)CCN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-8b 6.854 234
c1ccccc1[C@]2(C(=O)OC)[C@H](C2)CN(CC3)CCC3(O)c4ccc(Cl)cc4 (+)-7(MR 200) 8.821 235
c1ccccc1[C@@]2(C(=O)OC)[C@@H](C2)CN(CC3)CCC3(O)c4ccc(Cl)cc4 (-)-7(MR 201) 8.252 235
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.658 235
CN(C)C/C=C(\C)c1ccc(cc1)OC 11 6.094 67
c1ccccc1C(\C)=C\CN(C)Cc2ccccc2 13 7.036 67
COc(cc1)ccc1C(\C)=C\CN(C)Cc2ccccc2 14 8.280 67
c1ccc(OC)cc1C(\C)=C\CN(C)Cc2ccccc2 15 8.000 67
C1CCCCN1C/C=C(\C)c(c2)ccc(c23)cccc3 16 9.013 67
C1CCCCN1C/C=C(\C)c2ccc(cc2)-c3ccccc3 17 9.066 67
c1ccccc1C(\C)=C\CN2CCCCC2 18 6.338 67
COc(cc1)ccc1C(\C)=C\CN2CCCCC2 19 7.854 67
c1ccc(OC)cc1C(\C)=C\CN2CCCCC2 20 7.041 67
c1cccc(c12)ccc(c2)C(\C)=C\CN(CC3)CCC3Cc4ccccc4 21 7.638 67
c1ccccc1-c(cc2)ccc2C(\C)=C\CN(CC3)CCC3Cc4ccccc4 22 8.154 67
c1ccccc1C(\C)=C\CN(CC2)CCC2Cc3ccccc3 23 8.971 67
COc(cc1)ccc1C(\C)=C\CN(CC2)CCC2Cc3ccccc3 24 8.383 67
c1ccc(OC)cc1C(\C)=C\CN(CC2)CCC2Cc3ccccc3 25 8.114 67
C1COCCN1C/C=C(\C)c(c2)ccc(c23)cccc3 26 8.018 67
C1COCCN1C/C=C(\C)c2ccc(cc2)-c3ccccc3 27 7.936 67
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 6.751 236
c1ccccc1CN(CC2)CCC23c4c(C=CO3)n(nc4)-c5ccccc5 26 8.830 237
c1ccccc1CN(CC2)CCC23c4c(C=CO3)n(C)nc4 27 7.921 237
c1ccccc1Cn(nc2)c(CCO3)c2C34CCN(CC4)Cc5ccccc5 28a 8.767 237
c1ccccc1CCCN(CC2)CCC23c4c(CCO3)n(nc4)Cc5ccccc5 28c 9.092 237
c1ccccc1Cn(nc2)c(CCO3)c2C34CCN(CC4)CC5CCCCC5 28d 9.367 237
CC(C)CCN(CC1)CCC12c3c(CCO2)n(nc3)Cc4ccccc4 28e 9.009 237
CC(C)=CCN(CC1)CCC12c3c(CCO2)n(nc3)Cc4ccccc4 28f 9.013 237
c1ccccc1CN(CC2)CCC23c4c(CCO3)n(C)nc4 29a 8.036 237
c1ccccc1CCCN(CC2)CCC23c4c(CCO3)n(C)nc4 29c 7.770 237
CC(C)CCN(CC1)CCC12c3c(CCO2)n(C)nc3 29d 7.523 237
CC(C)=CCN(CC1)CCC12c3c(CCO2)n(C)nc3 29e 7.854 237
CC(=O)[C@H]1CC[C@H]([C@@]12C)[C@H]3[C@H](CC2)[C@]4(C)C(CC3)=CC(=O)CC4 progesterone 6.180 237
c1cc(F)ccc1C(=O)CCCN(CC2)CC[Si]2(O)c3ccc(Cl)cc3 sila-haloperidol 8.469 238
Cc(c1)ccc(OCCF)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3a 4.643 239
c1c(Br)cc(OC)c(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3b 4.815 239
Cc(c1)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3c 6.481 239
c1c(Br)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3d 5.968 239
c1c(I)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3e 5.886 239
c1c(I)cc(OC)c(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3f 5.668 239
c1cc(F)ccc1C(=O)C2CCN(CC2)[C@@H](C3)[C@@H](O)Cc(c34)cccc4 (-)-9e 6.181 240
c1cc(F)ccc1C(=O)C2CCN(CC2)[C@H](C3)[C@H](O)Cc(c34)cccc4 (+)-9e 6.731 240
FCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OCCF)cccc3 20c 5.361 241
FCCOCCOCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 18c 5.312 241
FCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 18a 5.321 241
CN(C)c(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OCCF)cccc3 20a 5.708 241
c1sccc1-c(cc2)ccc2C(=O)NCCCCN3CCN(CC3)c4c(OCCF)cccc4 20e 4.680 241
FCCc(cc1)ccc1C(=O)NC/C=C/CN2CCN(CC2)c3c(OCCF)cccc3 21b 5.143 241
c1sccc1-c(cc2)ccc2C(=O)NC/C=C/CN3CCN(CC3)c4c(OCCF)cccc4 21e 5.109 241
CCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCC3 1 9.222 242
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCCN3CCCCC3 2 8.638 242
CCC(=O)c(cc1)cc(c12)oc(=O)n2CCCN3CCCCC3 3 8.071 242
CCCCC(=O)c(cc1)cc(c12)oc(=O)n2CCN3CCCCC3 4 7.638 242
CCCCC(=O)c(cc1)cc(c12)oc(=O)n2CCCN3CCCCC3 5 7.398 242
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCN3CCCCC3 6 7.328 242
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CCCCC(=O)c(cc1)cc(c12)sc(=O)n2CCN3CCCCC3 7 7.310 242
c1ccccc1C(=O)c(cc2)cc(c23)sc(=O)n3CCN4CCCC4 8 7.268 242
CCC(=O)c(cc1)cc(c12)sc(=O)n2C(=O)CC 9 7.201 242
CCC(=O)c(cc1)cc(c12)oc(=O)n2CCN3CCCCC3 10 7.143 242
C1COCCN1CCn2c(=O)oc(c23)cc(cc3)Cc4ccccc4 11 7.143 242
c1ccccc1C(=O)c(cc2)cc(c23)sc(=O)n3CCN4CCCCC4 12 7.081 242
c1ccccc1C(=O)c(cc2)cc(c23)sc(=O)n3CCN(C)C 13 6.979 242
CCCCCc(cc1)cc(c12)oc(=O)n2CCN3CCOCC3 14 6.752 242
c1ccccc1C(=O)c(cc2)cc(c23)oc(=O)n3CCN4CCCC4 15 6.733 242
c1ccccc1C(=O)c(cc2)cc(c23)oc(=O)n3CCN4CCCCC4 16 6.627 242
CCCCC(=O)c(cc1)cc(c12)oc(=O)n2CCN3CCCC3 17 6.491 242
c1ccccc1C(=O)c(cc2)cc(c23)oc(=O)n3CCN(C)C 18 6.438 242
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCN3CCCC3 19 6.243 242
CCC(=O)c(cc1)cc(c12)oc(=O)n2CCN3CCCC3 20 6.210 242
CCCCC(=O)c(cc1)cc(c12)sc(=O)n2CCN(C)C 21 6.202 242
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 8.456 243
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Cl)cc4 2 7.714 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 7 7.917 244
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Cl)cc4 6 6.616 244
c1cc(Br)ccc1C2(O)CCN(CC2)Cc3c[nH]c(c34)cccc4OC 8 5.592 244
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 9 6.967 244
COc1cccc(c12)[nH]cc2CN(CC3)CCC34C(=O)N(C)CN4c5ccccc5 14 5.502 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3c4ccccc4 17 6.480 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(cc4)SC 20 7.402 244
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(cc4)SC 21 6.627 244
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCN 1a 5.604 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCN 1b 5.848 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCCCCCCCN 1c 6.872 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCNC
c4cc(Br)ccc4 2a 7.179 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCNCc4cc(F)ccc4 2b 9.523 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCNCc4cc(I)ccc4 2c 7.195 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCNC
c4ccc(Br)cc4 2d 8.770 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCNC
c4ccc(F)cc4 2e 7.655 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCNCc4ccc(I)cc4 2f 9.469 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNC
c4cc(Br)ccc4 3a 6.949 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNC
c4cc(F)ccc4 3b 9.337 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNCc
4cc(I)ccc4 3c 9.252 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNC
c4ccc(Br)cc4 3d 7.365 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNC
c4ccc(F)cc4 3e 9.000 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCCNC
c4ccc(I)cc4 3f 9.187 245
c1cc(Cl)ccc1C(=O)NCCCCCCN2[C@H](CCC3)C[C@@H](C[C@@H]23)OC(=O)Nc(c(cc4)OC)cc4C 4a 5.855 245
c1cc(Br)ccc1C(=O)NCCCCCCN2[C@H](CCC3)C[C@@H](C[C@@H]23)OC(=O)Nc(c(cc4)OC)cc4C 4b 5.690 245
c1cc(F)ccc1C(=O)NCCCCCCN2[C@H](CCC3)C[C@@H](C[C@@H]23)OC(=O)Nc(c(cc4)OC)cc4C 4c 5.906 245
c1cc(I)ccc1C(=O)NCCCCCCN2[C@H](CCC3)C[C@@H](C[C@@H]23)OC(=O)Nc(c(cc4)OC)cc4C 4d 5.850 245
N1C(=O)N[C@@H]([C@@H]12)CS[C@@H]2CCCCC(=O)NCCCCCCN3
[C@H](CCC4)C[C@@H](C[C@@H]34)OC(=O)Nc(c(cc5)OC)cc5C 5 5.468 245
N1C(=O)N[C@@H]([C@@H]12)CS[C@@H]2CCCCC(=O)NCCCCCCCC
CCN3[C@H](CCC4)C[C@@H](C[C@@H]34)OC(=O)Nc(c(cc5)OC)cc5C 6 4.990 245
N1C(=O)N[C@@H]([C@@H]12)CS[C@@H]2CCCC(=O)N
CCCCCC(=O)NCCCCCCN3[C@H](CCC4)C[C@@H](C[C@@H]34)OC(=O)Nc(c(cc5)OC)cc5C 7 4.984 245
N1C(=O)N[C@@H]([C@@H]12)CS[C@@H]2CCCC(=O)NCCCCCC(=O)N
CCCCCCCCCCN3[C@H](CCC4)C[C@@H](C[C@@H]34)OC(=O)Nc(c(cc5)OC)cc5C 8 5.418 245
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3
CCCCCCNS(=O)(=O)c(ccc4)c(c45)cccc5N(C)C 9 4.898 245
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.839 245
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c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 5 8.699 246
c1cc(I)ccc1C2(O)CCN(CC2)Cc3c[nH]c(c34)cccc4OC 6 6.055 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 7 6.706 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccccc4 8 5.816 246
FCCOc1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 9 5.492 246
FCCOc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 10 6.644 246
COc1cccc(c12)[nH]cc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 11 5.384 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 12 5.753 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 13 7.821 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 14 8.921 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(cc4)SC 15 8.093 246
c1cccc(c12)oc(c2)CN(CC3)CCC3(O)c4ccc(Br)cc4 18 8.611 246
c1cccc(c12)oc(c2)CN(CC3)CCC3(O)c4ccc(I)cc4 19 8.851 246
c1cccc(c12)sc(c2)CN(CC3)CCC3(O)c4ccc(Br)cc4 20 8.672 246
c1cccc(c12)occ2CN(CC3)CCC3(O)c4ccc(Br)cc4 21 9.229 246
c1cccc(c12)occ2CN(CC3)CCC3(O)c4ccc(I)cc4 22 9.292 246
c1cccc(c12)occ2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 23 5.750 246
c1cccc(c12)scc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 24 5.726 246
c1cccc(c12)occ2CN(CC3)CCC34C(=O)N(C)CN4c5ccccc5 25 6.150 246
c1ccccc1N2CN(CCF)C(=O)C23CCN(CC3)Cc4coc(c45)cccc5 26 7.553 246
c1cccc(c12)scc2CN(CC3)CCC34C(=O)N(C)CN4c5ccccc5 27 6.480 246
c1ccccc1N2CN(Cc3cn(nn3)CCF)C(=O)C24CCN(CC4)Cc5coc(c56)cccc6 29 6.096 246
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3(O)c4ccc(Cl)cc4 2 6.380 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 3 6.364 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3n4c(=O)[nH]c(c45)cc(Cl)cc5 4 6.801 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC34C(=O)NCN4c5ccccc5 5 5.510 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cccc4 6 5.930 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OCCF)cccc4 7 4.867 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4ccc(cc4)OC 8 6.770 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cc(cc4)OC 9 6.208 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c(cc4)c(OC)cc4C 10 6.424 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cccc4 11 5.580 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OCCF)cccc4 12 4.680 247
C1CC(=O)Nc(c12)cc(cc2)OCCCN3CCN(CC3)c4c(OC)cccc4 13 6.120 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCN3CCN(CC3)c4c(OC)cccc4 14 5.585 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCCN3CCN(CC3)c4c(OC)cccc4 15 5.870 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCCN3CCN(CC3)c4c(OC)cccc4 16 5.792 247
c1ccccc1CCN(C[C@@H]2CCCO)CCN2Cc3ccccc3 15 7.180 248
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2N(C)C 19a 7.623 249
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@@H]2N(C)C 19b 6.620 249
c1cc(Cl)c(Cl)cc1CC(=O)N[C@@H]2CC[C@@H](CN3C)N(C[C@H]23)Cc4ccccc4 22a 6.883 249
c1cc(Cl)c(Cl)cc1CC(=O)N[C@H]2CC[C@@H](CN3C)N(C[C@H]23)Cc4ccccc4 22b 6.735 249
O[C@@H]1CC[C@@H](CN2C)N(C[C@H]12)Cc3ccccc3 8a(2R) 5.620 250
O[C@H]1CC[C@@H](CN2C)N(C[C@H]12)Cc3ccccc3 8a(2S) 5.304 250
c1ccccc1CCN2C[C@H](CC[C@H]3O)N(C[C@@H]23)Cc4ccccc4 8c(2R) 7.530 250
c1ccccc1CCN2C[C@H](CC[C@@H]3O)N(C[C@@H]23)Cc4ccccc4 8c(2S) 7.478 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2OC 12a(2R) 5.870 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2OCc4ccccc4 13a(2R) 7.790 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CCC2(OC)OC 15a 5.456 250
c1cc(Cl)c(Cl)cc1CC(=O)NCC[C@@H]2C[C@@H](C[C@@H](O2)OC)NCc3ccccc3 22beta 7.081 251
c1cc(Cl)c(Cl)cc1CC(=O)NCC[C@@H]2C[C@@H](NC)C[C@@H](O2)OC 25beta 5.848 251
c1ccccc1CC(=O)NCC[C@@H]2C[C@H](C[C@H](O2)OC)NCc3ccccc3 29alpha 6.602 251
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3Cc4ccccc4 (1R)-14a 8.420 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3CCc4ccccc4 (1R)-14b 8.569 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@H]3Cc4c(C)cccc4 (1S)-14c 8.301 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3Cc4ccc(cc4)OC (1R)-14d 7.886 252
c1ccccc1[C@H](CO)N(C[C@@H]2C)CCc(c23)cccc3 (1R)-14e 9.161 252
c1ccccc1[C@H](CO)N(C[C@H]2C)CCc(c23)cccc3 (1S)-14e 8.678 252
c1ccccc1C[C@H]2CNCCc(c23)cccc3 (1R)-15a 8.469 252
c1ccccc1C[C@@H]2CNCCc(c23)cccc3 (1S)-15a 7.585 252
c1ccccc1CC[C@H]2CNCCc(c23)cccc3 (1R)-15b 8.276 252
c1cccc(C)c1C[C@H]2CNCCc(c23)cccc3 (1R)-15c 7.854 252
c1cccc(C)c1C[C@@H]2CNCCc(c23)cccc3 (1S)-15c 8.244 252
COc(cc1)ccc1C[C@H]2CNCCc(c23)cccc3 (1R)-15d 8.638 252
COc(cc1)ccc1C[C@@H]2CNCCc(c23)cccc3 (1S)-15d 8.081 252
C[C@H]1CNCCc(c12)cccc2 (1R)-15e 8.000 252
C[C@@H]1CNCCc(c12)cccc2 (1S)-15e 8.046 252
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 1 6.055 253
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c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C2)CCc(c3)c2cc(c34)OCO4 2 7.085 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc4c(c3)OCCO4 3 6.471 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc4c(c3)OCCCO4 4 5.845 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCNCCc2cc(OC)c(cc2)OC 5 6.056 253
c1cccc(c12)[nH]cc2CN3CCN(CC3)c4ccc(F)cc4 1a 5.439 254
c1cccc(c12)[nH]cc2CN3CCN(CC3)c4c(F)ccc(F)c4 1b 6.666 254
c1cccc(c12)[nH]cc2CN3CCN(CC3)c(c4)ccc(Cl)c4Cl 1c 6.900 254
c1cc(F)ccc1N(CC2)CCN2Cc3cn(c(c34)cccc4)CN5CCN(CC5)c6ccc(F)cc6 2a 5.570 254
c1cccc(c12)n(cc2C)CN3CCN(CC3)c4ccc(F)cc4 3a 6.000 254
c1ccccc1CCN2CCN(CC2)Cn(cc3C)c(c34)cccc4 3b 7.848 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4ccc(F)cc4 4a 6.341 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4c(F)cccc4 4b 6.578 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4ccccc4 4c 5.826 254
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.036 255
CCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCCC3 9 9.252 255
CCCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCC3 10 8.432 255
C1CCCCN1CCCn2c(=O)sc(c23)cc(cc3)CCC 11 8.921 255
C1CCCCN1CCCCn2c(=O)sc(c23)cc(cc3)CCC 12 8.538 255
CCCc(cc1)cc(c12)sc(=O)n2CCN(C3)C[C@](C)([C@]34C)CCC4 13 8.854 255
CCCc(cc1)cc(c12)OCC(=O)N2CCN3CCCCC3 16 7.553 255
c1cccc(OC)c1CC(=O)N(C)CCN2CCCC2 4 5.263 256
c1ccc(OC)cc1CC(=O)N(C)CCN2CCCC2 5 5.509 256
COc(cc1)ccc1CC(=O)N(C)CCN2CCCC2 6 5.654 256
c1cccc([N+]([O-])=O)c1CC(=O)N(C)CCN2CCCC2 7 6.133 256
c1ccc([N+]([O-])=O)cc1CC(=O)N(C)CCN2CCCC2 8 5.733 256
c1cc([N+]([O-])=O)ccc1CC(=O)N(C)CCN2CCCC2 9 6.061 256
c1cccc(OC)c1CCN(C)CCN2CCCC2 10 7.804 256
c1ccc(OC)cc1CCN(C)CCN2CCCC2 11 7.623 256
COc(cc1)ccc1CCN(C)CCN2CCCC2 12 7.519 256
c1cccc([N+]([O-])=O)c1CCN(C)CCN2CCCC2 13 8.114 256
c1ccc([N+]([O-])=O)cc1CCN(C)CCN2CCCC2 14 8.194 256
c1cc([N+]([O-])=O)ccc1CCN(C)CCN2CCCC2 15 8.367 256
c1cccc(N)c1CCN(C)CCN2CCCC2 16 6.536 256
c1ccc(N)cc1CCN(C)CCN2CCCC2 17 6.237 256
c1cc(N)ccc1CCN(C)CCN2CCCC2 18 6.559 256
c1cc(Cl)c(Cl)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 1 7.553 257
c1cccc([N+]([O-])=O)c1CC(=O)N2CCN(CC2)CCCc3ccccc3 2 8.102 257
c1ccc([N+]([O-])=O)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 3 8.119 257
c1cc([N+]([O-])=O)ccc1CC(=O)N2CCN(CC2)CCCc3ccccc3 4 7.854 257
c1cccc(OC)c1CC(=O)N2CCN(CC2)CCCc3ccccc3 5 7.252 257
c1ccc(OC)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 6 7.585 257
COc(cc1)ccc1CC(=O)N2CCN(CC2)CCCc3ccccc3 7 7.886 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(Cl)c(Cl)cc3 8 8.658 257
c1ccccc1CCCN2CCN(CC2)CCc3c([N+]([O-])=O)cccc3 9 8.921 257
c1ccccc1CCCN2CCN(CC2)CCc3cc([N+]([O-])=O)ccc3 10 9.143 257
c1ccccc1CCCN2CCN(CC2)CCc3ccc([N+]([O-])=O)cc3 11 8.585 257
c1ccccc1CCCN2CCN(CC2)CCc3c(N)cccc3 12 8.319 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(N)ccc3 13 8.699 257
c1ccccc1CCCN2CCN(CC2)CCc3ccc(N)cc3 14 8.387 257
c1ccccc1CCCN2CCN(CC2)CCc3c(OC)cccc3 15 8.409 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)ccc3 16 8.854 257
c1ccccc1CCCN2CCN(CC2)CCc3ccc(cc3)OC 17 8.886 257
c1cccc(OC)c1CC(=O)N2CCN(CC2)C(=O)Cc3c(OC)cccc3 18 5.834 257
c1cccc(OC)c1CCN2CCN(CC2)CCc3c(OC)cccc3 21 6.839 257
c1ccc(OC)cc1CCN2CCN(CC2)CCc3cc(OC)ccc3 22 8.276 257
COc(cc1)ccc1CCN2CCN(CC2)CCc3ccc(cc3)OC 23 8.086 257
CC(C)(C)OC(=O)NCCC(=O)N1CCN(CC1)CCCc2ccccc2 25 7.066 257
CC(C)(C)OC(=O)NCCCC(=O)N1CCN(CC1)CCCc2ccccc2 26 9.495 257
NCC(=O)N1CCN(CC1)CCCc2ccccc2 27 8.387 257
NCCC(=O)N1CCN(CC1)CCCc2ccccc2 28 6.830 257
NCCCC(=O)N1CCN(CC1)CCCc2ccccc2 29 6.695 257
c1ccccc1CCCN2CCN(CC2)CCN 30 8.585 257
c1ccccc1CCCN2CCN(CC2)CCCN 31 6.742 257
NCCCCN1CCN(CC1)CCCc2ccccc2 32 6.752 257
c1cc(Cl)c(Cl)cc1CCN2CCCC2 4 7.542 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN2CCCC2 5 7.860 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN(C)CCN2CCCC2 6 6.959 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN(C)CCN(C)CCN2CCCC2 7 6.644 258
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C1CCCN1CCCN(C)CCN(C)Cc2cc(Cl)c(Cl)cc2 8 7.524 258
c1cc(Cl)c(Cl)cc1CN(C)CCCN(C)CCN2CCCC2 9 8.097 258
C1CCCN1CCN(C)CCN(C)Cc2cc(Cl)c(Cl)cc2 10 8.827 258
c1cc(Cl)c(Cl)cc1CCN(C)CCCN(C)CCCN2CCCC2 11 7.111 258
C1CCCN1CCCCN(C)CCCN(C)CCc2cc(Cl)c(Cl)cc2 12 6.893 258
c1cc(Cl)c(Cl)cc1CCN(C)CCCCN(C)CCCCN2CCCC2 13 5.950 258
c1cc(Cl)c(Cl)cc1CCN(CCN)CCN2CCCC2 14 7.390 258
NCCNCCc1cc(Cl)c(Cl)cc1 15 6.409 258
c1cc(Cl)c(Cl)cc1CCNCCNCCN 16 6.614 258
c1cc(Cl)c(Cl)cc1CCNCCNCCN2CCCC2 17 7.268 258
164
Table F.2: Sigma 2: DTG/DXL rat liver dataset
SMILES Name p𝐾i Ref.
c1cc(I)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-8 7.279 159
c1ccc(I)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-9 7.620 159
c1ccccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(OC)ccc4 (+)-10 7.284 159
COc(cc1)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-4 7.666 159
c1ccc(OC)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-6 7.418 159
c1ccc(Cl)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-7 7.650 159
c1cc(Cl)ccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 (+)-5 8.194 159
COc(cc1)ccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-4 7.090 159
c1cc(Cl)ccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-5 7.577 159
c1ccc(OC)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-6 7.334 159
c1ccc(Cl)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 (-)-7 6.910 159
C1CN(C)[C@H](C2)CC(=O)C[C@@]12c3cc(O)ccc3 (-)-1 4.602 159
c1ccccc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 CB-64L 6.812 161
c1cc(Cl)c(Cl)cc1/C=C([C@H](C2)N(C)CC3)/C(=O)C[C@@]23c4cc(O)ccc4 CB-182 7.450 161
c1ccccc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 CB-64D 7.783 161
c1cc(Cl)c(Cl)cc1/C=C([C@@H](C2)N(C)CC3)/C(=O)C[C@]23c4cc(O)ccc4 CB-184 7.873 161
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)OC Ibogaine 6.697 162
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)O O-des-methyl-Ibogaine 5.282 162
C1CNC(C)=C(C1=c23)N=c2cc(cc3)OC Harmaline 4.703 162
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4cc(cc5)OC Tabernanthine 6.712 162
CC(C)(C)Oc(c1)ccc2[nH]c(c3c12)[C@H]4[C@H]5N(CC3)C[C@@H](C4)C[C@@H]5CC 10-t-butoxy-ibogamine 6.607 163
c1ccccc1C(=O)O[C@H]([C@@H]2C(=O)OC)C[C@@H](N3C)CC[C@H]23 cocaine 5.054 59
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 S(-)-3-PPP 6.631 59
c1ccccc1C2(CCCC2)C(=O)OCCOCCN(CC)CC carbetapentane 7.710 59
CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2 caramiphen 7.810 59
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCN(c3ccc(F)cc3)c4ccc(F)cc4 11 7.730 59
c1cc(F)ccc1N(c2ccc(F)cc2)CCCN(C[C@H]3C)C[C@@H](C)N3CCc4cc(Cl)c(Cl)cc4 12 5.932 59
c1ccccc1N(c2ccccc2)CCCN(C[C@H]3C)C[C@H](C)N3CCc4cc(Cl)c(Cl)cc4 13 6.666 59
C1CNCCN1CCCN(c2ccc(F)cc2)c3ccc(F)cc3 15 6.415 59
c1cc(F)ccc1N(c2ccc(F)cc2)CCCN3CCN(CC3)Cc4ccccc4 17 7.107 59
c1ccccc1C2(CCCCC2)C(=O)OCCN3CCOCC3 PRE084 7.333 59
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-1d 6.827 165
c1ccccc1CN2CC[C@@H]3[C@@H](C)[C@H]2Cc(c34)cccc4 (-)-2a 6.883 165
c1ccccc1CN2CC[C@H]3[C@H](C)[C@@H]2Cc(c34)cccc4 (+)-2a 6.231 165
c1cccc(c12)C[C@@H]3[C@H](CC)[C@H]2CCN3Cc4ccccc4 (-)-2b 6.939 165
c1cccc(c12)C[C@H]3[C@@H](CC)[C@@H]2CCN3Cc4ccccc4 (+)-2b 6.321 165
c1cccc(c12)C[C@@H]3[C@H](C(C)C)[C@H]2CCN3Cc4ccccc4 (-)-2c 6.876 165
c1cccc(c12)C[C@H]3[C@@H](C(C)C)[C@@H]2CCN3Cc4ccccc4 (+)-2c 6.025 165
c1cccc(c12)[C@H]([C@H](C)C=C2)CCNCc3ccccc3 (+)-10a 6.217 165
c1cccc(c12)[C@@H]([C@@H](C)C=C2)CCNCc3ccccc3 (-)-10a 6.431 165
c1cccc(c12)[C@H]([C@H](CC)C=C2)CCNCc3ccccc3 (+)-10b 6.120 165
c1cccc(c12)[C@@H]([C@@H](CC)C=C2)CCNCc3ccccc3 (-)-10b 6.071 165
c1cccc(c12)[C@H]([C@H](C(C)C)C=C2)CCNCc3ccccc3 (+)-10c 6.069 165
c1cccc(c12)[C@@H]([C@@H](C(C)C)C=C2)CCNCc3ccccc3 (-)-10c 6.105 165
CC(=O)Nc(c1)ccc(c1[C@]23C)C[C@@H]([C@H]2C)N(CC3)Cc4ccccc4 (+)-3a 5.851 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(F)c4 (+)-3e 6.578 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)N(C)C (+)-3c 6.588 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(Br)c4 (+)-3g 6.300 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)N (+)-3b 6.080 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(Cl)c4 (+)-3f 6.368 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-1f 5.767 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)NS(=O)(=O)C (+)-3d 5.721 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cccc4 (+)-2d 6.312 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(I)c4 (+)-3h 5.691 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(F)c4 (-)-3e 7.367 26
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cccc3 (-)-2b 6.530 26
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(F)c3 (-)-4a 7.286 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-1f 6.717 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(Cl)c4 (-)-3f 6.419 26
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)cccc4 (-)-2d 6.638 26
CC(C)CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(F)c3 (-)-4b 7.249 26
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(F)c3 (+)-4a 6.812 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)CC(=C4[C@@]23C)CCC(=O)C4 (+)-10 6.161 26
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Br)c(c4Br)O (+)-2a 5.697 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4Br)O (+)-3a 6.461 171
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c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Br)c(c4)O (+)-4a 5.914 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(I)c(c4)O (+)-5a 6.224 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)cc(Cl)c(c4Cl)O (+)-6a 5.664 171
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4Cl)O (+)-7a 6.117 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(Br)c(c3Br)O (+)-2b 6.676 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3Br)O (+)-3b 6.548 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(Br)c(c3)O (+)-4b 6.438 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)cc(I)c(c3)O (+)-5b 6.652 171
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cc(Br)c(c3)O (-)-4b 7.138 171
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)cc(I)c(c3)O (-)-5b 7.027 171
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3Cl)O (+)-7b 5.305 171
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3ccc(F)cc3 2a 8.424 174
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3c(F)cccc3 2b 7.693 174
c1cc(Br)ccc1C(=O)NC2CCN(CC2)Cc3ccc(F)cc3 2c 8.396 174
c1cc(Br)ccc1C(=O)NC2CCN(CC2)Cc3c(F)cccc3 2d 7.642 174
c1c(Br)c(N)c(I)c(OC)c1C(=O)NCCN(CC)CC 2 5.629 176
COc(cc1)c(I)cc1C(=O)NCCN(CC)CC IMBA 5.186 176
CC(=O)Nc(c(I)c1)cc(OC)c1C(=O)NCCN(CC)CC 6 3.939 176
c1c(I)c(N)cc(OC)c1C(=O)NCCN(CC)CC 7 4.670 176
CC(=O)Nc(cc1)c(I)cc1C(=O)NCCN(CC)CC 9 3.830 176
CCN(CC)CCNC(=O)c1c(I)ccc(c1)OC 12 6.460 176
c1c(I)ccc(OC)c1C(=O)NCCN(CC)CC 15 5.991 176
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.333 176
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.453 259
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.616 259
c1ccccc1CN2CCN(CC2)Cc3ccccc3 3 5.895 179
c1ccc(OC)cc1CN2CCN(CC2)Cc3ccccc3 4 6.967 179
COc(cc1)ccc1CN2CCN(CC2)Cc3ccccc3 5 6.793 179
c1cccc(Cl)c1CN2CCN(CC2)Cc3ccccc3 6 6.278 179
c1ccc(Cl)cc1CN2CCN(CC2)Cc3ccccc3 7 7.249 179
c1cc(Cl)ccc1CN2CCN(CC2)Cc3ccccc3 8 6.728 179
c1cc(Cl)c(Cl)cc1CN2CCN(CC2)Cc3ccccc3 9 8.123 179
c1cc(Cl)cc(Cl)c1CN2CCN(CC2)Cc3ccccc3 10 6.910 179
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 5.812 183
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.893 183
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.921 183
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCC2 1 8.092 183
c1ccc(I)cc1CCN(C)CCN2CCCC2 2 8.041 183
c1cc(I)ccc1CCN(C)CCN2CCCC2 3 7.366 183
C1CCCN1CCN(C)Cc2c(I)cccc2 4 7.317 183
C1CCCN1CCN(C)Cc2cc(I)ccc2 5 7.472 183
C1CCCN1CCN(C)Cc2ccc(I)cc2 6 7.611 183
c1ccc(Br)cc1CCN(C)CCN2CCCC2 9 7.223 183
c1cc(Br)ccc1CCN(C)CCN2CCCC2 10 7.488 183
C1CCCN1CCN(C)Cc2cc(Br)ccc2 11 6.658 183
c1ccc(F)cc1CCN(C)CCN2CCCC2 12 6.985 183
c1cc(F)ccc1CCN(C)CCN2CCCC2 13 6.907 183
c1ccc(Cl)cc1CCN(C)CCN2CCCC2 14 7.548 183
c1cc(Cl)ccc1CCN(C)CCN2CCCC2 15 7.297 183
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 6.860 260
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-l-pentazocine 7.438 260
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(CC4)CCO Fluphenazine 7.577 260
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF10047 5.575 260
C1CC1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-Cyclazocine 4.982 260
C1CC1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O (-)-Cyclazocine 5.920 260
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCN(c3ccccc3)c4ccccc4 25 6.738 191
c1cc(F)ccc1C(c2ccc(F)cc2)OCCN(CC3)CCN3CCCc4ccccc4 3 6.936 191
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCn(c3cccc4)c(c5c34)cccc5 11 6.839 191
C[C@@H]1CN(C[C@H](C)N1)CCCN(c2ccccc2)c3ccccc3 24 6.455 191
CN1[C@@H](C)CN(C[C@H]1C)CCCn(c2cccc3)c(c4c23)cccc4 10 6.638 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(c3)[N+]([O-])=O)c(c4c23)cccc4 7 6.714 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 1 6.520 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(Br)c3)c(c4c23)ccc(Br)c4 5 6.171 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2ccc(c3)N)c(c4c23)cccc4 8 5.780 191
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2c(Br)cc(Br)c3)c(c4c23)ccc(Br)c4 6 5.701 191
c1cc(I)ccc1C(=O)NCCN(CC)CC IDAB 5.690 193
c1cc(I)ccc1C(=O)NCCN2CCCCC2 IPAB 6.688 193
c1cc(Br)ccc1CCN(C)CCN2CCCCC2 BrPEMP 8.072 195
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c1cc(I)ccc1CCN(C)CCN2CCCCC2 IPEMP 7.818 195
CCN(CC)CCNS(=O)(=O)c1ccc(Br)cc1 1 5.549 196
CCN(CC)CCNS(=O)(=O)c1ccc(I)cc1 2 5.621 196
C1CCCN1CCNS(=O)(=O)c2ccc(Br)cc2 3 5.828 196
C1CCCN1CCNS(=O)(=O)c2ccc(I)cc2 4 5.999 196
C1CCCCN1CCNS(=O)(=O)c2ccc(Br)cc2 5 6.338 196
C1CCCCN1CCNS(=O)(=O)c2ccc(I)cc2 6 6.686 196
C1CCCCCN1CCNS(=O)(=O)c2ccc(Br)cc2 7 6.703 196
C1CCCCCN1CCNS(=O)(=O)c2ccc(I)cc2 8 6.724 196
C1CCCCCN1CCN(C)S(=O)(=O)c2ccc(Br)cc2 9 7.353 196
C1CCCCCN1CCN(C)S(=O)(=O)c2ccc(I)cc2 10 7.629 196
C1CCCCN1CCNS(=O)(=O)c(cc2)cc(I)c2OC 11 6.348 196
C1CCCCCN1CCN(C)S(=O)(=O)c(cc2)cc(I)c2OC 12 6.472 196
COc(cc1)c(I)cc1C(=O)NCCN2CCCCC2 PIMBA 6.686 197
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 5.866 198
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.213 198
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)-3-PPP 6.921 198
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.098 198
c1ccccc1C(\CC)=C(c2ccccc2)/c3ccc(cc3)OCCN(C)C Tamoxifen 6.870 198
C1CCCN1CCOc(cc2)ccc2Cc3ccccc3 PBPE 6.917 198
c1ccccc1C(C)(C)c2ccc(cc2)OCCN3CCCC3 PCPE 6.921 198
c1ccccc1Cc2ccc(cc2)OCCN3CCOCC3 MBPE 5.732 198
c1ccccc1C(C)(C)c2ccc(cc2)OCCN3CCOCC3 MCPE 5.871 198
CCCSc(nsn1)c1C2=CCCNC2 P-TZTP 6.398 199
c1cc(F)ccc1-n(c(c23)cccc3)cc2CCCCN4CCN(CC4)c5ccc(I)cc5 Indole-I 6.790 261
O1COc(c12)ccc(c2)CN3CCN(CC3)Cc4ccc(I)cc4 BP-I 7.214 262
O1COc(c12)ccc(c2)CN3CCN(CC3)Cc4ccc(F)cc4 BP-F 7.282 262
O1COc(c12)ccc(c2)CN3CCN(CC3)Cc4ccc(C)cc4 BP-CH3 7.303 262
O1COc(c12)ccc(c2)CN3CCN(CC3)Cc4ccc([N+]([O-])=O)cc4 BP-NO2 7.393 262
O1COc(c12)ccc(c2)CN3CCN(CC3)Cc4ccc(Br)cc4 BP-Br 7.393 262
c1ccccc1CCN2CCCCC2 9 6.951 263
C1CCCCN1CCCc2ccccc2 10 7.602 263
c1ccccc1CCN(CC2)CCC2C 13 7.478 263
CC1CCN(CC1)CCCc2ccccc2 14 7.917 263
c1ccccc1CCN(CC2)Cc(c23)cccc3 15 7.242 263
c1ccccc1CCCN(CC2)Cc(c23)cccc3 16 7.848 263
c1ccccc1CCN2CCN(CC2)c3ccccn3 17 6.924 263
c1ccccc1CCCN2CCN(CC2)c3ccccn3 18 8.309 263
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)C BD1047 7.328 211
c1cc(Cl)c(Cl)cc1CCN2CCN(C)CC2 BD1063 6.348 211
c1cc(Cl)c(Cl)cc1CCN(C2)CCN([C@H]23)CCC3 BD1018 7.310 213
c1cc(Cl)c(Cl)cc1CCN(C2)CCN([C@@H]23)CCC3 BD1031 7.097 213
c1cc(Cl)c(Cl)cc1CCN[C@H]2[C@H](CCCC2)N3CCCC3 LR132 6.154 213
c1cc(Cl)c(Cl)cc1CCNCCN2CCCC2 BD1060 8.523 214
C1CCCN1CCN(CC=C)CCc2cc(Cl)c(Cl)cc2 BD1052 8.699 214
c1cc(Cl)c(Cl)cc1CCN(CC)CCN2CCCC2 BD1067 8.699 214
c1cccc(OC)c1CCN(CC)CCN2CCCCC2 UMB98 6.148 215
c1ccc(OC)cc1CCN(CC)CCN2CCCCC2 UMB99 5.994 215
COc(cc1)ccc1CCN(CC)CCN2CCCCC2 UMB100 6.020 215
c1cccc(OC)c1CCN(C)CCN2CCCCC2 UMB101 6.412 215
c1ccc(OC)cc1CCN(C)CCN2CCCCC2 UMB102 6.421 215
COc(cc1)ccc1CCN(C)CCN2CCCCC2 UMB103 6.376 215
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccccc3 1a 6.590 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(cc3)OC 1b 6.569 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(O)cc3 1c 6.293 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc(F)cc3 1d 6.827 216
c1ccc(O)cc1C2(C(=O)CC)CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 1e 6.421 216
c1ccccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2a 6.661 216
COc(cc1)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2b 5.992 216
c1cc(O)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2c 5.655 216
c1cc(F)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2d 6.152 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@@H]([C@@H]3C)Cc(c4[C@]23C)ccc(c4)O 2e 5.966 216
c1ccccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3a 5.771 216
COc(cc1)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3b 6.348 216
c1cc(O)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3c 5.798 216
c1cc(F)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3d 5.878 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O 3e 6.101 216
c1ccccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4a 6.018 216
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COc(cc1)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4b 6.004 216
c1cc(O)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4c 5.567 216
c1cc(F)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4d 6.310 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@@H]([C@@H]3CCCC4)Cc(c5[C@]234)ccc(c5)O 4e 5.928 216
c1ccccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5a 5.742 216
COc(cc1)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5b 5.821 216
c1cc(O)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5c 5.835 216
c1cc(F)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5d 5.876 216
c1cc([N+]([O-])=O)ccc1CN(CC2)[C@H]([C@H]3CCCC4)Cc(c5[C@@]234)ccc(c5)O 5e 5.661 216
N#CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 2 4.721 217
N#CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 3 4.292 217
N#CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 4 5.076 217
N#CCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 5 5.553 217
N#CCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 6 6.420 217
N#CCCCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 7 6.824 217
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 8 5.495 217
C=CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 9 6.208 217
C=CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 10 6.745 217
C=CCCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 11 7.097 217
CC#CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 12 5.357 217
C#CCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 13 5.658 217
C#CCCCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O 14 6.357 217
N#CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 16 4.032 217
N#CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 18 4.469 217
N#CCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 19 4.886 217
N#CCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 20 5.244 217
N#CCCCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 21 5.721 217
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 22 4.569 217
C=CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 23 5.119 217
C=CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 24 5.602 217
C=CCCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 25 6.119 217
CC#CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 26 4.921 217
C#CCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 27 4.824 217
C#CCCCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O 28 5.456 217
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCCCC2 LR172 8.699 218
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 5.713 264
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.538 264
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-pentazocine 7.886 264
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.420 264
C=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-SKF10047 5.364 264
c1cccc(OC)c1CC(=O)N(C)CCN2CCCC2 4 5.499 256
c1ccc(OC)cc1CC(=O)N(C)CCN2CCCC2 5 5.955 256
COc(cc1)ccc1CC(=O)N(C)CCN2CCCC2 6 5.914 256
c1cccc([N+]([O-])=O)c1CC(=O)N(C)CCN2CCCC2 7 5.827 256
c1ccc([N+]([O-])=O)cc1CC(=O)N(C)CCN2CCCC2 8 6.268 256
c1cc([N+]([O-])=O)ccc1CC(=O)N(C)CCN2CCCC2 9 6.225 256
c1cccc(OC)c1CCN(C)CCN2CCCC2 10 6.842 256
c1ccc(OC)cc1CCN(C)CCN2CCCC2 11 6.680 256
COc(cc1)ccc1CCN(C)CCN2CCCC2 12 6.592 256
c1cccc([N+]([O-])=O)c1CCN(C)CCN2CCCC2 13 6.507 256
c1ccc([N+]([O-])=O)cc1CCN(C)CCN2CCCC2 14 7.021 256
c1cc([N+]([O-])=O)ccc1CCN(C)CCN2CCCC2 15 7.203 256
c1cccc(N)c1CCN(C)CCN2CCCC2 16 6.194 256
c1ccc(N)cc1CCN(C)CCN2CCCC2 17 5.650 256
c1cc(N)ccc1CCN(C)CCN2CCCC2 18 6.011 256
c1cc(Cl)c(Cl)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 1 7.108 257
c1cccc([N+]([O-])=O)c1CC(=O)N2CCN(CC2)CCCc3ccccc3 2 7.119 257
c1ccc([N+]([O-])=O)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 3 7.187 257
c1cc([N+]([O-])=O)ccc1CC(=O)N2CCN(CC2)CCCc3ccccc3 4 6.777 257
c1cccc(OC)c1CC(=O)N2CCN(CC2)CCCc3ccccc3 5 6.532 257
c1ccc(OC)cc1CC(=O)N2CCN(CC2)CCCc3ccccc3 6 6.686 257
COc(cc1)ccc1CC(=O)N2CCN(CC2)CCCc3ccccc3 7 6.333 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(Cl)c(Cl)cc3 8 7.411 257
c1ccccc1CCCN2CCN(CC2)CCc3c([N+]([O-])=O)cccc3 9 8.310 257
c1ccccc1CCCN2CCN(CC2)CCc3cc([N+]([O-])=O)ccc3 10 8.027 257
c1ccccc1CCCN2CCN(CC2)CCc3ccc([N+]([O-])=O)cc3 11 7.602 257
c1ccccc1CCCN2CCN(CC2)CCc3c(N)cccc3 12 7.745 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(N)ccc3 13 7.432 257
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c1ccccc1CCCN2CCN(CC2)CCc3ccc(N)cc3 14 7.854 257
c1ccccc1CCCN2CCN(CC2)CCc3c(OC)cccc3 15 8.125 257
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)ccc3 16 7.991 257
c1ccccc1CCCN2CCN(CC2)CCc3ccc(cc3)OC 17 7.544 257
c1ccc(OC)cc1CC(=O)N2CCN(CC2)C(=O)Cc3cc(OC)ccc3 19 7.928 257
COc(cc1)ccc1CC(=O)N2CCN(CC2)C(=O)Cc3ccc(cc3)OC 20 6.128 257
c1cccc(OC)c1CCN2CCN(CC2)CCc3c(OC)cccc3 21 7.770 257
c1ccc(OC)cc1CCN2CCN(CC2)CCc3cc(OC)ccc3 22 7.538 257
COc(cc1)ccc1CCN2CCN(CC2)CCc3ccc(cc3)OC 23 7.004 257
CC(C)(C)OC(=O)NCC(=O)N1CCN(CC1)CCCc2ccccc2 24 6.757 257
CC(C)(C)OC(=O)NCCC(=O)N1CCN(CC1)CCCc2ccccc2 25 5.341 257
CC(C)(C)OC(=O)NCCCC(=O)N1CCN(CC1)CCCc2ccccc2 26 6.900 257
NCC(=O)N1CCN(CC1)CCCc2ccccc2 27 6.519 257
NCCC(=O)N1CCN(CC1)CCCc2ccccc2 28 5.749 257
NCCCC(=O)N1CCN(CC1)CCCc2ccccc2 29 5.416 257
c1ccccc1CCCN2CCN(CC2)CCN 30 6.726 257
c1ccccc1CCCN2CCN(CC2)CCCN 31 5.699 257
NCCCCN1CCN(CC1)CCCc2ccccc2 32 6.000 257
c1cc(Cl)c(Cl)cc1CCN2CCCC2 4 7.111 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN2CCCC2 5 7.842 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN(C)CCN2CCCC2 6 7.271 258
c1cc(Cl)c(Cl)cc1CCN(C)CCN(C)CCN(C)CCN(C)CCN2CCCC2 7 6.790 258
C1CCCN1CCCN(C)CCN(C)Cc2cc(Cl)c(Cl)cc2 8 7.738 258
c1cc(Cl)c(Cl)cc1CN(C)CCCN(C)CCN2CCCC2 9 7.279 258
C1CCCN1CCN(C)CCN(C)Cc2cc(Cl)c(Cl)cc2 10 7.917 258
c1cc(Cl)c(Cl)cc1CCN(C)CCCN(C)CCCN2CCCC2 11 7.827 258
C1CCCN1CCCCN(C)CCCN(C)CCc2cc(Cl)c(Cl)cc2 12 6.818 258
c1cc(Cl)c(Cl)cc1CCN(C)CCCCN(C)CCCCN2CCCC2 13 6.939 258
c1cc(Cl)c(Cl)cc1CCN(CCN)CCN2CCCC2 14 6.870 258
NCCNCCc1cc(Cl)c(Cl)cc1 15 5.626 258
c1cc(Cl)c(Cl)cc1CCNCCNCCN 16 6.270 258
c1cc(Cl)c(Cl)cc1CCNCCNCCN2CCCC2 17 6.955 258
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Table F.3: Sigma 2: DTG/PTZ rat brain dataset
SMILES Name p𝐾i Ref.
FC(F)(F)Oc(cc1)ccc1CCN(C)CCN2CCCC2 9 7.444 265
FC(F)(F)Oc(cc1)ccc1CCN(CC)CCN2CCCC2 10 7.495 265
FC(F)(F)Oc(cc1)ccc1CCN(C)CCN2CCCCC2 11 7.602 265
FC(F)(F)Oc(cc1)ccc1CCN(CC)CCN2CCCCC2 12 7.585 265
c1cccc(OC(F)(F)F)c1CCN(C)CCN2CCCC2 18 7.367 265
c1cccc(OC(F)(F)F)c1CCN(CC)CCN2CCCC2 19 7.086 265
c1cccc(OC(F)(F)F)c1CCN(C)CCN2CCCCC2 20 7.237 265
c1cccc(OC(F)(F)F)c1CCN(CC)CCN2CCCCC2 21 7.260 265
c1ccc(OC(F)(F)F)cc1CCN(C)CCN2CCCC2 27 7.398 265
c1ccc(OC(F)(F)F)cc1CCN(CC)CCN2CCCC2 28 7.367 265
c1ccc(OC(F)(F)F)cc1CCN(C)CCN2CCCCC2 29 7.509 265
c1ccc(OC(F)(F)F)cc1CCN(CC)CCN2CCCCC2 30 7.824 265
c1cc(F)ccc1CC[C@H]2CCCN([C@@H]23)CCCC3 10beta-b 5.887 130
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.055 130
c1cc(Cl)ccc1CSC[C@@H]2CCCN([C@@H]23)CCCC3 8 6.730 131
c1ccccc1CCSC[C@@H]2CCCN([C@@H]23)CCCC3 9 6.808 131
c1cc(F)ccc1CCSC[C@@H]2CCCN([C@@H]23)CCCC3 10 6.833 131
c1cc(Cl)ccc1CSC[C@H]2CCCN([C@@H]23)CCCC3 17 6.632 131
c1ccccc1CCSC[C@H]2CCCN([C@@H]23)CCCC3 18 6.859 131
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.104 131
COCCN1CCN(CC1)C[C@H](C2=O)CCN2c3ccc(Cl)cc3 MS-377 5.161 132
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 6.569 132
C1CCCn(c12)c(=O)c(c(n2)C)CCN(CC3)CCC3c4noc(c45)cc(F)cc5 Risperidone 5.276 132
c1ccccc1CN(C)CCCN(C2=O)CN([C@H]23)Cc4c(C3)cccc4 1 6.254 266
c1ccccc1CN(C)CCCN(C2=O)CN([C@@H]23)Cc4c(C3)cccc4 2 6.085 266
C[C@@]12C(C)(C)[C@@H](CC1)CN(C2)C3CCCCC3 3 8.959 267
C1CCCCC1CN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 4 8.503 267
C1CCCCC1CN(C2)C[C@@H](CC3)C(C)(C)[C@]23C 5 8.451 267
C1CCCCC1CCN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 6 9.553 267
C1CCCCC1CCN(C2)C[C@@H](CC3)C(C)(C)[C@]23C 7 9.638 267
C1CCCCC1CCCN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 8 9.252 267
C1CCCCC1CCCCN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 9 8.168 267
C1CCCC1CCN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 10 9.155 267
C1CCCCCC1CCN(C2)C[C@H](CC3)C(C)(C)[C@@]23C 11 9.602 267
C[C@@]12C(C)(C)[C@@H](CC1)CN(C2)CCC3CCCCCCC3 12 9.481 267
C1[C@@H](C2)C[C@H](C3)C[C@@H]2[C@H]([C@@H]13)CCN(C4)C[C@H](CC5)C(C)(C)[C@@]45C 13 9.114 267
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.775 267
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.157 267
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF10047 4.848 267
c1ccccc1CC[C@H]2CCCN([C@@H]23)CCCC3 ANS-1 6.127 148
c1ccccc1CC[C@@H]2CCCN([C@@H]23)CCCC3 ANS-2 6.523 148
c1cc(F)ccc1CC[C@@H]2CCCN([C@@H]23)CCCC3 ANS-3 6.658 148
Fc1ccc(cc1)SC[C@H]2CCCN([C@@H]23)CCCC3 ANS-4 6.365 148
Fc1ccc(cc1)SC[C@@H]2CCCN([C@@H]23)CCCC3 ANS-5 6.461 148
c1ccccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 FN/C-1 6.194 148
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.041 148
c1cc(Cl)c(Cl)cc1CCN2CCN(C)CC2 BD1063 6.357 10
COc(cc1)ccc1CCN(CC)CCN2CCCC2 UMB115 5.521 268
c1ccc(OC)cc1CCN(CC)CCN2CCCC2 UMB116 6.712 268
c1cccc(OC)c1CCN(CC)CCN2CCCC2 UMB117 6.883 268
C1CN(C)C[C@@H]2CCC[C@@H]3Oc(c4[C@]123)c(OC)ccc4 (-)-3a 5.126 269
C1CC1CN(CC2)C[C@@H]3CCC[C@@H]4Oc(c5[C@]234)c(OC)ccc5 (-)-3b 5.485 269
c1ccccc1CCN(CC2)C[C@@H]3CCC[C@@H]4Oc(c5[C@]234)c(OC)ccc5 (-)-3c 5.485 269
C1CC1CN(CC2)C[C@H]3CCC[C@H]4Oc(c5[C@@]234)c(OC)ccc5 (+)-3b 5.360 269
c1ccccc1CCN(CC2)C[C@H]3CCC[C@H]4Oc(c5[C@@]234)c(OC)ccc5 (+)-3c 5.593 269
c1ccccc1CCN(CC2)C[C@@H]3CCC[C@@H]4Oc(c5[C@]234)c(O)ccc5 (-)-1c 5.269 269
C1CC1CN(CC2)C[C@H]3CCC[C@H]4Oc(c5[C@@]234)c(O)ccc5 (+)-1b 5.987 269
c1ccccc1CCN(CC2)C[C@H]3CCC[C@H]4Oc(c5[C@@]234)c(O)ccc5 (+)-1c 6.580 269
CC(C)=CCN(CC1)[C@@H]([C@@H]2C)Cc(c3[C@]12C)ccc(c3)O (-)-pentazocine 7.252 269
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-pentazocine 5.866 269
COc1ccc(Br)c(OC)c1C(=O)NC[C@@H]2CCCN2CC Remoxipride 6.496 6
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)C\2=C\CCN4CCN(CC4)CCO Cis-(z)-flupenthixol 6.572 6
C[C@@H]1CN(C[C@H](C)N1)CCCn(c2cccc3)c(c4c23)cccc4 Rimcazole 5.935 6
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c(cc3C(F)(F)F)ccc3 Trifluperidol 6.917 6
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(CC4)CCO Fluphenazine 6.682 6
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FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(C)CC4 Trifluoperazine 6.241 6
CN(C)CCCN1c(cccc2)c2Sc(c13)ccc(Cl)c3 Chlorpromazine 5.788 6
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN(C)C Trifluopromazine 5.727 6
C1CCCn(c12)c(=O)c(c(n2)C)CCN(CC3)CCC3c4noc(c45)cc(F)cc5 Risperidone 5.766 6
c1cc(F)ccc1C(c2ccc(F)cc2)CCCN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 Pimozide 5.485 6
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.268 6
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.367 6
c1ccccc1C(=O)O[C@H]([C@@H]2C(=O)OC)C[C@@H](N3C)CC[C@H]23 cocaine 4.888 270
C1CCCN1C[C@@H](C)N(C)CCc2cc(Cl)c(Cl)cc2 LR176 7.357 270
S=C=NCCN1[C@@H](C)CN(C[C@H]1C)CCCn(c2cccc3)c(c4c23)cccc4 SH1/57 5.522 270
C[C@@H]1CN(C[C@H](C)N1)CCCN(c2ccccc2)c3ccccc3 SH2/21 6.057 270
c1ccccc1CCCN2[C@@H](C)CN(C[C@H]2C)CCCN(c3ccccc3)c4ccccc4 SH3/24 6.793 270
c1ccccc1CCN2CCN(CC2)c3ccccn3 UMB24 6.770 271
c1cccc(c12)n(cc2)CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM360 9.678 272
c1cc(F)ccc1-c2cn(c(c23)cccc3)CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC CM361 8.360 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN(CC3)CC=C3c4ccc(F)cc4 CM401 9.180 272
c1cccc(c12)oc(=O)n2CCCCN(CC3)CC=C3c4ccc(F)cc4 CM406 9.244 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(cc4)OC CM407 7.460 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4c(F)cccc4 CM408 8.399 272
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(cc4)OC CM433 7.551 272
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4cc(OC)ccc4 CM442 7.722 272
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c(c4Cl)cccc4Cl CM449 7.622 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c(c4Cl)cccc4Cl CM450 7.689 272
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c(c4Cl)cccc4Cl CM452 6.388 272
c1cccc(c12)oc(=S)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM454 8.879 272
c1cc([N+]([O-])=O)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM458 8.876 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4c(Br)cc(F)cc4 CM461 8.996 272
COc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM464 8.708 272
COc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM465 8.152 272
c1cc(F)ccc1N(CC2)CCN2CCCCn3c(=O)oc(c34)cc(cc4)OCc5ccccc5 CM483 8.366 272
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4cc(F)ccc4 CM490 8.428 272
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4cc(F)ccc4 CM491 8.000 272
CC(=O)c1cccc(c12)n(c(=O)o2)CCCCN3CCN(CC3)c4ccc(F)cc4 CM498 8.189 272
c1c(Br)ccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM539 8.519 272
c1cc(F)ccc1N(CC2)CCN2CCCCn3c(=O)oc(c34)ccc(c4)-c5ccc(F)cc5 CM540 7.896 272
CC(=O)c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM564 8.268 272
CS(=O)(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM567 6.952 272
c1cc(F)ccc1N(CC2)CCN2CCCCn3c(=O)oc(c34)cc(cc4)S(=O)(=O)N5CCCC5 CM569 8.080 272
S=C=Nc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM572 8.172 272
c1cccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c(c4[N+]([O-])=O)ccc(F)c4 CM585 8.435 272
c1cccc(c12)sc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 MES71 8.523 272
CCC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4c(F)cc(F)cc4 MES74 8.327 272
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM398 9.367 273
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)CCC34c5c(CO4)cccc5 CM699 10.854 273
CCCCCn1c(=O)n(c(c12)cccc2)CCCCN3CCN(CC3)c4ccc(F)cc4 CM775 8.370 273
c1cccc(c12)n(CCC)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM777 9.178 274
c1ccccc1-n(c(c23)cccc2)c(=O)n3CCCCN4CCN(CC4)c5ccc(F)cc5 CM778 8.175 274
CCCCCCCCCCn1c(=O)n(c(c12)cccc2)CCCCN3CCN(CC3)c4ccc(F)cc4 CM781 8.342 274
c1cc(F)ccc1-n2c(=O)n(c(c23)ccc(c3)C(=O)C)CCCCN4CCN(CC4)c5ccc(F)cc5 CM782 7.164 274
CC(=O)c(c1)ccc(c12)n(c(=O)n2CCC)CCCCN3CCN(CC3)c4ccc(F)cc4 NF12 6.431 274
CCCCCn1c(=O)n(c(c12)ccc(c2)C(=O)C)CCCCN3CCN(CC3)c4ccc(F)cc4 NF8 8.668 274
c1cc(F)cc(c12)sc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 AZ-68 9.660 275
c1cc(F)cc(c12)sc(=S)n2CCCCN3CCN(CC3)C4CCCCC4 AZ-78 9.300 275
c1cc(F)cc(c12)sc(n2)SCCCCN3CCN(CC3)C4CCCCC4 AZ-81 7.860 275
c1cc(F)cc(c12)SCC(=O)N2CCCCN3CCN(CC3)C4CCCCC4 AZ-87 8.191 275
c1cc(Br)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM138 8.350 275
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM142 8.152 275
CCc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM146 8.592 275
O=C1CCN(CC1)CCCCn2c(=O)oc(c23)cccc3 CM152 7.105 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)Cc4ccccc4 CM159 7.333 275
C1CN(C)CCN1CCCCn2c(=O)oc(c23)cccc3 CM160 5.623 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)CC4CC4 CM162 7.330 275
c1cccc(c12)oc(=O)n2CCCCN(CC3)CC=C3c4ccc(Cl)cc4 CM165 7.840 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)CCc4ccccc4 CM166 7.033 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c(cc4)ccc4[N+]([O-])=O CM167 6.646 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccccn4 CM168 6.892 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(Cl)cc4 CM169 6.617 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM170 9.155 275
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c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)CC4CCCCC4 CM171 7.856 275
c1cccc(c12)oc(=O)n2CCCCN(CC3)CCC3c4ccccc4 CM172 7.764 275
CCc(c1)ccc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM174 7.235 275
c1cccc(c12)oc(=O)n2CCN(CC3)CC=C3c4ccc(Cl)cc4 CM175 6.210 275
c1ccccc1CCN2CCN(CC2)CCn3c(=O)oc(c34)cccc4 CM176 7.663 275
c1cccc(c12)oc(=O)n2CCN3CCN(CC3)c4ccc(Cl)cc4 CM179 5.646 275
c1cccc(c12)oc(=O)n2CCN3CCN(CC3)CC4CCCCC4 CM181 8.054 275
c1cccc(c12)oc(=O)n2CCN(CC3)CCC3c4ccccc4 CM182 6.109 275
CC(=O)c(c1)ccc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM184 7.983 275
c1cc([N+]([O-])=O)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM188 8.609 275
CC(=O)Nc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM191 7.111 275
c1cccc(c12)oc(=O)n2CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM295 8.818 275
FCCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCCC3 CM304 6.439 275
c1cccc(c12)sc(=S)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM307 8.180 275
c1cccc(c12)sc(=S)n2CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM308 9.252 275
c1cc(F)ccc1-n(c(c23)cccc2)c(=O)n3CCCCN4CCN(CC4)c5ccc(F)cc5 CM322 8.777 275
c1cc(F)ccc1-n(c(c23)cccc2)c(=O)n3CCCCN4CCN(CC4)C5CCCCC5 CM325 8.674 275
C1CCCCC1N(CC2)CCN2CCCCn3c(=O)oc(c34)cc(cc4)-c5ccc(F)cc5 CM343 7.419 275
CC(=O)c(c1)ccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM356 8.917 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4c(F)cccc4 CM362 8.554 275
c1c(Br)ccc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM365 10.260 275
C1CCCCC1N(CC2)CCN2CCCCn3c(=O)oc(c34)ccc(c4)-c5ccc(F)cc5 CM366 11.215 275
c1cccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)C4CCCCC4 CM396 8.590 275
c1cccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM397 9.337 275
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c(c4[N+]([O-])=O)ccc(F)c4 CM592 8.201 275
c1cccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c(c4N)ccc(F)c4 CM599 8.445 275
[O-][N+](=O)c(c1)ccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM608 8.326 275
c1c(N)ccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM609 7.575 275
S=C=Nc(c1)ccc(c12)n(C)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM617 7.521 275
c1c(F)ccc(c1N=C=S)N(CC2)CCN2CCCCn3c(=O)n(C)c(c34)cccc4 CM621 7.900 275
CC(=O)c1cc(O)c(cc1)NCCCCN2CCN(CC2)c3ccc(F)cc3 CM623 7.356 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4c(F)cc(F)cc4 CM624 8.708 275
CC(=O)c(cc1)cc(c12)oc(=S)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM625 8.726 275
CC(=O)c(cc1)cc(c12)OCC(=O)N2CCCCN3CCN(CC3)c4ccc(F)cc4 CM627 8.198 275
CC(=O)c(cc1)cc(c12)oc(=O)n2CCCCN3CCCN(CC3)c4ccc(F)cc4 CM673 7.296 275
c1cccc(c12)[nH]c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM728 7.529 275
CCCCCCCc(cc1)cc(c12)sc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 SN-55 7.503 275
CCCCCCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 SN-57 7.533 275
C1CCCCN1CCCCn2c(=O)oc(c23)cccc3 SN-60 6.672 275
c1cccc(c12)oc(=O)n2CCCCCCN3CCN(CC3)Cc4ccccc4 SN-61 6.970 275
CCC(=O)c(c1)ccc(c12)oc(=O)n2CCN3CCCCCC3 SN-71 5.630 275
CCCc(c1)ccc(c12)oc(=O)n2CCN3CCCCCC3 SN-72 5.742 275
c1ccccc1C(=O)c(cc2)cc(c23)sc(=O)n3CCN4CCCCCC4 SN-78 6.066 275
C1CCCCCN1CCn2c(=O)sc(c23)cc(cc3)Cc4ccccc4 SN-81 6.649 275
c1cc(N)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 SN-228 6.751 275
CC(=O)Nc(cc1)cc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 SN-248 7.318 275
FC(F)(F)c1ccc(cc1)N(CC2)CCN2CCCCn3c(=O)oc(c34)cccc4 SN-250 7.005 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c4ccccc4 SN-251 7.942 275
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)c(cc4)ccc4C SN-252 6.971 275
C1CN(C)CCC1(C#N)c2ccccc2 2 5.669 276
c1ccccc1C2(C#N)CCN(CC2)CC=C 3 6.179 276
c1ccccc1C2(C#N)CCN(CC2)CCC 4 6.845 276
c1ccccc1C2(C#N)CCN(CC2)CC(=C)C 5 6.317 276
c1ccccc1C2(C#N)CCN(CC2)CC(C)C 6 7.201 276
c1ccccc1C2(C#N)CCN(CC2)Cc3ccccc3 7 6.182 276
c1ccccc1C2(C#N)CCN(CC2)CCc3ccccc3 8 6.928 276
c1ccccc1C2(C#N)CCN(CC2)CCCc3ccccc3 9 7.337 276
c1ccccc1C2(C#N)CCN(CC2)CCCCc3ccccc3 10 5.883 276
c1ccccc1CCN2CCCCC2 AC927 6.860 276
c1cccc(c12)oc(=O)n2CCN3CCN(CC3)C4CCCCC4 5a 8.265 277
c1cccc(c12)sc(=O)n2CCN3CCN(CC3)C4CCCCC4 5b 8.648 277
c1cccc(c12)oc(=O)n2CCCN3CCN(CC3)C4CCCCC4 5c 8.058 277
c1cccc(c12)sc(=O)n2CCCN3CCN(CC3)C4CCCCC4 5d 8.516 277
c1cccc(c12)oc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 5e 8.738 277
c1cccc(c12)sc(=O)n2CCCCN3CCN(CC3)C4CCCCC4 5f 9.409 277
c1cccc(c12)oc(=O)n2CCCCCN3CCN(CC3)C4CCCCC4 5g 8.230 277
c1cccc(c12)sc(=O)n2CCCCCN3CCN(CC3)C4CCCCC4 5h 8.613 277
c1cccc(c12)oc(=O)n2CCCCCCN3CCN(CC3)C4CCCCC4 5i 8.514 277
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c1cccc(c12)sc(=O)n2CCCCCCN3CCN(CC3)C4CCCCC4 5j 8.827 277
c1cccc(c12)oc(n2)SCCCCN3CCN(CC3)C4CCCCC4 8 8.424 277
c1cccc(c12)oc(=S)n2CCCCN3CCN(CC3)C4CCCCC4 13a 9.114 277
c1cccc(c12)sc(=S)n2CCCCN3CCN(CC3)C4CCCCC4 13b 9.260 277
CCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCCC3 1 6.080 277
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.094 277
c1cccc(c12)n(cc2)CCCCN3CCN(CC3)C4CCCCC4 4a 8.721 278
c1cccc(c12)n(cc2)CCCCN3CCN(CC3)c4ccc(F)cc4 4b 7.875 278
c1cccc(c12)n(cc2)CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC 4c 8.437 278
CC(=O)c(c1)ccc(c12)n(cc2)CCCCN3CCN(CC3)C4CCCCC4 4d 8.636 278
CC(=O)c(c1)ccc(c12)n(cc2)CCCCN3CCN(CC3)c4ccc(F)cc4 4e 8.481 278
CC(=O)c(c1)ccc(c12)n(cc2)CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC 4f 8.848 278
c1ccccc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)C5CCCCC5 9a 7.910 278
c1ccccc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)c5ccc(F)cc5 9b 8.002 278
c1ccccc1-c2cn(c(c23)cccc3)CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC 9c 7.335 278
c1cc(F)ccc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)C5CCCCC5 9d 7.647 278
c1cc(F)ccc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)c5ccc(F)cc5 9e 7.079 278
c1cc(F)ccc1-c2cn(c(c23)cccc3)CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC 9f 8.128 278
c1occc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)C5CCCCC5 9g 7.997 278
c1occc1-c2cn(c(c23)cccc3)CCCCN4CCN(CC4)c5ccc(F)cc5 9h 6.804 278
c1occc1-c2cn(c(c23)cccc3)CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC 9i 7.920 278
c1cc(C(F)(F)F)ccc1C(=N\OCCN)\CCCCOC Fluvoxamine 5.074 279
c1cccc(c12)[C@@H](NC)CC[C@H]2c(c3)ccc(Cl)c3Cl Sertraline 5.276 279
FC(F)(F)c1ccc(cc1)O[C@@H](CCNC)c2ccccc2 S(+)-Fluoxetine 5.261 279
CN(C)CCCN(c(c12)cccc1)c3c(CC2)cccc3 Imipramine 5.676 279
O1COc(c12)ccc(c2)OC[C@H]3[C@@H](CCNC3)c4ccc(F)cc4 Paroxetine 4.641 279
CNCCCN(c(c12)cccc1)c3c(CC2)cccc3 Desipramine 4.942 279
FC(F)(F)c1ccc(cc1)O[C@H](CCNC)c2ccccc2 R(-)-Fluoxetine 4.618 279
CN[C@@H](C)Cc1ccccc1 METH 7.331 280
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.229 224
c1cc(Cl)ccc1CN(CC2)CCC23N=Nc4c(N3)cccc4 4 6.461 224
c1ccccc1CCCCN(CC2)CCC23N=Nc4c(N3)cccc4 8 7.367 224
c1ccccc1CCCCCN(CC2)CCC23N=Nc4c(N3)cccc4 9 7.284 224
c1ccccc1C(=O)CCCN(CC2)CCC23N=Nc4c(N3)cccc4 10 6.558 224
c1ccccc1CN(CC2)CCC23CCc4c(S3)cccc4 1(Spipithane) 6.400 281
c1ccccc1CN(CC2)CCC23CCc4c(O3)cccc4 2 7.660 281
c1ccccc1CN(CC2)CCC23Cc4c(CC3)cccc4 3 7.850 281
c1ccccc1CN(CC2)CCC23OCc4c(S3)cccc4 4 6.650 281
c1ccccc1CN(CC2)CCC23Oc4c(CO3)cccc4 5 6.640 281
c1ccccc1CN(CC2)CCC23CC(=O)c4c(O3)cccc4 6 6.520 281
c1ccccc1CN(CC2)CCC2[C@@H](CC3)Sc(c34)cccc4 7 7.240 281
c1ccccc1CN(CC2)CCC2[C@H](CC3)Sc(c34)cccc4 7 7.240 281
c1ccccc1CN(CC2)CCC2[C@@H](CC3=O)Oc(c34)cccc4 8 6.760 281
c1ccccc1CN(CC2)CCC2[C@H](CC3=O)Oc(c34)cccc4 8 6.760 281
c1ccccc1CN(CC2)CCC2[C@@H](CC3=O)Sc(c34)cccc4 9 5.810 281
c1ccccc1CN(CC2)CCC2[C@H](CC3=O)Sc(c34)cccc4 9 5.810 281
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 6.950 281
c1ccccc1CCN2CCN(CC2)c3ccncc3 1 7.157 282
c1ccccc1CCCN2CCN(CC2)c3ccncc3 2 7.076 282
c1ccccc1CCN2CCN(CC2)c3cccnc3 3 6.357 282
c1ccccc1CCCN2CCN(CC2)c3cccnc3 4 6.959 282
C1CCCCN1CCCc2ccccc2 UMB23 7.495 283
c1cc(Cl)c(Cl)cc1CCN(CC)CCN2CCCCC2 UMB82 7.538 283
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Table F.4: Sigma 2: DTG/PTZ rat liver dataset
SMILES Name p𝐾i Ref.
c1ccccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 9 5.991 103
c1ccc(F)cc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 10 6.152 103
c1cc(F)ccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 11 6.083 103
c1ccc(OC)cc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 12 6.452 103
COc(cc1)ccc1CN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 13 6.371 103
c1ccc(F)cc1CCN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 14 6.602 103
c1cc(F)ccc1CCN2[C@H](C3)C[C@@H](C4)C[C@H]3C[C@]24O 15 6.697 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccccc4 23 7.022 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4cc(F)ccc4 24 6.879 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccc(F)cc4 25 7.046 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4cc(OC)ccc4 26 7.194 103
[C@H]12C[C@H]3C[C@@H](C2)N([C@@H](C1)C3)Cc4ccc(cc4)OC 27 7.268 103
c1ccc(F)cc1CCN([C@@H](C2)C3)[C@H](C4)C[C@@H]3C[C@@H]24 28 7.398 103
c1cc(F)ccc1CCN([C@@H](C2)C3)[C@H](C4)C[C@@H]3C[C@@H]24 29 7.469 103
COc1cccc(c12)[C@@H](CCC2)N3CCN(CC3)C4CCCCC4 R-4 7.708 70
COc1cccc(c12)[C@H](CCC2)N3CCN(CC3)C4CCCCC4 S-4 7.747 70
COc1cccc(c12)[C@@H](CCC2)CN(CC3)CCC3N4CCCCC4 R-10 7.592 70
COc1cccc(c12)[C@H](CCC2)CN(CC3)CCC3N4CCCCC4 S-10 7.730 70
COc1cccc(c12)[C@H](CCC2)CCN3CCN(CC3)C4CCCCC4 R-11 8.036 70
COc1cccc(c12)[C@@H](CCC2)CCN3CCN(CC3)C4CCCCC4 S-11 7.801 70
CCN1CCN(CC1)C2CCCCC2 13 6.457 70
C1CCCCC1CCCN2CCN(CC2)C3CCCCC3 12 8.328 70
C1CCCCC1N2CCN(CC2)C3CCCCC3 24 7.939 70
C1CCCCC1C(=O)N2CCN(CC2)C3CCCCC3 26 6.697 70
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.590 143
c1ccccc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-7 8.437 143
c1ccccc1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-7 8.321 143
COc(cc1)ccc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-8 8.799 143
COc(cc1)ccc1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-8 8.917 143
c1ccc(OC)cc1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-9 8.688 143
c1cccc(OC)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-10 8.162 143
COc1cccc(OC)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-11 8.101 143
COc1cccc(OC)c1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-11 9.678 143
Fc1cccc(F)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-12 7.851 143
Fc1cccc(F)c1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-12 8.714 143
c1cccc(Cl)c1[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-13 7.676 143
c1cccc(Cl)c1[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-13 8.305 143
c1cccc(c1C)[C@H]2CC[C@H](CC2)N3CCN(CC3)C4CCCCC4 cis-14 8.780 143
c1cccc(c1C)[C@H]2CC[C@@H](CC2)N3CCN(CC3)C4CCCCC4 trans-14 8.783 143
COc1cccc(c12)[C@@H](CCC2)NC(=O)CN3CCN(CC3)C4CCCCC4 R-9 7.996 144
COc1cccc(c12)[C@H](CCC2)NC(=O)CN3CCN(CC3)C4CCCCC4 S-9 8.228 144
COc1cccc(c12)[C@@H](CCC2)NCCN3CCN(CC3)C4CCCCC4 R-11 7.842 144
COc1cccc(c12)[C@H](CCC2)NCCN3CCN(CC3)C4CCCCC4 S-11 8.070 144
C1CCCCC1N(CC2)CCN2CCO[C@H](CCC3)c(c34)cccc4OC R-14 7.955 144
C1CCCCC1N(CC2)CCN2CCO[C@@H](CCC3)c(c34)cccc4OC S-14 8.327 144
c1ccc(OC)c(c12)cccc2NC(=O)CN3CCN(CC3)C4CCCCC4 20 7.635 144
c1ccc(OC)c(c12)cccc2NCCN3CCN(CC3)C4CCCCC4 21 7.733 144
C1CCCCC1N(CC2)CCN2CCOc3cccc(c34)c(OC)ccc4 22 8.620 144
Cc(c1)ccc(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 2 8.061 145
Cc(c1)ccc(OC)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 11a 8.580 145
Cc(c1)ccc(OC)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 11b 7.583 145
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 12a 7.889 145
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 12b 7.674 145
COc(c1)c(OC)cc(Br)c1C(=O)NCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 13a 7.293 145
COc(c1)c(OC)cc(Br)c1C(=O)NCCCN2CCN(CC2)C3CCCCC3 13b 6.331 145
c1cccc(c12)CCN(C2=O)CCCN(CC3)Cc(c34)cc(OC)c(c4)OC 15a 8.315 145
c1cccc(c12)CCN(C2=O)CCCN3CCN(CC3)C4CCCCC4 15b 7.575 145
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.580 145
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.609 146
CCCCN(C[C@@H]1O)CCN1Cc2ccccc2 3b 6.290 149
c1ccccc1CN2CCN(C[C@@H]2O)Cc3ccccc3 3c 6.752 149
c1ccccc1CN2CCN(C[C@@H]2O)Cc3ccc(cc3)OC 3d 7.153 149
c1ccccc1CCN(C[C@@H]2O)CCN2Cc3ccccc3 3e 6.879 149
c1ccccc1CN2CCN(C[C@@H]2O)C3CCCCC3 3f 6.967 149
c1ccccc1CN2CCCN(C[C@@H]2CO)Cc3ccccc3 4a 6.427 151
174
COC(OC)CN(C[C@@H]1CO)CCCN1Cc2ccccc2 4b 5.045 151
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.595 152
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 7.111 152
CC1(C)CCCN(C1)CCC[C@H](CCC2)c(c23)cccc3OC S-39 6.660 152
CC1(C)CCCN(C1)CCC[C@@H](CCC2)c(c23)cccc3OC R-39 6.759 152
CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 6.674 152
c1cc(Cl)c(Cl)cc1CCN(C)CCN2CCCC2 BD1008 7.082 152
CC1(C)CCCN(C1)CCCC2=CCc(c23)cccc3 23 6.456 152
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.506 153
CC1CCN(CC1)CCOc2ccc(Cl)cc2 12 6.622 153
CC1CCN(CC1)C[C@@H](C)Oc2ccc(Cl)cc2 R-13 6.479 153
CC1CCN(CC1)C[C@H](C)Oc2ccc(Cl)cc2 S-13 6.498 153
c1cc(Cl)ccc1O[C@H](C)CCN(CC2)CCC2C R-14 7.181 153
c1cc(Cl)ccc1O[C@@H](C)CCN(CC2)CCC2C S-14 7.857 153
CC1CCN(CC1)CCCOc2ccc(Cl)cc2 15 7.413 153
CC1CCN(CC1)C[C@@H](C)COc2ccc(Cl)cc2 R-16 7.389 153
CC1CCN(CC1)C[C@H](C)COc2ccc(Cl)cc2 S-16 7.208 153
CC1CCN(CC1)[C@H](C)COc2ccc(Cl)cc2 R-17 7.281 153
CC1CCN(CC1)[C@@H](C)COc2ccc(Cl)cc2 S-17 6.730 153
CC1CCN(CC1)[C@H](C)CCOc2ccc(Cl)cc2 R-18 7.821 153
CC1CCN(CC1)[C@@H](C)CCOc2ccc(Cl)cc2 S-18 7.500 153
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.550 154
c1ccccc1CCN2CCCCC2 AC927 6.712 154
COc1cccc(c12)[C@@H](CCC2)CCCN3CCN(CC3)C4CCCCC4 S-33 8.063 154
COc1cccc(c12)[C@H](CCC2)CCCN3CCN(CC3)C4CCCCC4 R-33 8.680 154
c1cccc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 43 9.161 154
c1ccc(OC)c(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 44 8.034 154
c1cccc(c12)cccc2CCCCN3CCN(CC3)C4CCCCC4 45 7.516 154
c1cccc(c12)cccc2CCCCCN3CCN(CC3)C4CCCCC4 46 9.244 154
C1CCCCN1CCCc2cccc(c23)cc(cc3)OC 21 6.757 155
CC1(C)CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 26 6.623 155
CC1(C)CCCCN1CCCc2cccc(c23)cc(cc3)OC 25 7.027 155
CC1CCN(CC1)CCCc2cccc(c23)cc(cc3)OC 24 7.410 155
CC1(C)CCN(CC1)CCCc2cccc(c23)cc(cc3)OC 27 7.580 155
C1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 28 6.821 155
CC1(C)CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 33 7.171 155
CC1(C)CCCCN1CCCCc2cccc(c23)cc(cc3)OC 32 7.544 155
CC1CCN(CC1)CCCCc2cccc(c23)cc(cc3)OC 31 7.747 155
CC1(C)CCN(CC1)CCCCc2cccc(c23)cc(cc3)OC 34 7.747 155
C[C@@H]1CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 23R 7.220 155
C[C@H]1CCCN(C1)CCCc2cccc(c23)cc(cc3)OC 23S 7.227 155
C[C@@H]1CCCCN1CCCc2cccc(c23)cc(cc3)OC 22R 7.064 155
C[C@H]1CCCCN1CCCc2cccc(c23)cc(cc3)OC 22S 6.983 155
C[C@@H]1CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 30R 7.194 155
C[C@H]1CCCN(C1)CCCCc2cccc(c23)cc(cc3)OC 30S 7.485 155
C[C@@H]1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 29R 7.308 155
C[C@H]1CCCCN1CCCCc2cccc(c23)cc(cc3)OC 29S 7.269 155
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.491 155
c1cccc(OC)c1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-19 6.616 156
c1ccc(OC)cc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-20 7.442 156
COc(cc1)ccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-21 7.195 156
c1ccccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-29 7.208 156
Cc1ccc(cc1)[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-30 7.149 156
c1cc(Cl)ccc1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-31 6.824 156
Fc1cccc(F)c1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-32 6.357 156
COc1cccc(OC)c1[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-33 6.163 156
c1ccc(C)c(c1C)[C@H]2CC[C@H](CC2)N(CC3)CCN3c4ccccn4 cis-34 7.220 156
c1cccc(OC)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-19 7.523 156
c1ccc(OC)cc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-20 7.660 156
COc(cc1)ccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-21 6.654 156
c1ccccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-29 7.570 156
Cc1ccc(cc1)[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-30 7.529 156
c1cc(Cl)ccc1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-31 7.536 156
Fc1cccc(F)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-32 6.860 156
COc1cccc(OC)c1[C@H]2CC[C@@H](CC2)N(CC3)CCN3c4ccccn4 trans-33 7.602 156
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.507 156
c1cccc(c12)CCC[C@@H]2CCCN3CCN(CC3)C4CCCCC4 R-3 9.310 157
c1cccc(c12)CCC[C@H]2CCCN3CCN(CC3)C4CCCCC4 S-3 8.928 157
175
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.495 158
c1cc(I)ccc1CN(CC2)CCC23c4c(CO3)cccc4 Spiro-I 6.469 166
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 5.716 95
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.740 95
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.420 95
c1ccccc1C(c2ccccc2)(c3ccccc3)SCCNC(=O)CN(CCSC(c4ccccc4)(c5ccccc5)
c6ccccc6)CCCN7[C@H](CCC8)C[C@@H](C[C@@H]78)OC(=O)Nc(c(cc9)OC)cc9C 1 5.871 95
I\C=C\CN(CCC)[C@H](C1)CCc(c12)ccc(c2)O S-trans-7-OH-PIPAT 6.449 95
s1cccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12a 5.337 167
CN(C)c(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12b 5.805 167
CSc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12c 5.698 167
c1nc(Cl)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12d 5.754 167
c1cccc(c12)[nH]c(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12e 5.711 167
c1cccc(c12)ncc(n2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12f 6.350 167
c1cccc(c12)oc(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12g 6.169 167
c1cccc(c12)sc(c2)C(=O)NCCCCN3CCN(CC3)c4c(OC)cccc4 12h 5.846 167
FCCc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12i 5.657 167
Cc(s1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12j 6.034 167
s1c(Br)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 12k 6.417 167
c1cc(Cl)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13a 5.253 167
c1cc(F)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13b 5.795 167
CN(C)c(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13c 5.170 167
COc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13d 5.151 167
CSc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13e 5.075 167
c1cccc(c12)oc(c2)C(=O)NCCCCN3CCN(CC3)c(c4Cl)cccc4Cl 13f 5.435 167
FCCc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13g 5.142 167
Cc(s1)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13h 5.438 167
s1c(Br)ccc1C(=O)NCCCCN2CCN(CC2)c(c3Cl)cccc3Cl 13i 5.521 167
CCCCNCCCc1ccccc1 1a 7.824 168
CCCCCCCNCCCc1ccccc1 2a 7.481 168
CCCCCCCCCCCCNCCCc1ccccc1 3a 5.678 168
CCCCCCCCCCCCCCCCCCNCCCc1ccccc1 4a 4.699 168
CCCCNCCCc1ccc([N+]([O-])=O)cc1 1b 7.658 168
CCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 2b 7.959 168
CCCCCCCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 3b 5.620 168
CCCCCCCCCCCCCCCCCCNCCCc1ccc([N+]([O-])=O)cc1 4b 5.046 168
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.453 169
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.375 169
CCCN(CCC)CCc1cc(c(cc1)OC)OCCc2ccccc2 NE100 6.770 169
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC dextromethorphan 5.466 169
c1cc(F)ccc1C(=O)CN2[C@@H](CC[C@@H]23)C[C@@H](C3)c4ccccc4 11 7.135 175
c1cc(F)ccc1C(=O)CCCN2[C@@H](CC[C@@H]23)C[C@@H](C3)c4ccccc4 12 7.814 175
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23c4c(N(C)C3)cccc4 24a 7.216 175
c1cc(F)ccc1C(=O)CCCN(CC2)CCC23c4c(CC3)cccc4 24b 8.481 175
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.511 177
CC1(C)CCCN(C1)CCCc2cccc(c23)c(OC)ccc3 11 6.192 177
CC1(C)CCCN(C1)CCCc2cccc(c23)ccc(c3)OC 13 6.173 177
COc(cc1)cc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 15 8.045 177
C1CCCCC1N(CC2)CCN2CCCc3cccc(c34)ccc(c4)OC 16 8.082 177
CC1(C)CCCN(C1)CCCc2cccc(c23)cc(O)cc3 17 6.222 177
CC1(C)CCCN(C1)CCCc2cccc(c23)ccc(c3)O 18 6.385 177
c1cc(O)cc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 19 7.578 177
c1c(O)ccc(c12)cccc2CCCN3CCN(CC3)C4CCCCC4 20 7.928 177
c1cccc2n(c(c3c12)cccc3)CCCN(C4)CCCC4(C)C 26 5.349 177
c1cccc2n(c(c3c12)cccc3)CCCCN(C4)CCCC4(C)C 27 6.284 177
c1cccc2n(c(c3c12)cccc3)CCCCCN(C4)CCCC4(C)C 28 6.932 177
c1cccc2n(c(c3c12)cccc3)CCCN4CCN(CC4)C5CCCCC5 29 7.900 177
CC1(C)CCCN(C1)CCCc2cccc(c23)occ3 16 7.374 178
CC1(C)CCCN(C1)CCCc2cccc(c23)scc3 17 7.197 178
CC1(C)CCCN(C1)Cc(c2)oc(c23)cccc3 22 5.742 178
c1cccc(c12)n(cc2)CCCN(C3)CCCC3(C)C 28 6.712 178
c1cccc(c12)n(nn2)CCCN(C3)CCCC3(C)C 29 5.701 178
c1cccc(c12)n(cc2C)CCCN(C3)CCCC3(C)C 30 6.959 178
C1CCCCC1CCCCN(C2)CCCC2(C)C 31 7.708 178
CC1(C)CCCN(C1)CCNc(n2)sc(c23)cccc3 37 6.130 178
s1ccnc1NCCN(C2)CCCC2(C)C 38 5.478 178
CC1(C)CCCN(C1)CCCCN(C2)CCCC2(C)C 41 6.383 178
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.465 178
176
C1CCCCCN1CCCn2c(=O)sc(c23)cccc3 RB2 6.752 284
C1CCCCCN1CCCCn2c(=O)sc(c23)cccc3 RB4 6.996 284
C1CCCCCN1CCCCCn2c(=O)sc(c23)cccc3 RB6 8.602 284
C1CCCCCN1CCCCCCn2c(=O)sc(c23)cccc3 RB8 8.620 284
C1CCCCCN1CCCn2c(=O)sc(c23)cc(cc3)CCC RB10 7.764 284
C1CCCCCN1CCCCn2c(=O)sc(c23)cc(cc3)CCC RB14 8.367 284
C1CCCCCN1CCCCCn2c(=O)sc(c23)cc(cc3)CCC RB16 8.796 284
C1CCCCCN1CCCCCCn2c(=O)sc(c23)cc(cc3)CCC RB18 8.638 284
CCCCc(cc1)cc(c12)sc(=O)n2CCCN3CCCCCC3 RB20 7.815 284
C1CCCCCN1CCCCCCn2c(=O)sc(c23)cc(cc3)CCCC RB24 8.387 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCCN3CCCCCC3 RB26 6.516 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCN3CCCCCC3 RB28 7.519 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCCN3CCCCCC3 RB30 8.081 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCCCN3CCCCCC3 RB32 8.959 284
C1CCCCCN1CCCCn2c(=O)sc(c23)cc(cc3)CCCC RB34 8.357 284
CCCC(=O)c(cc1)cc(c12)sc(=O)n2CCCN3CCCCCC3 RB36 6.983 284
CCCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCN3CCCCCC3 RB38 7.666 284
CCCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCCN3CCCCCC3 RB40 8.244 284
C1CCCN1CCn2c(=O)sc(c23)cccc3 RB65 5.083 284
C1CCCCCN1CCn2c(=O)sc(c23)cccc3 RB67 6.145 284
CCCC(=O)c(cc1)cc(c12)sc(=O)n2CCCCCCN3CCCCCC3 RB70 8.638 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCN3CCCCCC3 RB74 5.661 284
CCC(=O)c(cc1)cc(c12)sc(=O)n2CCN3CCCC3 RB75 5.320 284
CCCc(cc1)cc(c12)sc(=O)n2CCN3CCCCCC3 SN-56 6.569 284
c1ccccc1C(=O)O[C@H]([C@@H]2C(=O)OC)C[C@H](CC[C@H]23)N3CCc4ccc([N+]([O-])=O)cc4 5 2.272 96
c1ccccc1C(=O)O[C@H]([C@@H]2C(=O)OC)C[C@H](CC[C@H]23)N3CCc4ccc(N)cc4 6 4.777 96
c1cc(F)ccc1CCC(=O)N(CCC)CCc2ccc([N+]([O-])=O)cc2 11 4.905 96
c1cc(F)ccc1CCCN(CCC)CCc2ccc(N)cc2 13 6.921 96
c1cc(F)ccc1CCCN(CCC)CCc2cc(I)c(N)cc2 14 4.377 96
c1cc(F)ccc1CCCN(CCC)CCc2cc(I)c(cc2)N=[N+]=[N-] 15 5.889 96
NCCc1c[nH]c(c12)cccc2 tryptamine 5.309 285
CN(C)CCc1c[nH]c(c12)cccc2 N,N’-dimethyltryptamine 4.663 285
CNCCc1c[nH]c(c12)cccc2 N-methyltryptamine 4.892 285
NCCc1ccccc1 PEA 5.136 285
CNCCc1ccccc1 N-methylPEA 4.659 285
CN(C)CCc1ccccc1 N,N’-dimethylPEA 4.674 285
NCCc1ccc(O)cc1 tyramine 3.217 285
CNCCc1ccc(O)cc1 N-methyltyramine 5.180 285
CN(C)CCc1ccc(O)cc1 N,N’-dimethyltyramine 4.192 285
COc(cc1)ccc1CN2C[C@@H](CC[C@@H]3O)N(C[C@H]23)Cc4ccccc4 15 5.770 180
COc(cc1)ccc1CN2C[C@H](CC[C@H]3O)N(C[C@@H]23)Cc4ccccc4 ent-15 6.094 180
COc(cc1)ccc1CN2C[C@@H](CC[C@H]3O)N(C[C@H]23)Cc4ccccc4 20 6.356 180
COc(cc1)ccc1CN2C[C@H](CC[C@@H]3O)N(C[C@@H]23)Cc4ccccc4 ent-20 6.152 180
COc(cc1)ccc1CN2C[C@@H](CC[C@@H]3OC)N(C[C@H]23)Cc4ccccc4 17 5.614 180
COc(cc1)ccc1CN2C[C@H](CC[C@H]3OC)N(C[C@@H]23)Cc4ccccc4 ent-17 6.242 180
COc(cc1)ccc1CN2C[C@@H](CC[C@H]3OC)N(C[C@H]23)Cc4ccccc4 22 5.842 180







c1cc(Cl)c(Cl)cc1CC(=O)N2C[C@@H](N(C[C@@H]23)C(=O)OC)CC[C@H]3N4CCCC4 24 6.205 181







c1cc(Cl)c(Cl)cc1CC(=O)N2C[C@H](N(C[C@H]23)C(=O)OC)CC[C@@H]3N4CCCC4 ent-24 5.824 181
C1CCCN1[C@H]2CC[C@@H](N(C[C@@H]23)C(=O)CC)CN3C(=O)Cc4cc(Cl)c(Cl)cc4 ent-26 5.678 181
CCCN(CCC)CCc1ccc([N+]([O-])=O)cc1 2 4.271 286
CCCCN(CCCC)CCCc1ccc([N+]([O-])=O)cc1 3 6.394 286
CCCCN(CCCC)C(=O)CCc1ccc(F)cc1 4 3.898 286
c1cc([N+]([O-])=O)ccc1CN(CCC)C(=O)CCc2ccc(F)cc2 6 3.627 286
CCCCN(CCCC)CCCc1ccc(F)cc1 9 6.164 286
CCCCCCCCN(CCCCCCCC)CCCc1ccc(F)cc1 10 5.782 286
CCCNCCCc1ccc(F)cc1 13 6.638 286
c1cc(F)ccc1CCCN(CCC)Cc2ccc(N)cc2 14 5.668 286
c1cc(F)ccc1CCCN(CCC)Cc2cc(I)c(N)cc2 16 3.875 286
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c1cc([N+]([O-])=O)ccc1CCCN(CCC)CCc2ccc(N)cc2 20 7.078 286
c1cccc(c12)C(=O)N(C2=O)CCCCN(C3)CCc(c34)ccc(c4)[N+]([O-])=O 3b 7.058 287
c1ccc([N+]([O-])=O)cc1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 5a 2.917 287
c1cc([N+]([O-])=O)ccc1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 5d 4.833 287
c1ccc(OC)c(O)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 5i 4.169 287
COc(cc1)c(OC)c(OC)c1C(=O)NCCCCN(C2)CCc(c23)ccc(c3)[N+]([O-])=O 5e 4.986 287
c1ccc(OC)c(OC)c1C(=O)NCCCCN(C2)CCc(c23)ccc(c3)[N+]([O-])=O 5f 5.104 287
c1cc(I)c(OC)c(O)c1C(=O)NCCCCN(C2)CCc(c23)ccc(c3)[N+]([O-])=O 5g 4.127 287
c1ccc(OC)c(O)c1C(=O)NCCCCN(C2)CCc(c23)ccc(c3)[N+]([O-])=O 5h 4.951 287
C=CCN(C[C@H]12)[C@@H](CC=C1)CN2Cc3ccc(cc3)OC 2 5.625 55
C=CCN(C[C@@H]12)[C@H](CC=C1)CN2Cc3ccc(cc3)OC ent-2 5.613 55
COc(cc1)ccc1CN2C[C@H](CC=C3)N(C[C@@H]23)Cc4ccccc4 3 7.409 55
COc(cc1)ccc1CN2C[C@@H](CC=C3)N(C[C@H]23)Cc4ccccc4 ent-3 6.372 55
C=CCN1C[C@H](CCC2)N(C[C@@H]12)Cc3ccc(cc3)OC 23 6.693 184
C=CCN1C[C@@H](CCC2)N(C[C@H]12)Cc3ccc(cc3)OC ent-23 6.475 184
C=CCN(C[C@H]12)[C@@H](CCC1=O)CN2Cc3ccc(cc3)OC 12 5.041 184
C=CCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-12 5.721 184
C=CCN(C[C@H]12)[C@@H](CC[C@H]1O)CN2Cc3ccc(cc3)OC 15a 5.321 184
C=CCN(C[C@@H]12)[C@H](CC[C@@H]1O)CN2Cc3ccc(cc3)OC ent-15a 5.917 184
C=CCN(C[C@H]12)[C@@H](CC[C@H]1O)CN2Cc3c(OC)cc(cc3)OC 15b 5.836 184
C=CCN(C[C@@H]12)[C@H](CC[C@@H]1O)CN2Cc3c(OC)cc(cc3)OC ent-15b 5.287 184
CO[C@@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3ccc(cc3)OC 16a 5.772 184
CO[C@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3ccc(cc3)OC ent-16a 5.810 184
CO[C@@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3c(OC)cc(cc3)OC 16b 5.678 184
CO[C@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3c(OC)cc(cc3)OC ent-16b 4.870 184
CO[C@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3ccc(cc3)OC 21a 5.678 184
CO[C@@H]1CC[C@@H](N(C[C@@H]12)CC=C)CN2Cc3ccc(cc3)OC ent-21a 4.650 184
CO[C@H]1CC[C@H](N(C[C@H]12)CC=C)CN2Cc3c(OC)cc(cc3)OC 21b 5.116 184
C=CCN1C[C@H](CCC2)N(C[C@@H]12)Cc3c(OC)cc(cc3)OC 23b 5.631 184
C=CCN1C[C@@H](CCC2)N(C[C@H]12)Cc3c(OC)cc(cc3)OC ent-23b 5.733 184
CCCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-7 5.745 54
CC(C)=CCN(C[C@H]12)[C@@H](CCC1=O)CN2Cc3ccc(cc3)OC 12 6.075 54
CC(C)=CCN(C[C@@H]12)[C@H](CCC1=O)CN2Cc3ccc(cc3)OC ent-12 5.886 54
COc(cc1)ccc1CN2C[C@H](CCC3=O)N(C[C@@H]23)Cc4ccccc4 14 6.152 54
COc(cc1)ccc1CN2C[C@@H](CCC3=O)N(C[C@H]23)Cc4ccccc4 ent-14 5.444 54
COc(cc1)ccc1CN2C[C@H](CCC3=O)N(C[C@@H]23)c4ccccc4 16 5.423 54
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3
OCc4ccccc4 9 4.815 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3
OCc4ccccc4 12 4.660 185
CCN(CC)C(=O)c1ccc(cc1)[C@H](c2ccccc2)N3C[C@@H](CCC4)N(C[C@H]34)CC=C 24 6.910 185
CCN(CC)C(=O)c1ccc(cc1)[C@@H](c2ccccc2)N3C[C@@H](CCC4)N(C[C@H]34)CC=C 25 7.081 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3
OCc4ccccc4 ent-9 5.821 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\
c4ccccc4 ent-15 5.561 185
CCN(CC)C(=O)c1ccc(cc1)CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3
OCc4ccccc4 ent-12 5.810 185
CCN(CC)C(=O)c1ccc(cc1)[C@@H](c2ccccc2)N3C[C@H](CCC4)N(C[C@@H]34)CC=C ent-24 6.163 185
CCN(CC)C(=O)c1ccc(cc1)[C@H](c2ccccc2)N3C[C@H](CCC4)N(C[C@@H]34)CC=C ent-25 6.545 185
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3OCc4ccccc4 8a 6.096 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3OCc4ccccc4 8b 6.398 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3OCc4ccccc4 11a 6.238 186




COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@H]3Oc4ccccc4 13b 6.329 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3Oc4ccccc4 15a 5.076 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CC[C@@H]3Oc4ccccc4 15b 5.680 186
COc(cc1)ccc1CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\c4ccccc4 17a 6.240 186
COc(cc1)cc(OC)c1CN2C[C@@H](N(C[C@@H]23)CC=C)CCC\3=C\c4ccccc4 17b 6.799 186
c1cccc2[nH]c(c3c12)[C@H]4CN(CC=C)[C@@H](C3)CN4Cc5ccc(cc5)OC 20a 4.627 186
c1cccc2[nH]c(c3c12)[C@H]4CN(CC=C)[C@@H](C3)CN4Cc5c(OC)cc(cc5)OC 20b 5.475 186
COc(cc1)cc(OC)c1CN2C[C@H](C3)N(CC=C)C[C@@H]2c(c3c45)[nH]c4ccc(c5)OC 21b 5.030 186
COc(cc1)ccc1CN([C@@H]2CN3CC=C)C[C@@H]3Cc(c4C)c2nc(c45)cccc5 23a 5.251 186
COc(cc1)cc(OC)c1CN([C@@H]2CN3CC=C)C[C@@H]3Cc(c4C)c2nc(c45)cccc5 23b 5.076 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3OCc4ccccc4 ent-8a 5.323 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3OCc4ccccc4 ent-8b 5.551 186
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COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3OCc4ccccc4 ent-11a 5.190 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3Oc4ccccc4 ent-13a 6.064 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3OCc4ccccc4 ent-11b 4.644 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@@H]3Oc4ccccc4 ent-13b 5.231 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3Oc4ccccc4 ent-15a 6.162 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CC[C@H]3Oc4ccccc4 ent-15b 6.042 186
COc(cc1)ccc1CN2C[C@H](N(C[C@H]23)CC=C)CCC\3=C\c4ccccc4 ent-17a 6.247 186
COc(cc1)cc(OC)c1CN2C[C@H](N(C[C@H]23)CC=C)CCC\3=C\c4ccccc4 ent-17b 6.168 186
c1cccc2[nH]c(c3c12)[C@@H]4CN(CC=C)[C@H](C3)CN4Cc5c(OC)cc(cc5)OC ent-20b 5.493 186
COc(cc1)cc(OC)c1CN2C[C@@H](C3)N(CC=C)C[C@H]2c(c3c45)[nH]c4ccc(c5)OC ent-21b 4.991 186
COc(cc1)ccc1CN([C@H]2CN3CC=C)C[C@H]3Cc(c4C)c2nc(c45)cccc5 ent-23a 4.243 186
COc(cc1)cc(OC)c1CN([C@H]2CN3CC=C)C[C@H]3Cc(c4C)c2nc(c45)cccc5 ent-23b 5.251 186
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 1 6.620 58
c1cccc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 2 6.759 58
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 3 7.433 58
c1cc(Cl)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 4 7.093 58
c1cc(Cl)c(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 5 7.836 58
c1cc(Cl)cc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 6 7.611 58
Clc1cccc(Cl)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 7 7.150 58
c1cccc(Br)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 8 7.062 58
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 9 7.818 58
c1cc(Br)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 10 7.622 58
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 11 6.176 58
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 12 6.815 58
c1cc(F)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 13 7.160 58
c1cc(F)cc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 14 6.886 58
c1c(F)ccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 15 6.888 58
Fc1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 16 6.684 58
c1cc(F)c(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 17 7.272 58
c1c(F)cc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 18 7.428 58
c1cccc(c1C(F)(F)F)CC(=O)NC2CCN(CC2)Cc3ccccc3 19 7.208 58
FC(F)(F)c1cc(ccc1)CC(=O)NC2CCN(CC2)Cc3ccccc3 20 7.423 58
FC(F)(F)c1ccc(cc1)CC(=O)NC2CCN(CC2)Cc3ccccc3 21 7.272 58
c1cccc([N+]([O-])=O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 22 6.307 58
c1ccc([N+]([O-])=O)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 23 7.101 58
c1cc([N+]([O-])=O)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 24 6.977 58
c1cc([N+]([O-])=O)cc([N+]([O-])=O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 25 6.614 58
c1cccc(O)c1CC(=O)NC2CCN(CC2)Cc3ccccc3 26 6.465 58
c1cc(O)c(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 30 6.121 58
c1ccc(OC)cc1CC(=O)NC2CCN(CC2)Cc3ccccc3 32 6.487 58
COc(cc1)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 33 6.316 58
O1COc(c12)ccc(c2)CC(=O)NC3CCN(CC3)Cc4ccccc4 38 6.538 58
COc(cc1)cc(OC)c1NC(=O)NC2CCN(CC2)Cc3ccccc3 39 6.644 58
CSc(cc1)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 41 7.079 58
CSc(cc1)ccc1NC(=O)NC2CCN(CC2)Cc3ccccc3 42 7.094 58
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)Cc4ccccc4 1 7.456 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCC4 2 8.167 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCCC4 3 8.678 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)C4CCCCCC4 4 8.585 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 5 8.620 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC3CCN(CC3)[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 6 7.260 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)Cc4ccccc4 7 7.377 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCC4 8 7.569 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCCC4 9 7.602 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)C4CCCCCC4 10 7.770 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 11 6.863 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@H]3CCN(C3)[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 12 7.155 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)Cc4ccccc4 13 7.682 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCC4 14 7.815 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCCC4 15 8.009 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)C4CCCCCC4 16 8.000 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 17 6.554 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]3CCN(C3)[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 18 7.670 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3Cc4ccccc4 19 6.654 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCC4 20 6.818 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCC4 21 7.292 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCCC4 22 6.833 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3C4CCCCCC4 23 7.357 187
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c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3[C@@H]([C@@H]45)[C@@H](CCC5)CCC4 24 6.573 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@@H]3CCCN3[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 25 6.851 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3Cc4ccccc4 26 6.684 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCC4 27 7.022 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCC4 28 7.456 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCCC4 29 7.602 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3C4CCCCCC4 30 7.244 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)NC[C@H]3CCCN3[C@@H]([C@@H]45)[C@H]6C[C@@H](C5)C[C@@H](C4)C6 31 6.499 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)
C5CCCCC5 32 8.319 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)
C5CCCCCC5 33 8.102 187
c1cccc(c12)c(Br)cc(c2OC)C(=O)N[C@@H]([C@H]34)[C@@H](CCC3)CN(C4)C
c5ccccc5 37 6.602 187
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.770 187
c1ccc(OC)c(OC)c1-c([nH]2)ncc2CNC3CCN(CC3)Cc4ccccc4 5c 6.854 188
c1ccccc1CC2CCN(CC2)Cc3cnc([nH]3)-c4c(OC)c(OC)cc(Br)c4 5m 6.947 188
c1ccccc1C2CCN(CC2)Cc3cnc([nH]3)-c4c(OC)c(OC)cc(Br)c4 5l 6.385 188
c1ccccc1CN(CC2)CCC2c(on3)nc3-c4c(OC)c(OC)ccc4 7d 6.600 188
c1c(I)cc(OC)c(OC)c1C(=O)N[C@@H]([C@H]23)[C@@H](CCC2)CN(C3)C
c4ccccc4 IABN 6.377 188
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.545 57
c1sccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 2 6.473 57
s1cccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 1 6.406 57
c1cccc(c12)cccc2CC(=O)NC3CCN(CC3)Cc4ccccc4 7 7.404 57
c1cccc(c12)cccc2NC(=O)NC3CCN(CC3)Cc4ccccc4 8 7.602 57
c1cccc(c12)ccc(c2)CC(=O)NC3CCN(CC3)Cc4ccccc4 9 6.952 57
c1cc(I)ccc1CC(=O)NC2CCN(CC2)Cc3ccccc3 16 7.212 57
c1c(Br)ccc(c12)[nH]cc2CC(=O)NC3CCN(CC3)Cc4ccccc4 11 6.169 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3c(F)cccc3 17 6.166 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 19 7.081 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3c(I)cccc3 20 6.200 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 21 6.719 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 22 6.159 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(cc3C(F)(F)F)ccc3 24 6.290 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(cc3)ccc3C(F)(F)F 25 6.522 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 26 6.496 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(Cl)c(Cl)cc3 27 6.373 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc3cc(F)c(F)cc3 28 6.635 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(c3)ccc(c34)OCO4 29 6.766 57
c1ccccc1CC(=O)NC2CCN(CC2)Cc(c3)ccc(c34)cccc4 30 6.722 57
c1ccccc1CC(=O)NC2CCN(CC2)CCc3ccccc3 31 6.971 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 32 6.855 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 33 6.742 57
c1cccc(F)c1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 34 6.634 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 35 7.508 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 36 7.299 57
c1ccc(F)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 37 6.776 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 38 8.028 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 39 7.518 57
c1ccc(Cl)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 40 6.591 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccc(F)cc3 41 8.218 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3cc(I)ccc3 42 7.227 57
c1ccc(Br)cc1CC(=O)NC2CCN(CC2)Cc3ccc(I)cc3 43 7.044 57
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.240 189
c1ccccc1C[C@H]2CN[C@H](C)Cc(c23)cccc3 14a 5.512 189
c1cccc(c12)C[C@@H](CC)NC[C@@H]2Cc3ccccc3 14b 5.988 189
c1cccc(c12)C[C@@H](CCCC)NC[C@@H]2Cc3ccccc3 14c 6.110 189
c1ccccc1C[C@H]2CN[C@H](c3ccccc3)Cc(c24)cccc4 14d 5.633 189
c1ccccc1C[C@@H]2CN[C@@H](C)Cc(c23)cccc3 ent-14a 5.986 189
c1cccc(c12)C[C@H](CC)NC[C@H]2Cc3ccccc3 ent-14b 6.688 189
c1cccc(c12)C[C@H](CCCC)NC[C@H]2Cc3ccccc3 ent-14c 7.387 189
c1ccccc1C[C@@H]2CN[C@@H](c3ccccc3)Cc(c24)cccc4 ent-14d 6.553 189
C[C@H](C1)NCCc(c12)cccc2 12a 5.515 190
CC[C@H](C1)NCCc(c12)cccc2 12b 5.983 190
CCCC[C@H](C1)NCCc(c12)cccc2 12c 5.519 190
CCCC[C@@H](C1)NCCc(c12)cccc2 ent-12c 5.686 190
c1cccc(c12)CCN[C@@H](C2)c3ccccc3 12d 6.210 190
180
c1cccc(c12)CCN[C@H](C2)c3ccccc3 ent-12d 6.370 190
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.695 192
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.107 192
c1cc(I)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 4-IBP 7.599 194
c1ccc(I)cc1C(=O)NC2CCN(CC2)Cc3ccccc3 3-IBP 7.073 194
c1cccc(I)c1C(=O)NC2CCN(CC2)Cc3ccccc3 2-IBP 7.529 194
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OCF FM-SA4503 6.602 288
CN(C)[C@H]([C@H]1O2)CC[C@H]2Cc(c13)cccc3 12 5.538 289
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.662 200
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)OC ibogaine 7.044 200
c1ccccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-Vesamicol 7.462 201
c1cc(F)ccc1CN(C2)CC[C@@H](O)[C@@H]2N(CC3)CCC3c4ccccc4 (+)-FBT 7.445 201
c1cc(F)ccc1CN(C2)CC[C@H](O)[C@H]2N(CC3)CCC3c4ccccc4 (-)-FBT 6.960 201
c1ccccc1C(c2ccccc2)O[C@@H](C3)C[C@@H](N4C)CC[C@H]34 Benztropine 7.458 202
Clc1c(Cl)ccc(c1)NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6a 6.676 203
Clc1c(Cl)ccc(c1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3a 7.548 203
COc(c(Cl)c1)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3b 8.137 203
c1cc(Cl)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3c 7.996 203
c1ccc(Br)cc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3d 7.821 203
c1cc(Br)ccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3e 8.538 203
Cc1c(C)cccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3f 7.821 203
c1cc(C)cc(c1C)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3g 7.836 203
CCc1ccc(cc1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3h 7.917 203
Cc1cc(c(cc1)OC)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3i 8.495 203
[O-][N+](=O)c(c1)ccc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3C
c4ccccc4 3j 8.268 203
c1cc([N+]([O-])=O)cc(c1C)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3C
c4ccccc4 3n 8.509 203
CCCCc1ccc(cc1)NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3l 7.963 203
c1ccc(SC)cc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3m 7.652 203
c1cccc(Br)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3o 7.529 203
COc(cc1)ccc1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3Cc4ccccc4 3p 7.415 203
Clc1c(Cl)ccc(c1)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4a 7.060 203
COc(c(Cl)c1)cc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 4b 7.640 203
c1cc(O)cc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4c 7.197 203
c1ccc(Br)cc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4d 7.963 203
c1cc(Br)ccc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4e 7.963 203
Cc1c(C)cccc1NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4f 8.310 203
c1cc(C)cc(c1C)NC(=O)O[C@@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4g 8.119 203
CCc1ccc(cc1)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4h 7.836 203
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4i 8.509 203
[O-][N+](=O)c(c1)ccc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 4j 7.777 203
c1cc([N+]([O-])=O)cc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
[c4ccccc4 4k 8.260 203
CCCCc1ccc(cc1)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4l 7.578 203
c1ccc(SC)cc1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4m 8.076 203
[O-][N+](=O)c1cccc(c1C)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 4n 7.721 203
COc(c1)ccc(OC)c1NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 4o 7.572 203
CC(C)c(cc1)cc(c1CC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 4p 8.229 203
COc(c1)ccc(OC)c1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6e 6.219 203
c1ccc(Br)cc1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6c 6.993 203
Brc1cccc(c1OC)NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6f 6.820 203
c1cc(Br)ccc1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6d 6.395 203
COc(c(Cl)c1)cc(OC)c1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3C
c4ccccc4 6h 6.362 203
c1c(Cl)ccc(OC)c1NC(=O)N[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 6i 6.191 203
c1cc([N+]([O-])=O)cc(OC)c1NC(=O)O[C@@H](C2)C[C@H](CC[C@H]23)N3C
c4ccccc4 3k 8.699 203
COc(c1)c(OC)cc(c12)CN(CC2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6b 6.337 204
CCN(CC)Cc1ccc([nH]1)-c2c(OC)c(OC)cc(Br)c2 6g 6.152 204
c1ccccc1CN(Cc2ccccc2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6h 6.544 204
C1CCCCN1Cc2ccc([nH]2)-c3c(OC)c(OC)cc(Br)c3 6i 6.291 204
c1ccccc1C2CCN(CC2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6j 6.660 204
c1ccccc1CC2CCN(CC2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6k 6.453 204
181
c1cccc(c12)CN(C2)Cc3ccc([nH]3)-c4c(OC)c(OC)cc(Br)c4 6q 6.513 204
COc(c1)c(OC)cc(c12)CN(CC2)Cc3ccc([nH]3)-c(c4OC)cc(Br)c(c45)cccc5 11a 7.585 204
c1cccc(c12)CN(C2)Cc3ccc([nH]3)-c(c4OC)cc(Br)c(c45)cccc5 11d 7.060 204
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 1b 7.523 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccccc4 2a 8.921 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCc4ccccc4 3 8.699 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCc4ccccc4 4 8.538 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCC
c4ccccc4 5 8.745 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCCCCC




Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(F)cc4 2b 8.229 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(I)cc4 2c 6.851 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(C)cc4 2d 7.081 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc([N+]([O-])=O)cc4 2e 7.939 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(N)cc4 2f 8.301 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4c(F)cccc4 1c 6.686 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4cc(F)ccc4 1d 6.498 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(I)cc4 1e 7.514 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4cc(I)ccc4 1g 7.293 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc(C)cc4 1h 7.810 98
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccc([N+]([O-])=O)cc4 1i 7.599 98
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCN(CC3)Cc(c34)cccc4 11a 7.321 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCN(CC3)Cc(c34)cc(OC)c(c4)OC 11b 7.674 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCCCN(CC3)Cc(c34)cc(OC)c(c4)OC 12 7.754 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCN(CC2)Cc(c23)cccc3 13a 6.145 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 13b 7.785 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 14 8.086 205
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)CCC2c(c3Cl)cccc3Cl 15 7.125 205
c1cccc(c12)c(Br)cc(c2OC)C(=O)NCCCCN(CC3)CCC3c(c4Cl)cccc4Cl 16 7.578 205
c1c(Br)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cccc3 17 7.049 205
c1c(Br)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 18 7.907 205
Cc(c1)ccc(OC)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 19 7.876 205
Cc(c1)ccc(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 20 7.987 205
c1cc(F)ccc1CN(CC2)CCC23c4c(C(=O)O3)cccc4 2c 5.717 206
c1cc(F)ccc1CN(CC2)CCC23c4c(CO3)cccc4 2d 6.883 206
c1ccccc1CN(CC2)CCC23c4c(CC(=O)O3)cccc4 18 5.937 208
c1ccccc1CN(CC2)CCC23c4c(C=CO3)cccc4 19 6.520 208
c1ccccc1CN(CC2)CCC23c4c(CCO3)cccc4 20 7.001 208
c1ccccc1CN(CC2)CCC23c4c(C(=O)O3)cccc4 25 5.836 208
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.194 208
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.466 208
c1ccccc1CN(C)CCCc2cn(c(c23)cccc3)-c4ccc(F)cc4 1a 6.352 290
c1ccc(Cl)cc1CN(C)CCCc2cn(c(c23)cccc3)-c4ccc(F)cc4 1c 6.908 290
c1cc(C)cc(C)c1CN(C)CCCc2cn(c(c23)cccc3)-c4ccc(F)cc4 1l 7.329 290
c1ccccc1CN(C)CCCCc2cn(c(c23)cccc3)-c4ccc(F)cc4 2a 7.239 290
c1ccc(Cl)cc1CN(C)CCCCc2cn(c(c23)cccc3)-c4ccc(F)cc4 2c 7.592 290
c1cc(F)ccc1-n(c(c23)cccc3)cc2CCCCN(C)Cc4c(C)cc(C)cc4 2l 8.229 290
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5ccc(cc5)OC 3b 6.033 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c(cc5)ccc5C 3c 5.796 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)c(sc4)-c5cccc(c56)cccc6 3f 7.292 220
c1ccccc1CN(CC2)CCC23c4c(CCO3)csc4 5 6.638 220
c1ccccc1CN(CC2)CCC23c4c(C=CO3)csc4 14 7.073 220
Cn1c(=O)sc(c12)cc(cc2)CCN(CC3)CCC3Cc4ccccc4 8 8.301 222
Cn1c(=O)sc(c12)cc(cc2)CCN3CCN(CC3)Cc4ccccc4 10 8.523 222
Cn1c(=O)sc(c12)cc(cc2)CCN3CCN(CC3)Cc4c(Cl)cc(Cl)cc4 12 8.097 222
Cn1c(=O)sc(c12)cc(cc2)CCN3CCN(CC3)Cc4cc(Cl)c(Cl)cc4 14 8.301 222
C[C@@H]1CN(C[C@H](C)N1)CCc(cc2)cc(c23)sc(=O)n3C 16 5.699 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN(CC3)CCC3c4ccccc4 7 8.523 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN(CC3)CCC3Cc4ccccc4 9 8.301 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN3CCN(CC3)Cc4c(Cl)cc(Cl)cc4 13 8.046 222
C[C@@H]1CN(C[C@H](C)N1)CCCCc(cc2)cc(c23)sc(=O)n3C 17 7.000 222
Cn1c(=O)sc(c12)cc(cc2)CCN(CC3)CCC3c4ccccc4 6 8.699 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN3CCN(CC3)Cc4ccccc4 11 8.699 222
Cn1c(=O)sc(c12)cc(cc2)CCCCN3CCN(CC3)Cc4cc(Cl)c(Cl)cc4 15 8.699 222
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.377 225
182
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.446 226
c1cccc(O)c1C(=O)CCCCCN2CCN(CC2)c3noc(c34)cccc4 40 6.740 227
c1cccc(OC)c1C(=O)CCCCCN2CCN(CC2)c3noc(c34)cccc4 43 6.833 227
c1cc(F)ccc1C(=O)NCCN(CC)CC F-FBZA 3.921 231
CN(C)C/C=C(\C)c(c1)ccc(c12)cc(cc2)OC 2a 6.151 291
COc(cc1)cc(c12)ccc(c2)C(\C)=C\CN(C)Cc3ccccc3 2b 6.246 291
C1CCCCN1C/C=C(\C)c(c2)ccc(c23)cc(cc3)OC 2c 6.866 291
c1ccccc1-c(cc2)ccc2C(\C)=C\CN(C)Cc3ccccc3 2d 6.510 291
c1ccccc1CN(CC2)CCC23c4c(C=CO3)n(nc4)-c5ccccc5 26 6.254 237
c1ccccc1CN(CC2)CCC23c4c(C=CO3)n(C)nc4 27 6.368 237
c1ccccc1Cn(nc2)c(CCO3)c2C34CCN(CC4)Cc5ccccc5 28a 6.112 237
c1ccccc1CCCN(CC2)CCC23c4c(CCO3)n(nc4)Cc5ccccc5 28c 6.991 237
c1ccccc1Cn(nc2)c(CCO3)c2C34CCN(CC4)CC5CCCCC5 28d 7.367 237
CC(C)CCN(CC1)CCC12c3c(CCO2)n(nc3)Cc4ccccc4 28e 7.081 237
CC(C)=CCN(CC1)CCC12c3c(CCO2)n(nc3)Cc4ccccc4 28f 6.570 237
c1ccccc1CN(CC2)CCC23c4c(CCO3)n(C)nc4 29a 6.719 237
c1cccc(I)c1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-oIV 6.256 292
c1cccc(I)c1C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-oIV 6.703 292
c1ccc(I)cc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-mIV 7.368 292
c1ccc(I)cc1C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-mIV 7.398 292
c1cc(I)ccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-pIV 7.638 292
c1ccccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-Vesamicol 6.376 292
c1ccccc1C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-Vesamicol 6.445 292
c1cc(I)ccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-pIV 7.551 293
c1cc(I)ccc1C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-pIV 7.690 293
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 5.572 293
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.648 293
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 6.959 293
c1ccccc1C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-Vesamicol 6.481 294
c1ccccc1C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-Vesamicol 6.461 294
c1cccc(c1C)C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-OMV 6.662 294
c1cccc(c1C)C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-OMV 6.575 294
Cc1ccc(cc1)C2CCN(CC2)[C@@H]3[C@@H](O)CCCC3 (+)-PMV 7.390 294
Cc1ccc(cc1)C2CCN(CC2)[C@H]3[C@H](O)CCCC3 (-)-PMV 7.373 294
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 5.607 294
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.684 294
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 6.777 294
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 6.616 294
c1cc(F)ccc1C(=O)CCCN(CC2)CC[Si]2(O)c3ccc(Cl)cc3 sila-haloperidol 6.510 238
c1cc(O)ccc1[C@H](O)[C@H](C)N(CC2)CCC2Cc3ccccc3 1 7.007 295
Cc(c1)ccc(OCCF)c1C(=O)NCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3a 6.991 239
c1c(Br)cc(OC)c(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3b 6.413 239
Cc(c1)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3c 8.158 239
c1c(Br)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3d 9.187 239
c1c(I)ccc(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3e 8.975 239
c1c(I)cc(OC)c(OCCF)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 3f 9.585 239
c1cc(F)ccc1C(=O)C2CCN(CC2)[C@@H](C3)[C@@H](O)Cc(c34)cccc4 (-)-9e 6.496 240
c1cc(F)ccc1C(=O)C2CCN(CC2)[C@H](C3)[C@H](O)Cc(c34)cccc4 (+)-9e 6.556 240
FCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OCCF)cccc3 20c 6.100 241
FCCOCCOCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 18c 5.951 241
FCCOc(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OC)cccc3 18a 6.180 241
CN(C)c(cc1)ccc1C(=O)NCCCCN2CCN(CC2)c3c(OCCF)cccc3 20a 6.187 241
c1sccc1-c(cc2)ccc2C(=O)NCCCCN3CCN(CC3)c4c(OCCF)cccc4 20e 5.225 241
FCCc(cc1)ccc1C(=O)NC/C=C/CN2CCN(CC2)c3c(OCCF)cccc3 21b 5.695 241
c1sccc1-c(cc2)ccc2C(=O)NC/C=C/CN3CCN(CC3)c4c(OCCF)cccc4 21e 5.879 241
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Cl)cc4 2 5.742 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 7 5.671 244
c1cc(Cl)ccc1C2(O)CCN(CC2)Cc3c[nH]c(c34)cccc4OC 5 5.904 244
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Cl)cc4 6 5.721 244
c1cc(Br)ccc1C2(O)CCN(CC2)Cc3c[nH]c(c34)cccc4OC 8 6.025 244
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 9 5.568 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3c4ccccc4 17 5.862 244
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(cc4)SC 20 6.054 244
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.616 246
c1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 5 5.658 246
c1cc(I)ccc1C2(O)CCN(CC2)Cc3c[nH]c(c34)cccc4OC 6 6.013 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 7 5.487 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccccc4 8 5.559 246
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FCCOc1cccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 9 5.022 246
FCCOc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 10 4.982 246
COc1cccc(c12)[nH]cc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 11 4.792 246
COc(c1)ccc(c12)[nH]cc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 12 4.565 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(Br)cc4 13 8.721 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(I)cc4 14 8.257 246
c1ccnc(c12)[nH]cc2CN(CC3)CCC3(O)c4ccc(cc4)SC 15 8.111 246
c1cccc(c12)oc(c2)CN(CC3)CCC3(O)c4ccc(Br)cc4 18 5.854 246
c1cccc(c12)oc(c2)CN(CC3)CCC3(O)c4ccc(I)cc4 19 5.626 246
c1cccc(c12)sc(c2)CN(CC3)CCC3(O)c4ccc(Br)cc4 20 5.707 246
c1cccc(c12)occ2CN(CC3)CCC3(O)c4ccc(Br)cc4 21 6.424 246
c1cccc(c12)occ2CN(CC3)CCC3(O)c4ccc(I)cc4 22 6.406 246
c1cccc(c12)occ2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 23 4.743 246
c1cccc(c12)scc2CN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 24 4.836 246
c1cccc(c12)occ2CN(CC3)CCC34C(=O)N(C)CN4c5ccccc5 25 4.604 246
c1ccccc1N2CN(CCF)C(=O)C23CCN(CC3)Cc4coc(c45)cccc5 26 4.993 246
c1cccc(c12)scc2CN(CC3)CCC34C(=O)N(C)CN4c5ccccc5 27 4.694 246
c1ccccc1N2CN(Cc3cn(nn3)CCF)C(=O)C24CCN(CC4)Cc5coc(c56)cccc6 29 4.657 246
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3(O)c4ccc(Cl)cc4 2 5.083 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3n4c(=O)[nH]c(c45)cccc5 3 4.439 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC3n4c(=O)[nH]c(c45)cc(Cl)cc5 4 4.772 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN(CC3)CCC34C(=O)NCN4c5ccccc5 5 4.700 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cccc4 6 6.223 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OCCF)cccc4 7 5.302 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4ccc(cc4)OC 8 6.177 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cc(cc4)OC 9 5.476 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCN3CCN(CC3)c(cc4)c(OC)cc4C 10 5.194 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OC)cccc4 11 5.883 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCN3CCN(CC3)c4c(OCCF)cccc4 12 5.305 247
C1CC(=O)Nc(c12)cc(cc2)OCCCN3CCN(CC3)c4c(OC)cccc4 13 5.720 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCN3CCN(CC3)c4c(OC)cccc4 14 5.547 247
C1CC(=O)Nc(c12)cc(cc2)OCCCCCN3CCN(CC3)c4c(OC)cccc4 15 6.636 247
c1cc(=O)[nH]c(c12)cc(cc2)OCCCCCN3CCN(CC3)c4c(OC)cccc4 16 6.216 247
c1ccccc1CCN(C[C@@H]2CCCO)CCN2Cc3ccccc3 15 5.924 248
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2N(C)C 19a 6.452 249
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@@H]2N(C)C 19b 5.854 249
c1cc(Cl)c(Cl)cc1CC(=O)N[C@@H]2CC[C@@H](CN3C)N(C[C@H]23)Cc4ccccc4 22a 5.955 249
c1cc(Cl)c(Cl)cc1CC(=O)N[C@H]2CC[C@@H](CN3C)N(C[C@H]23)Cc4ccccc4 22b 6.580 249
O[C@@H]1CC[C@@H](CN2C)N(C[C@H]12)Cc3ccccc3 8a(2R) 5.379 250
O[C@H]1CC[C@@H](CN2C)N(C[C@H]12)Cc3ccccc3 8a(2S) 5.539 250
c1ccccc1CCN2C[C@H](CC[C@H]3O)N(C[C@@H]23)Cc4ccccc4 8c(2R) 6.231 250
c1ccccc1CCN2C[C@H](CC[C@@H]3O)N(C[C@@H]23)Cc4ccccc4 8c(2S) 6.465 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2OC 12a(2R) 6.485 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CC[C@H]2OCc4ccccc4 13a(2R) 7.517 250
c1ccccc1CN(C[C@H]23)[C@H](CN3C)CCC2(OC)OC 15a 5.738 250
c1cc(Cl)c(Cl)cc1CC(=O)NCC[C@@H]2C[C@@H](C[C@@H](O2)OC)NCc3ccccc3 22beta 5.599 251
c1ccccc1CC(=O)NCC[C@@H]2C[C@H](C[C@H](O2)OC)NCc3ccccc3 29alpha 5.213 251
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3Cc4ccccc4 (1R)-14a 8.013 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@H]3Cc4ccccc4 (1S)-14a 7.886 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3CCc4ccccc4 (1R)-14b 8.444 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@H]3CCc4ccccc4 (1S)-14b 7.456 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@H]3Cc4c(C)cccc4 (1S)-14c 7.538 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@@H]3Cc4ccc(cc4)OC (1R)-14d 7.824 252
c1ccccc1[C@H](CO)N(CCc(c23)cccc2)C[C@H]3Cc4ccc(cc4)OC (1S)-14d 8.602 252
c1ccccc1[C@H](CO)N(C[C@@H]2C)CCc(c23)cccc3 (1R)-14e 8.229 252
c1ccccc1C[C@H]2CNCCc(c23)cccc3 (1R)-15a 8.394 252
c1ccccc1C[C@@H]2CNCCc(c23)cccc3 (1S)-15a 8.237 252
c1ccccc1CC[C@H]2CNCCc(c23)cccc3 (1R)-15b 8.959 252
c1ccccc1CC[C@@H]2CNCCc(c23)cccc3 (1S)-15b 8.377 252
c1cccc(C)c1C[C@H]2CNCCc(c23)cccc3 (1R)-15c 8.284 252
c1cccc(C)c1C[C@@H]2CNCCc(c23)cccc3 (1S)-15c 8.553 252
COc(cc1)ccc1C[C@H]2CNCCc(c23)cccc3 (1R)-15d 8.102 252
COc(cc1)ccc1C[C@@H]2CNCCc(c23)cccc3 (1S)-15d 8.155 252
C[C@H]1CNCCc(c12)cccc2 (1R)-15e 8.000 252
C[C@@H]1CNCCc(c12)cccc2 (1S)-15e 7.699 252
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3Cc4ccccc4 1a 8.314 296
Cc1cc(c(cc1)OC)NC(=O)O[C@H](C[C@H]23)C[C@@H](CCC2)N3CCc4ccc(N)cc4 2f 8.785 296
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.557 296
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c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.326 296
c1cc(O)ccc1[C@@H](O)[C@@H](C)N(CC2)CCC2Cc3ccccc3 Ifenprodil 8.569 296
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 5.842 296
[C@@H]12CC[C@H](N2C)C[C@H](C1)OC(=O)c3c[nH]c(c34)cccc4 3-Tropanylindole-3-carboxylate 5.413 296
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 5.543 296
c1cccc(c12)n(C)cc2C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C GR113808 6.863 296
CN(C)CCCc(c(O)cc1)cc1C(=O)Nc(cc2)ccc2-c3ccncc3 GR55562 5.247 296
c1cc(F)ccc1C(=O)C2CCN(CC2)CCn(c3=O)c(=O)[nH]c(c34)cccc4 Ketanserin 5.627 296
c1c(Cl)cc(Cl)cc1C(=O)O[C@@H](C2)C[C@@H](N3C)CC[C@H]23 MDL72222 7.932 296
CC(C)NC[C@H](O)COc1cccc(c12)[nH]cc2 Pindolol 5.706 296
C1CCCCC1C(=O)N(c2ccccn2)CCN3CCN(CC3)c4c(OC)cccc4 Way100635 5.442 296
Cc(c1)ccc(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC RHM-1 8.220 296
c1cccc(c12)[nH]cc2CN3CCN(CC3)c4ccc(F)cc4 1a 6.180 254
c1cccc(c12)[nH]cc2CN3CCN(CC3)c4c(F)ccc(F)c4 1b 6.379 254
c1cccc(c12)[nH]cc2CN3CCN(CC3)c(c4)ccc(Cl)c4Cl 1c 6.886 254
c1cc(F)ccc1N(CC2)CCN2Cc3cn(c(c34)cccc4)CN5CCN(CC5)c6ccc(F)cc6 2a 6.000 254
c1ccccc1CCN2CCN(CC2)Cn(cc3C)c(c34)cccc4 3b 7.253 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4ccc(F)cc4 4a 7.699 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4c(F)cccc4 4b 8.004 254
c1cccc(c12)n(cc2)CCCN3CCN(CC3)c4ccccc4 4c 7.125 254
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O d-pentazocine 6.485 297
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 6.886 297
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 6.629 297
c1ccccc1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1a 6.609 297
c1cccc(Cl)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1b 6.524 297
c1cc(Cl)ccc1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1c 6.370 297
c1cc(Cl)cc(Cl)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1d 6.418 297
c1cccc(F)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1e 6.672 297
c1cc(C)ccc1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1h 6.936 297
c1cccc(C)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1g 6.471 297
c1cc(F)ccc1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1f 6.770 297
c1cc(C)cc(C)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1i 6.728 297
Cc1cc(C)cc(C)c1CN(CC2)CCC2Cn3c(=O)oc(c34)cccc4 1j 5.540 297
c1cccc(c12)cccc2CN(CC3)CCC3Cn4c(=O)oc(c45)cccc5 1l 5.889 297
c1ccccc1CN(C)CCCn2c(=O)oc(c23)cccc3 2a 5.950 65
c1cccc(Cl)c1CN(C)CCCn2c(=O)oc(c23)cccc3 2b 6.341 65
c1ccc(Cl)cc1CN(C)CCCn2c(=O)oc(c23)cccc3 2c 5.951 65
c1cc(Cl)ccc1CN(C)CCCn2c(=O)oc(c23)cccc3 2d 6.341 65
c1cccc(OC)c1CN(C)CCCn2c(=O)oc(c23)cccc3 2e 6.717 65
c1ccc(OC)cc1CN(C)CCCn2c(=O)oc(c23)cccc3 2f 5.672 65
c1cccc(c12)oc(=O)n2CCCN(C)Cc3ccc(cc3)OC 2g 5.585 65
c1cccc(C)c1CN(C)CCCn2c(=O)oc(c23)cccc3 2h 5.871 65
c1ccc(C)cc1CN(C)CCCn2c(=O)oc(c23)cccc3 2i 5.566 65
c1cc(C)ccc1CN(C)CCCn2c(=O)oc(c23)cccc3 2j 6.004 65
c1cc(C)cc(C)c1CN(C)CCCn2c(=O)oc(c23)cccc3 2k 5.685 65
c1ccccc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3a 6.921 65
c1cccc(Cl)c1CN(C)CCCCn2c(=O)oc(c23)cccc3 3b 7.427 65
c1cc(Cl)ccc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3d 7.441 65
c1ccc(OC)cc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3f 6.728 65
COc(cc1)ccc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3g 7.682 65
c1ccc(C)cc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3i 7.498 65
c1cc(C)ccc1CN(C)CCCCn2c(=O)oc(c23)cccc3 3j 7.640 65
c1cc(C)cc(C)c1CN(C)CCCCn2c(=O)oc(c23)cccc3 3k 8.159 65
185
Table F.5: Sigma 2: DTG/PTZ guinea pig brain dataset
SMILES Name p𝐾i Ref.
c1ccccc1CCCCN(CC2)CCC2Cc3ccccc3 5 8.509 100
c1ccccc1CCCCCN(CC2)CCC2Cc3ccccc3 7 8.553 100
C1CN(C)CCN1CCCCCc2ccccc2 8 7.102 100
CC1CCN(CC1)CCCCCc2ccccc2 9 8.155 100
C1CN(C)CCC1CCCCCc2ccccc2 10 7.013 100
C1CCCCN1CCCCCc2ccccc2 11 7.301 100
C1CCCCC1CCCCCc2ccc(N)cc2 12 4.264 100
C1CCCCN1CCCCCc2ccc(N)cc2 13 6.081 100
C1CCCCN1C\C=C\C=C\c(c2)ccc(c23)OCO3 14 6.256 100
C1CCCCN1CCCCCc(c2)ccc(c23)OCO3 15 7.201 100
C1CCCN1CCCCCc2ccccc2 3 7.155 101
CCN(CC)CCCCCc1ccccc1 4 7.051 101
CNCCCCCc1ccccc1 6a 5.101 101
CN(C)CCCCCc1ccccc1 6b 6.015 101
c1ccccc1CCCCCN(C)CCc2ccccc2 7 8.301 101
c1ccccc1CCCCCNCc2ccccc2 8a 7.469 101
c1ccccc1CCCCCN(C)Cc2ccccc2 8b 7.886 101
c1ccccc1CCCCCNCCc2ccccc2 9 7.824 101
c1ccccc1CCCCCNCCCc2ccccc2 10a 8.009 101
c1ccccc1CCCCCN(C)CCCc2ccccc2 10b 8.201 101
c1ccccc1CCCCCNCCCCc2ccccc2 11 7.167 101
c1ccccc1CCCN(CC2)CCC2Cc3ccccc3 21 8.481 101
N#Cc1ccc(cc1)OCC2CCN(CC2)CCCF 2 6.842 109
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C2)Cc(c23)cc(OC)c(c3)OC 3 9.086 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)CCc(c23)cc(OC)c(c3)OC 4 6.134 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)c(c23)cc(OC)c(c3)OC 5 5.014 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCC2)Cc(c23)cc(OC)c(c3)OC 6 6.502 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCCC2)c(c23)cc(OC)c(c3)OC 7 5.048 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CCC2)c(c23)cc(OC)c(c3)OC 8 5.235 112
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C)CCc2cc(OC)c(cc2)OC 9 5.672 112
c1ccccc1C[C@@H](C)NCCCc2ccccc2 5(R) 7.215 298
c1ccccc1C[C@H](C)NCCCc2ccccc2 5(S) 7.420 298
c1ccccc1C[C@@H](C)NCCCCc2ccccc2 6(R) 7.319 298
c1ccccc1C[C@H](C)NCCCCc2ccccc2 6(S) 7.444 298
c1ccccc1C[C@@H](C)NCCCCCc2ccccc2 7(R) 8.000 298
c1ccccc1C[C@H](C)NCCCCCc2ccccc2 7(S) 7.721 298
c1ccccc1CCCCCCCNCc2ccccc2 22 7.409 298
c1ccccc1CCCNCCc2ccccc2 23 7.046 298
c1ccccc1CCCCNCCc2ccccc2 24 6.921 298
c1ccccc1CCCCCCCNCCc2ccccc2 27 7.481 298
c1ccccc1CCCNCCCc2ccccc2 28 7.194 298
CCCCCNCCCc1ccccc1 32 6.620 298
CCCN(C)CCCCCc1ccccc1 33 7.398 298
CN(C)CCCCCC1CCCCC1 38 6.710 298
CNCCCCCC1CCCCC1 39 6.456 298
FC(F)(F)c1cc(ccc1)CCN(C)CCCCCc2ccccc2 41 7.854 298
FC(F)(F)c1cc(ccc1)CCCCCN(C)CCc2ccccc2 42 8.444 298
c1ccc(C(F)(F)F)cc1C(=O)CCCCN(C)CCc2ccccc2 43 8.886 298
c1ccccc1C(=O)CCCCN(CC)CC 46 6.125 298
c1ccccc1C(=O)CCCCN(CC2)CCC2c3ccccc3 57 8.509 298
c1ccc(Cl)cc1C(=O)CCCCN2CCCCC2 58 7.481 298
c1ccc(Cl)cc1C(=O)CCCCN(CC2)CCC2c3ccccc3 59 8.796 298
c1cc(Cl)ccc1C(=O)CCCCN2CCCCC2 60 7.602 298
c1cc(Cl)ccc1C(=O)CCCCN(CC2)CCC2c3ccccc3 61 9.000 298
c1cc(Cl)ccc1CCCCCN(CC2)CCC2c3ccccc3 62 8.678 298
c1ccccc1C(=O)C2CCN(CC2)CCCCc3ccccc3 65 7.959 298
c1ccccc1C(c2ccccc2)C3CCN(CC3)CCCCc4ccccc4 67 6.629 298
c1ccccc1CCCCCN2CCN(CC2)Cc3ccccc3 68 7.959 298
c1ccccc1CCCCN2CCN(CC2)Cc3ccccc3 69 8.086 298
c1ccccc1C(=O)N2CCN(CC2)CCCCc3ccccc3 72 6.015 298
c1cccc(c12)C(=O)N(C2=O)CCCN(CC3)CCC3Cc4ccccc4 80 7.886 298
c1cccc(c12)C(=O)N(C2=O)CCCN3CCN(CC3)Cc4ccccc4 81 6.538 298
c1cccc(c12)C(=O)N(C2=O)CCCN(CC3)CCC3c4ccccc4 82 7.921 298
c1cccc(c12)C(=O)N(C2=O)CCCN3CCN(CC3)c4ccccc4 83 6.827 298
c1cccc(c12)C(=O)N(C2=O)CCCCN3CCN(CC3)c4ccccc4 84 7.699 298
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c1cc(O)ccc1CCN(CC2)CCC2Cc3ccccc3 85 9.155 298
CCCN1CCN(CC1)c2ccccc2 86 6.268 298
NCCCN1CCN(CC1)c2ccccc2 87 4.870 298
c1ccccc1C(=O)NCCCN2CCN(CC2)c3ccccc3 88 6.310 298
c1cc(Cl)ccc1C(=O)NCCCN2CCN(CC2)c3ccccc3 89 7.051 298
COc(cc1)ccc1C(=O)NCCCN2CCN(CC2)c3ccccc3 90 6.190 298
c1ccccc1CNCCCN2CCN(CC2)c3ccccc3 91 7.000 298
c1ccccc1CN(C(=O)C)CCCN2CCN(CC2)c3ccccc3 92 6.730 298
O=C1CCCC(=O)N1CCCN2CCN(CC2)c3ccccc3 93 6.015 298
O=C1CCC(=O)N1CCCN2CCN(CC2)c3ccccc3 94 5.658 298
c1cc([N+]([O-])=O)ccc1C2(CCCC2)C(=O)OCCN(CC3)CCC3c4ccccc4 RLH-033 6.979 114
CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2 Caramiphen 5.790 114
c1ccccc1C2(CCCC2)C(=O)OCCOCCN(CC)CC Carbetapentane 6.037 114
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.174 114
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.854 114
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)Pentazocine 5.870 114
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 (+)3-PPP 5.945 114
c1cc(O)ccc1[C@@H](O)[C@@H](C)N(CC2)CCC2Cc3ccccc3 Ifenprodil 8.967 118
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.101 118
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.399 118
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 7.200 118
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OCCF FE-SA4503 6.946 118
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 6.138 118
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CCc5c[nH]c(c56)cccc6 GA1-69 7.182 119
CC(C)[C@@H](N)CN1[C@@H](CC[C@@H]12)C[C@H](C2)OC(c3ccc(F)cc3)c4ccc(F)cc4 GA2-50 7.742 119
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CCN GA2-99 6.807 119
c1cc(F)ccc1C(c2ccc(F)cc2)O[C@@H](C3)C[C@H](CC[C@H]34)N4CC5CC5 JHW013 7.587 119
c1ccccc1CCCN2CCN(CC2)Cc3ccccc3 3a 7.464 34
c1ccccc1CCCN2CCN(CC2)Cc3c(Br)cccc3 3b 8.385 34
c1ccccc1CCCN2CCN(CC2)Cc3c([N+]([O-])=O)cccc3 3c 8.421 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(I)ccc3 3d 8.987 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(F)ccc3 3e 7.859 34
c1ccccc1CCCN2CCN(CC2)Cc3cc(OC)ccc3 3f 7.848 34
c1ccccc1CCCN2CCN(CC2)Cc3cc([N+]([O-])=O)ccc3 3g 8.799 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc(cc3)OC 3h 7.484 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc([N+]([O-])=O)cc3 3i 8.483 34
c1ccccc1CCCN2CCN(CC2)Cc3ccc(C)cc3 3j 7.757 34
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 8.019 34
c1ccccc1CCCN2CCN(CC2)CCc3cc(OC)c(cc3)OC SA4503 7.048 34
c1cc([N+]([O-])=O)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 2 7.319 128
c1cccc(F)c1C(=O)NC2CCN(CC2)Cc3ccccc3 3 6.391 128
c1cc(F)ccc1C(=O)NC2CCN(CC2)Cc3ccccc3 4 6.833 128
OCCN(CC1)CCC1COc2ccc(I)cc2 3 6.857 134
N#Cc1ccc(cc1)CN(CC2)CCC2COC/C=C/I 1 7.672 135
N#Cc1ccc(cc1)OCC2CCN(CC2)C/C=C/I 2 7.411 136
c1cc(I)ccc1C(=O)OC2CCN(CC2)CCCF 4 7.138 136
N#Cc1ccc(cc1)OCC2CCN(CCF)CC2 1 6.442 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3ccc(F)cc3 3 8.284 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3c(Br)cccc3 5 7.507 137
N#Cc1ccc(cc1)OCC2CCN(CC2)Cc3c(I)cccc3 6 7.029 137
c1cc(F)ccc1CN(CC2)CCC2COc(cc3)ccc3[N+]([O-])=O 7 8.409 137
FCCN(CC1)CCC1COc2ccc(I)cc2 8 6.991 137
C1CC1CN(CC2)CCC2COc3ccc(I)cc3 10 7.932 137
N#Cc1cc(ccc1)CN(CC2)CCC2COc3ccc(I)cc3 11 7.158 137
c1cccc(c1C#N)CN(CC2)CCC2COc3ccc(I)cc3 12 6.848 137
FCCCN(CC1)CCC1COc2ccc(Br)cc2 13 7.883 137
C1CC1CN(CC2)CCC2COc3ccc(Br)cc3 14 7.866 137
C1CC1CN(CC2)CCC2COc3cc(Br)ccc3 15 8.004 137
FCCCN(CC1)CCC1COc2c(F)c(F)c(F)c(F)c2F 16 8.276 137
c1cc(F)ccc1CN(CC2)CCC2COc3c(F)c(F)c(F)c(F)c3F 17 8.367 137
c1ccc(F)cc1CN(CC2)CCC2COc3c(F)c(F)c(F)c(F)c3F 18 7.620 137
CC1CCN(CC1)CCC=C2c(cccc3)c3Sc(c24)cccc4 5 7.585 182
c1ccccc1C(c2ccccc2)=CCCN(CC3)CCC3C 6 7.553 182
c1ccccc1C(c2ccccc2)CCCN(CC3)CCC3C 7 7.553 182
c1ccccc1C(c2ccccc2)=CCCCN(CC3)CCC3C 8 7.602 182
c1ccccc1C(c2ccccc2)CCCCN(CC3)CCC3C 9 7.770 182
CCN(CC)CCOC(=O)C(CCC)(c1ccccc1)c2ccccc2 11 5.959 182
c1ccccc1C(O)(c2ccccc2)CCCCN(CC)CC 13 6.097 182
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c1ccccc1C(c2ccccc2)CCCCN(CC)CC 14 7.292 182
c1ccccc1C(c2ccccc2)=CCCCN(C)CCc3ccccc3 15a 7.387 182
c1ccccc1C(c2ccccc2)=CCCCNCCc3ccccc3 15b 6.848 182
c1ccccc1C(c2ccccc2)CCCCN(C)CCc3ccccc3 16a 7.495 182
c1ccccc1C(c2ccccc2)CCCCNCCc3ccccc3 16b 7.000 182
c1ccccc1CCCCN2CCN(C)CC2 4 6.046 182
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.848 200
CC[C@H]1C[C@H](C2)CN(CC3)[C@@H]1[C@@H]2c(c3c45)[nH]c4ccc(c5)OC ibogaine 6.602 200
c1cc(F)ccc1-c2cn(c(c23)cccc3)CCCCN(CC4)Cc(c45)cc(OC)c(c5)OC CM353 8.349 219
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)Cc(c34)cc(OC)c(c4)OC CM398 8.347 219
c1cccc(c12)n(C)c(=O)n2CCCCN(CC3)CCC34c5c(CO4)cccc5 CM699 8.638 219
CCCCCn1c(=O)n(c(c12)cccc2)CCCCN3CCN(CC3)c4ccc(F)cc4 CM775 8.644 219
c1cccc(c12)n(CCC)c(=O)n2CCCCN3CCN(CC3)c4ccc(F)cc4 CM777 7.719 219
NC12C[C@@H]3C[C@H](C1)C[C@H](C2)C3 amantadine 4.582 223
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 dtg 7.041 223
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 haloperidol 7.879 223
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC dextromethorphan 4.081 223
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)O dextrorphan 4.993 223
c1cc(F)ccc1C(=O)CCCN(CC2)CCC2(O)c3ccc(Cl)cc3 Haloperidol 7.442 299
CC(C)=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-Pentazocine 6.341 299
CCCN(C1)CCC[C@@H]1c2cc(O)ccc2 R-(+)-PPP 6.355 299
c1ccccc1C2(CCCC2)C(=O)OCCOCCN(CC)CC Carbetapentane 5.817 299
c1cc(Cl)c(Cl)cc1CCN(C)[C@H]2[C@H](CCCC2)N3CCCC3 BD738 6.726 299
c1cc(Cl)c(Cl)cc1CCN(C)[C@@H]2[C@@H](CCCC2)N3CCCC3 BD737 6.299 299
FC(F)(F)c(c1)ccc(c12)Sc3c(cccc3)N2CCCN4CCN(CC4)CCO Fluphenazine 6.357 299
C1CCC[C@@H]2[C@@H](N(CC3)CC=C)Cc(c4[C@]123)ccc(c4)O Dextrallorphan 5.730 299
OCCN(CC1)CCN1CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4 Perphenazine 6.368 299
c1cccc(c1C)NC(=N)Nc(c2C)cccc2 DTG 7.425 299
CCCN(C1)CCC[C@H]1c2cc(O)ccc2 S-(-)-PPP 5.811 299
C1CCC[C@@H]2[C@@H](N(CC3)CC=C)Cc(c4[C@]123)ccc(c4)OC KCR-11-240.1 5.854 299
C=CCN(CC1)[C@H]([C@H]2C)Cc(c3[C@@]12C)ccc(c3)O (+)-SKF10047 5.370 299
c1cc(Cl)c(Cl)cc1CC(=O)N(C)[C@@H]2[C@@H](CCCC2)N3CCCC3 BD446 5.859 299
CC(C)(C)[C@@](C1)(O)CCN([C@H]1c2c34)C[C@@H]4c5c(cccc5)CCc3ccc2 (-)-Butaclamol 5.438 299
CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2 Caramiphen 5.543 299
C1CC1CN(CC2)[C@H]([C@H]3C)Cc(c4[C@@]23C)ccc(c4)O (+)-Cyclazocine 5.907 299
C1CCCC12CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)c4ncccn4 Buspirone 6.128 299
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)OC Dextromethorphan 4.272 299
c1cc(Cl)c(Cl)cc1CC(=O)N(C)[C@H]2[C@H](CCCC2)N3CCCC3 BD445 5.383 299
O1[C@@H]2C(=O)CC[C@@H]3[C@@H](N(CC4)CC5CC5)Cc6ccc(c1c6[C@]234)OC KCR-12-83.1 4.739 299
O1[C@@H]2C(=O)CC[C@@H]3[C@@H](N(CC4)CC5CC5)Cc6ccc(O)c1c6[C@]234 KCR-12-84.1 4.534 299
C1CCC[C@@H]2[C@@H](N(C)CC3)Cc(c4[C@]123)ccc(c4)O Dextrorphan 4.944 299
C1CCC[C@H]2[C@H](N(CC3)CC=C)Cc(c4[C@@]123)ccc(c4)O Levallorphan 4.864 299
COc(c1)ccc(c1[C@@]234)C[C@H](NCC4)[C@H]2CCCC3 KCR-11-239.1 4.728 299
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc(OC)c(c3)OC 1 8.569 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(C2)CCc(c3)c2cc(c34)OCO4 2 7.684 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc4c(c3)OCCO4 3 7.664 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCN(CC2)Cc(c23)cc4c(c3)OCCCO4 4 7.487 253
c1c(Br)cc(OC)c(OC)c1C(=O)NCCCCNCCc2cc(OC)c(cc2)OC 5 5.336 253
188
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Hi David,
Of course, you can use the figures for your dissertation.  At the moment, I don't have easy access to the original figures, so you will probably
need to scan the figures from the books.  If I find them, I will forward them to you.
Ken Domino
-------- Original Message --------
Subject: Permissions request for dissertation
From: David Watson <dewatson@go.olemiss.edu>
Date: Tue, May 15, 2012 3:34 pm
To: nppbooks@nppbooks.com
Dr. Domino,
I am requesting permission to use Figs. 1 from pages 40 and 56 of "Multiple Sigma and PCP Receptor Ligands: Mechanisms for
Neuromodulation and Neuroprotection?" in my dissertation titled "Quasi-comprehensive scaffold perception, pharmacophore
development, and structure--affinity relationships of sigma site ligands".
The references for the pertinent selections are:
Carroll, F. I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W. In Mul- tiple Sigma and PCP Receptor
Ligands: Mechanisms for Neuromodulation and Neuroprotection?; Ka- menka, J.-M., Domino, E. F., Eds.; NPP Books: Ann Arbor, MI,
1992; pp 33–44.
Gund, T. M.; Shukla, K.; Su, T.-P.; Parish, D. In Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and
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From: <kenneth.domino@domemtech.com>
Subject: RE: Permissions request for dissertation
Date: May 16, 2012 8:26:14 AM CDT







Stephen J. Cutler, Ph.D.
Chair & Professor
Director NIH COBRE CORE-NPN
Editor, Medicinal Chemistry Research









From: David Watson [mailto:dewatson@go.olemiss.edu] 
Sent: Tuesday, June 05, 2012 2:34 AM
To: Straalen van, Berendina, Springer SBM NL
Cc: Honour, Carolyn, Springer US; Stephen Cutler
Subject: Re: MCRE - Permissions request...
 
Thank you all very much for clarifying the matter for me, and for providing the permissions to use the selected figures in my dissertation.
 
On Jun 5, 2012, at 1:56 AM, Straalen van, Berendina, Springer SBM NL wrote:
Dear Dr. Watson,
The permission is also granted for UMI dissertations.
 
 
From: Honour, Carolyn, Springer US 
Sent: maandag 4 juni 2012 19:19
To: Straalen van, Berendina, Springer SBM NL
Subject: Fw: MCRE - Permissions request...
 
Dear Berendina




From: Stephen Cutler [mailto:cutler@olemiss.edu] 
Sent: Monday, June 04, 2012 11:23 AM
To: Honour, Carolyn, Springer US 




We have a graduate student, David Watson, who is interested in using some graphs/tables from previous Med Chem Res publications.  Some
of these articles were published more than 10 years ago.  About 2 years ago the University of Mississippi Graduate School converted from a
paper dissertation to an electronic version.    It is my understanding that more schools are going to this format of publishing their dissertations. 
 It appears that the ues of materials from Springer might be in conflict with the trend among Graduate Schools in the US.   Can you confirm if





From: David Watson [mailto:dewatson@olemiss.edu] 
Sent: Monday, June 04, 2012 10:07 AM
To: Stephen Cutler
Stephen Cutler <cutler@olemiss.edu>
To: David Watson <dewatson@go.olemiss.edu>, "Straalen van, Berendina, Springer SBM NL" <B.vanStraalen@springer.com>
Cc: "Honour, Carolyn, Springer US" <Carolyn.Honour@springer.com>
RE: MCRE - Permissions request...
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